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ABSTRACT
Background. Polycystic ovary syndrome (PCOS) is an endocrine disorder affecting millions of
women worldwide. The pathophysiology of this condition is unclear but is believed to be caused
by some genetic and environmental factors. PCOS is associated with a range of reproductive,
metabolic and dermatological disorders and therefore, the economic burden of this condition
can be potentially significant for the public health system in the UK.
Methods. The methodology used for this research includes several parts. Firstly, I conducted
literature reviews to identify studies reporting the prevalence of PCOS and morbidities associ-
ated PCOS. The Bayesian hierarchical model was then applied to model data from the published
studies. This forms the first part of this research for which the analysis was based on aggre-
gate data. In the second part, I investigated the incidence and prevalence of PCOS under the
specific UK context using data from The Health Improvement Network (THIN), a primary care
database with over 500 general practices contributing data each year. I then used a multi-state
Markov model to simulate the population dynamics of PCOS and evaluated the associated eco-
nomic burden of care as well as the quality of life for the entire population with this condition
in the UK.
Results. The prevalence estimates from community studies are generally much higher compared
with that from database studies. The prevalence of PCOS varies for different diagnostic criteria
and across distinct ethnic groups. Women with PCOS are at higher risk of type 2 diabetes,
obesity, cardiovascular diseases and pregnancy complications and are more likely to experience
psychological disorders. The prevalence of PCOS in the UK is estimated to be approximately
2% based on the primary care data, with an annual incidence rate of 2 per 1000 person-year.
There is wide variation in the prescriptions initiated for the PCOS patients. The prevalence of
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type 2 diabetes in the PCOS population is estimated to increase to approximately 26% in the
next 25 years in the UK, which significantly reduces the quality of life for individual patients
and incurs massive amount of healthcare-related costs for the National Health Service (NHS).
Conclusions. The large gap between the prevalence rates estimated from community and
database studies suggests that PCOS is a condition without much public awareness and under-
reporting is often observed. The differences in prevalence rates estimated according to different
diagnostic criteria indicates the potential issue of under- and over-diagnosis of the condition
at present. The ethnic variation in terms of the diagnostic criteria, disease monitoring and
management may need to be considered carefully. The prescribing patterns of PCOS in the
primary care suggest that currently, there is lack of most effective treatment for this condition
and patients generally receive treatments tailored to their external symptoms. The prevalence
of type 2 diabetes among PCOS patients is estimated to be high, resulting in massive amount
of healthcare costs and reduced quality of life for PCOS population in the UK. Early screening
is likely to help reduce the adverse outcomes associated with PCOS for this selected population
and it may be cost effective to include them in the current Diabetes Prevention Programme.
This may help improve the detection of symptoms indicative of diabetes in PCOS patients to
allow early interventions and save significant amount of healthcare costs for the NHS from the
country perspective.
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THESIS AIM AND STRUCTURE
The aim of the research presented in the current thesis was to apply statistical approach for
health research to explore various aspects of polycystic ovary syndrome (PCOS), a disease
affecting millions of women worldwide.
Specific objectives were to:
 Conduct search to identify relevant literature reporting epidemiological outcomes of PCOS
and use statistical approach to establish the prevalence of PCOS in population with dif-
ferent ethnicity backgrounds;
 Explore the incidence/prevalence and prescribing patterns of PCOS in the UK using pri-
mary care database;
 Investigate the population dynamics of PCOS and evaluate the healthcare-related eco-
nomic burden and quality of life associated with this condition in the UK from 2014 to
2039.
The thesis consists of two main parts. In Part I, which consists of 3 chapters, I present
existing evidence in the empirical studies and modelling results based on aggregate data from
literature review for PCOS, which are presented in Chapter 1, 2 and 3. In Part II (including
Chapter 4 and 5), I discuss analyses conducted for PCOS mainly under the specific UK context,
including an exploratory analysis on the epidemiological outcomes and an economic evaluation
using individual level patient data from primary care in the UK. Finally, Chapter 6 summarises
and concludes the main findings from the current research and discusses the impact of the
results from both a global and country perspective as well as the implication for practice and
future research.
The thesis is structured as follows: Chapter 1 gives an overview of PCOS including the
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discovery and major diagnostic criteria of PCOS, morbidities associated with PCOS and the
common treatments for the condition. This chapter aims at providing the reader some back-
ground information of PCOS such that the reader can grasp some basic understanding about
the disease.
Chapter 2 describes the proceedings and results of systematic literature reviews. This is
of great importance because from the literature review, I obtained extensive knowledge about
various aspects of PCOS. In addition, previous studies enable me to further investigate my main
research questions into depths. This chapter introduces the methods and results of database
searches, including details of search words, inclusion criteria for study selection, qualitative
results from individual studies and quality assessment for each study considered. The majority
of the data identified from this Chapter were further used to populate our statistical models,
which is discussed in Chapter 3.
Chapter 3 introduces the methods and main findings for our prevalence estimation of PCOS
and its associated diseases. I firstly provide some background information about evidence syn-
thesis and meta-analysis, which are the main methodologies leading the whole chapter. I then
discuss the specific modelling approach used to establish the prevalence of PCOS and its associ-
ated diseases by synthesising evidence from the published studies. Furthermore, the generalised
meta-analytic models using Bayesian methods are described, which forms the basis of the pack-
age I created for R named bmeta. The bmeta package was motivated by the need to combine
evidence from multiple sources for decision making. The implementation and graphical functions
as well as the web application of bmeta are discussed through sample data for PCOS obtained
from the literature review in Chapter 2.
Chapter 4 presents the methods and results from a database study where I used The Health
Improvement Network (THIN) to evaluate the epidemiology and prescribing patterns of PCOS
under the UK context. I firstly introduce the UK primary care and the motivation of this
database study. The data analysis plan (i.e. patient identification process, statistical modelling
approach for individual level patient data) and main findings for this database study are then
described. Finally, I interpret the results and compare with evidence from empirical studies to
make conclusions and discuss the potential implications.
In Chapter 5, I discuss the economic and utility analysis conducted for PCOS. I attempted to
estimate the healthcare burden of PCOS in the UK in the next 25 years by using a Markov multi-
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state model. Different health states through the disease progression were considered and included
in the model. The model was populated by data from multiple sources and for parameters that
lack enough data to inform, reasonable assumptions were used and uncertainties were assessed
through sensitivity analysis. The results from the model included the epidemiology of type
2 diabetes in the PCOS population, disease burden and quality of life for PCOS population
in the UK from 2014 to 2039. The implications of the main findings are described and some
recommendations for improving the current screening and diagnosis of PCOS are raised.
Finally, in Chapter 6, I summarise the main findings throughout the chapters of the thesis
and discuss the impact and implications of this research.
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Chapter 1
BACKGROUND
1.1 Chapter summary
Polycystic ovary syndrome (PCOS) has been recognised as the most common endocrine ab-
normality, affecting millions of women in reproductive age worldwide. In this chapter, I firstly
introduce the discovery of PCOS and the diagnostic criteria associated with it. I then discuss
PCOS-related diseases and common treatments prescribed to women with PCOS. This intro-
ductory chapter about PCOS aims at giving the reader a general understanding of the disease.
1.2 Discovery and definition of PCOS
Polycystic ovary syndrome (PCOS) remained clinically unexplored until 1935 when two Amer-
ican gynaecologists, Irving Stein and Michael Leventhal, reported seven women who presented
with amenorrhea and excess growth of terminal hair had enlarged ovaries containing small col-
lections of follicles (Adi and Tank, 2010). PCOS was called Stein-Leventhal Syndrome for a
number of decades after their first description to honour the pioneering achievements by these
two gynaecologists.
Since its discovery, many medical specialists have manifested great interests in this research
area and, over the past years, the scientific community has witnessed a rapid increase in the
amount of published literature for this complex syndrome. PCOS is nowadays recognised as
a heterogeneous endocrine abnormality whose principle clinical characteristics include oligo-
ovulation (light or infrequent menstrual periods) or anovulation (failure of the ovary to release
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ova for more than 3 months), hyperandrogenism (elevated androgen level which may lead to
acnes or excess growth of terminal hair on body and face), and polycystic ovaries (many small
cysts in the ovary) (Sirmans and Pate, 2014). Its pathophysiology remains largely unknown but
many believe that PCOS appears to be familial, with its various aspects differentially inherited
from one generation to the next (Livadas and Diamanti-Kandarakis, 2013).
The phenotypes of PCOS are observed to vary in each case as well as in different ethnic
groups and, for an individual case, symptoms and signs of PCOS also change gradually over
time, making its diagnosis and evaluation challenging for clinical practice (Livadas and Diamanti-
Kandarakis, 2013; Balen et al., 2005).
The three major diagnostic criteria for PCOS that are widely followed are the 1990 National
Institutes of Health (which is abbreviate as “NIH”, Zawadzki and Dunaif, 1992), the 2003
Rotterdam Consensus (“Rotterdam”, Rotterdam and ASRM-Sponsored, 2004a,b) and the 2006
Androgen Excess Society (“AES”, Azziz et al., 2006). Details of these 3 definitions are provided
in Table 1.1.
Table 1.1: Three major diagnostic criteria of PCOS.
1990 NIH 2003 Rotterdam 2006 AES
Includes all of the followings:
1. Clinical and/or biochemical
signs of hyperandrogenism
2. Menstrual dysfunction
AND exclusion of other
disorders*
Includes any 2 of the followings:
1. Clinical and/or biochemical
signs of hyperandrogenism
2. Ovarian dysfunction
(Oligo-ovulation or anovulation)
3. Polycystic ovaries
AND exclusion of related
disorders*
Includes all of the followings:
1. Hyperandrogenism
(hirsutism and/or
hyperandrogenemia)
2. Ovarian dysfunction
(Oligo-anovulation and/or
polycystic ovaries)
AND exclusion of related
disorders*
*Possibly exclude congenital adrenal hyperplasia, 21-hydroxylase-deficient non-classic adrenal hyperpla-
sia, androgen-secreting neoplasms, androgenic/anabolic drug use or abuse, Cushing’s syndrome, thyroid
dysfunction, the syndromes of severe insulin resistance and hyperprolactinemia
Arguably, the NIH is the strictest criterion while the Rotterdam covers a broadest spectrum.
The AES removes a combination of terms from the Rotterdam. Therefore, there is an inclusive
and exclusive relationship between the three major criteria of PCOS: the Rotterdam contains
the AES, which in turn contains the NIH.
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1.3 PCOS-related disorders
PCOS is associated with a variety of reproductive, cardiometabolic and dermatologic abnormal-
ities. Patients are often observed to have psychological problems as well as reduced quality of
life (Azziz et al., 2005).
Menstrual irregularity, one of the major diagnostic criteria of this complex syndrome, is
considered to be prevalent among the PCOS population in reproductive age (Fauser et al.,
2012). The cyclic vaginal bleeding (generally known as “menses” or “periods”), normally occurs
at intervals within the range of 22 to 35 days, with variation in length of no more than 2 or 3
days every month (Balen et al., 2005; Azziz et al., 2005). However, the frequency of ovulation
for PCOS patients is largely unpredictable (Fauser et al., 2012). The presence and severity of
ovulation dysfunction is related to many factors, for instance body mass index (obese or not), or
whether the patient has other hormonal disorders (Balen et al., 2005). As menstrual disturbance
is a common clinical presentation for PCOS patients, their overall fecundability is reduced and
a great number of PCOS patients is reported to suffer from infertility (Azziz et al., 2005).
Apart from infertility, there is evidence that menstrual dysfunction may result in an increased
risk of endometrial hyperplasia (Cheung, 2001), which is caused by the continuous secretion of
unopposed oestrogen without regular ovulation (Hardiman et al., 2003). This may further lead
to various gynaecological neoplasia although currently we still lack enough supporting evidence
due to the scarcity of large-scale studies (Balen et al., 2005).
A growing body of literature has suggested that PCOS patients are at increased risks for
cardiometabolic disturbances (Moran et al., 2010b) because insulin resistance is observed to
appear in approximately 50-70% of PCOS population (Ovalle and Azziz, 2002). The most
common metabolic disorder associated with PCOS is type 2 diabetes and it is suggested that
the healthcare-related economic burden of PCOS is largely attributed to diabetic care (Azziz
et al., 2005). The elevated level of insulin also stimulates the ovary to generate excess androgen
and inhibits the production of sex hormone-binding globulin (SHBG), with the latter process
allowing more free androgen as well as oestrogen to be biologically active (Tsilchorozidou et al.,
2004). This “vicious cycle” of continued excess hormonal secretion aggravates anovulation and
possibly endometrial hyperplasia that mentioned previously (Teede et al., 2010a).
Not surprisingly, it is also common for PCOS patients to have androgen excess diseases such
as hirsutism—the presence of excess terminal hairs in a male pattern in women (Bode et al.,
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2012), acne and alopecia. Studies have indicated that acne and hirsutism appear more frequently
in younger women while older women are more likely to experience alopecia (Balen et al., 2005).
However, due to the fact that levels of androgen in circulation are negatively associated with age,
it is expected that the degree of various symptoms of hyperandrogenism may decrease gradually
over time (Winters et al., 2000; Piltonen et al., 2004).
As women with PCOS are plagued with a great number of complications across the lifespan,
many of them experience different degree of psychological disorders and have reduced quality of
life. For example, infertility may lead to tensions between family members; acne and hirsutism
can result in altered self-perception and low self-esteem; metabolic disorders such as type 2
diabetes mellitus can cause severe problems at work (Balen et al., 2005; Li et al., 2011a).
Overall, it is universally accepted that PCOS is a complex and heterogeneous disorder ad-
versely affecting women throughout the lifespan. This pinpoints the importance of early detec-
tion, long term monitoring and management of PCOS for clinical practice as well as the public
awareness of this syndrome.
1.4 Treatments of PCOS
The exact ætiology of PCOS remains unclear and is believed to be due to some inherited
genetic characteristic. Consequently, PCOS itself is largely incurable and treatment are tailored
to various health consequences of PCOS (Barthelmess and Naz, 2014; Teede et al., 2010b).
As PCOS is largely caused by hormonal imbalances, many treatments are designed to break
the “vicious cycle” of excess hormonal production. Oral contraceptive pills (OCP) are the most
common treatment for PCOS women presenting menstrual disturbances but not desiring preg-
nancy (Barthelmess and Naz, 2014; Meyer et al., 2007). They help regulate the cycle of menses
and protect from endometrial hyperplasia (Teede et al., 2010b), with an additional advantage
of reducing androgen production, which relieves the clinical symptoms of hyperandrogenism
(Barthelmess and Naz, 2014; Meyer et al., 2007). However, there are concerns that high doses of
OCP may be a risk factor for both metabolic and cardiovascular diseases by worsening glucose
tolerance and arterial stiffness (Meyer et al., 2007).
This draws the attention to another treatment, metformin, which can ameliorate clinical
presentations of PCOS such as menstrual irregularity and hirsutism without negative car-
diometabolic impacts (Teede et al., 2007). It is also suggested by the International Diabetes
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Federation (IDF) that metformin can, to some extent, prevent diabetes when lifestyle modifica-
tion is not an adequate approach (Meyer et al., 2007; Alberti et al., 2007).
While both oral contraceptive pills and metformin are recommended treatments for PCOS
by numerous endocrine societies worldwide, it should be noted that neither of them are approved
specifically for PCOS by a majority of regulatory bodies (Teede et al., 2010b).
Lifestyle modification, including dietary therapies and regular exercises, is another treatment
option and has been proved to be especially suitable for obese PCOS women (Moran et al., 2009)
as obesity worsens hormonal imbalances and exacerbates many adverse health consequences
associated with PCOS (Legro, 2012). There is evidence that for the obese PCOS population,
weight loss is significantly beneficial to ameliorate anovulation, menstrual irregularity, infertility,
psychological disorders as well as cardiometabolic risk factors associated with PCOS (Clark et al.,
1998; Huber-Buchholz et al., 1999). Even for PCOS women who have normal weight, weight
control should still be emphasised (Barthelmess and Naz, 2014).
Several treatments have been proved to be effective for infertility. Ovulation induction using
clomiphene citrate or clomiphene is probably the simplest one (Barthelmess and Naz, 2014; Azziz
et al., 2005). Another method of ovulation induction called laparoscopic ovarian drilling (LOD)
can be used in case that clomiphene citrate therapy fails to induce ovulation (Barthelmess and
Naz, 2014). This has achieved a remarkably high success rate of 84% in infertile PCOS women
(Gjønnaess, 1994). A major advantage of this method is that it improves hormonal balances.
Specifically speaking, both insulin resistance and excess androgen production are improved by
means of LOD (Seow et al., 2007), which also lowers risks of multiple pregnancies and ovarian
hyperstimulation syndrome frequently associated with clomiphene citrate therapy (Flyckt and
Goldberg, 2011). Furthermore, there is a higher chance for PCOS women to have a second child
by using LOD (Nahuis et al., 2011).
In vitro fertilisation (IVF) is probably a last resort for infertile PCOS women if the above
methods fail to create a pregnancy (Barthelmess and Naz, 2014), with similar rates achieved as
women received a mechanical tubal factor (Homburg et al., 1993). A new method called in vitro
maturation has been utilised although its implantation has not achieved rates as high as that
of traditional IVF procedure. However, it reduces the multiple pregnancy rate while maintains
a similar delivery rate compared to outcomes of IVF (Shalom-Paz et al., 2012).
The most common treatments of hirsutism are pharmacological and cosmetic therapies
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(Moghetti and Toscano, 2006; Azziz et al., 2005). Pharmacological therapies aim at reduc-
ing the androgen level in hirsute PCOS women while cosmetic therapies help remove the excess
terminal hair. In terms of pharmacological therapies, oral contraceptives, which suppress excess
androgen production by the ovary, is widely used although limited efficacy is observed. Some
studies have suggested that anti-androgen drugs such as cyproterone acetate, spironolactone
and flutamide appear to be highly effective treatments for hirsutism (Moghetti and Toscano,
2006). Laser treatment, which can result in large reduction in the severity of excess facial hair,
is generally considered to be an optimal alternative for hirsutism (Clayton et al., 2005). It is
also worth mentioning that eflornithine cream has recently become a licensed treatment, with a
main function of removing excess facial hair (Moghetti and Toscano, 2006).
Acne, another dermatological disorder caused by hyerandrogenism in PCOS patients, is often
treated by a combination of anti-androgens (mentioned previously as an option for treating
hirsutism) and traditional methods. Applications of retinoids, tretinoin, antibacterial agents,
azelaic acid, benzoyl peroxide as well as antibiotics such as topical treatments have been proved
to be effective for ameliorating acne but each of them has limitations (Moghetti and Toscano,
2006; Balen et al., 2005). For example, tretinoin may lead to skin irritation (Moghetti and
Toscano, 2006).
In conclusion, treatments of health consequences associated with PCOS are of a wide variety
and many of them are interrelated. Therefore, an integrated care plan accounting for various
aspects of PCOS is probably in need to achieve best treatment outcomes for PCOS population.
In the next chapter, I will introduce the evidence on major aspects of PCOS obtained from
systematic literature review, which provide further insight into the epidemiology of PCOS and
its associated morbidities.
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Chapter 2
PREVALENCE AND
COMORBIDITIES OF PCOS:
EVIDENCE FROM LITERATURE
2.1 Chapter summary
This chapter presents existing evidence on major aspects of PCOS identified through systematic
literature reviews conducted in common online databases including PubMed, EMBASE, The
Cochrane Library and CINAHL. This mainly includes data from published studies in terms of
the epidemiology of PCOS in the general population and the prevalence of morbidities associated
with PCOS (e.g. type 2 diabetes, metabolic syndrome) among PCOS population. The methods
used for the literature search and results from qualitative analysis are presented below.
2.2 Aim
The aim of the reviews was firstly to expand my knowledge of PCOS and then collect relevant
data to explore its epidemiology. Given there had been no review for the prevalence of PCOS
in the general population when the search was conducted, it was hoped that the findings from
the review can provide guidance for this aspect and if sufficient data were identified, statistical
modelling can be used to investigate the epidemiology of PCOS under a specific country context
or for different ethnic populations. Another objective was to collect relevant data for common
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metabolic disorders associated with PCOS, which can give me a better understanding of the
relationship between PCOS and other disease areas and potentially be relevant when proceeding
to the latter part of this thesis, e.g. economic evaluation of PCOS in the UK (discussed in detail
in Chapter 5).
2.3 Methods
2.3.1 Search strategies
A literature review for prevalence studies of PCOS was conducted up to January 2015 in the
following electronic databases: PubMed, The Cochrane Library, EMBASE, CINAHL. These are
common databases where medical literature was indexed. The following combination of essential
search words were used to identify studies evaluating epidemiology of PCOS:
((Stein-Leventhal syndrome) OR (polycystic ovary syndrome) OR
(PCOS)) AND ((prevalence) OR (incidence) OR (epidemiology))
The search was restricted to the English language.
Another search was conducted to identify studies that reported relative risk of common
metabolic disorders associated with PCOS, including impaired glucose tolerance (IGT), type 2
diabetes (DM2), metabolic syndrome(MetS). The methods for the key words search followed
exactly the same as the previous review (Moran et al., 2010b). The updated search extended
from March 2009 to January 2015 was conducted in the following databases: PubMed, EMBASE,
CINAHL (Cumulated index to Nursing and Allied Health Literature). Only articles published
in English language were considered.
2.3.2 Inclusion and exclusion criteria
The inclusion/exclusion criteria of prevalence studies were developed considering a list of
factors, e.g. population, intervention, comparator, outcomes and study type (abbreviated as
PICOS), as displayed in Table 2.1.
In terms of PCOS-related metabolic disorders, I followed the selection criteria as the
previous review (Moran et al., 2010b).
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Table 2.1: Eligibility criteria for study inclusion/exclusion.
Criterion Description
Population
Restricted to the general population, excluding patients seeking
care for specific diseases, e.g. type 2 diabetes, infertility
Intervention Not applicable
Comparator Not applicable
Outcomes Epidemiological outcomes of PCOS, i.e. prevalence, incidence
Study type
Studies were excluded if they were:
1. Reviews of PCOS
2. Prevalence of PCOS-related disorders
2.3.3 Data extraction
The following information was extracted from each of the prevalence studies considered:
 General characteristics of the study including author, year of publication, study period
and location
 Characteristics of the study sample, e.g. sampling scheme, sample size, number of PCOS
cases, age range, body mass index (BMI) and ethnicity
 Definition of PCOS (3 major criteria as suggested in Table 1.1, ICD-9 codes, medical
diagnosed PCOS, clinical PCOS, self-reported PCOS)
The data from studies of PCOS-related metabolic disorders were extracted in the same way
as the previous review, including setting and recruitment methods, diagnostic criteria of PCOS
and metabolic disorders (i.e. IGT, DM2, MetS), characteristics of sample population (e.g. age,
BMI), the total number of individuals who developed metabolic disorders in cases and controls
as well as the total number of individuals in case and control arm.
2.3.4 Quality assessment
To ensure the quality of studies included in the qualitative analysis and quantitative analysis
in Chapter 3, a methodological evaluation was performed for all the prevalence studies.
Given that few instruments have been designed to evaluate prevalence studies, I referred to
the Newcastle-Ottawa Scale (Stang, 2010) and the Joanna Briggs Institute critical appraisal
tool (Munn et al., 2014) and modified a few items within some of their categories. Seven items
with respect to various aspects were included (shown in Table 2.2):
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Table 2.2: Definition of items and score awarding criteria in quality assessment for prevalence
studies.
Item assessed Score 1 Score 0
Sampling
Appropriate sampling with
target population clearly defined
and probability sampling applied
Inappropriate sampling, i.e. convenient
sampling OR cases based on medical
records where schematic sampling was
not applied OR sampling scheme not
stated/unknown
PCOS measured
reliably and
objectively
Systematic screening performed
for sample population and PCOS
strictly defined
Medical records based on studies
where no systematic screening was
performed OR studies which used
self-reported PCOS (e.g. based on
questionnaire)
Response rate
Low non-participant rates (<30%)
of the initial target sample
population for further study
(systematic screening) OR low
non-response rate (<30%) of a
deliberated designed questionnaire
High non-response rate or refusal
rate to further study (≥30%) of the
initial target sample population
OR high non-response rate (≥30%)
of a deliberated-designed questionnaire
OR studies based on electronic
medical record where incomplete
patient information (i.e. missing data)
is a routine problem, leading to
incomplete ascertainment of cases
OR not stated/unknown
Sample size Sample size clearly stated Sample size not stated/unknown
Crude number
of cases
Crude number of cases clearly
stated
Crude number of cases not clearly stated
Age range
Age range of the sample
population is approximately same
as the reproductive age,
e.g. 15-45 years, 18-45 years,
17-45 years
Otherwise (narrower age range
OR upper/lower bound of age range
lying outside the limit, e.g. 18-24 years,
12-44 years OR not stated/unknown)
Ethnicity
Ethnicity of PCOS cases and
sample population clearly stated
Ethnicity not clearly stated/unknown
The Newcastle-Ottawa scale was applied as the critical appraisal tool to assess the quality
of studies of PCOS-related metabolic disorders, as suggested by the previous review by Moran
et al. (2010b). The Newcastle-Ottawa scale for the current analysis mainly assesses the following
three aspects:
 Selection of subjects in PCOS and control group
(a) Adequate case definition
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– yes, with independent validation? 1
– yes, i.e. record linkage or based on self-reports
– no description
(b) Representativeness of cases
– consecutive or obviously representative series of cases?
– potential for selection bias or not stated
(c) Selection of controls
– community controls?
– hospital controls
– no description
(d) Definition of controls:
– no history of disease (end-point)?
– no description of source
 Comparability of cases and controls on the basis of the study design and analysis
(a) control for important factor such as age and BMI (most important factors)?
(b) control for any additional factors?
 Exposure
(a) ascertainment of exposure
– secure record (i.e. surgical records)?
– structured interview where blind to case/control status?
– interview not blinded to case/control status
– written self-report or medical record only
– no description
1A star (?) can be awarded to this item if a study provides adequate case definition. Similarly, for the remaining
items, a star indicates providing adequate and quality information for the item assessed.
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(b) same method of ascertainment for case and control group
– yes?
– no
(c) non-response rate
– same rate for both groups?
– non-respondents described
– rate different and no designation
Note that studies with 3 or 4 stars in the selection domain AND 1 or 2 stars in comparability
domain AND 2 or 3 stars in exposure domain were considered to be of good quality; those with
2 stars in selection domain AND 1 or 2 stars in comparability domain AND 2 or 3 stars in
exposure domain were considered to be of fair quality; those with 0 or 1 star in selection domain
OR 0 stars in comparability domain OR 0 or 1 stars in exposure domain were considered to be
of poor quality.
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2.4 Results
2.4.1 Search results
For prevalence studies, the search initially produced 2420 citations in total. Papers with
irrelevant titles or abstracts, e.g. reviews of epidemiology of PCOS or prevalence studies of
PCOS-related diseases, were excluded leaving 41 records for further consideration. The reference
list of included studies and relevant reviews were searched in order to locate other potential
eligible articles and 3 additional studies were identified. Two presentation posters were excluded
as these studies did not appear to have been published in peer reviewed journals. One study
was also excluded after full-text screening because it evaluated prevalence of PCOS in patients
with DM2. Figure 2.1 presents a consort diagram summarising the search.
Figure 2.1: Flow chart of search process of prevalence studies.
In terms of major PCOS-related diseases, seven reviews and meta-analyses were identified
and presented in Table 2.3. Notice that I further collected more studies for IGT, DM2 and MetS
with the updated number of studies. The search end date and the new PCOS criterion included
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are shown in the brackets. The consort diagram for the updated search for IGT, DM2 and
metabolic syndrome related to PCOS is shown in Figure 2.2. The extended search initially
yielded 2029 articles and after excluding irrelevant titles or abstracts, 128 studies were included
for full-text screening. Of these, 76 were removed due to various reasons, e.g. duplicates (studies
with different titles but included same study population thus reporting repeated results), lack
of data or unable to determine prevalence or incidence of IGT, DM2 or MetS, studies without
controls. In the previous review by Moran et al. (2010b), 35 studies were included and after this
updated search, I eventually found 87 eligible studies for inclusion.
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Table 2.3: Systematic reviews and meta-analyses of major PCOS-related diseases.
Article Disease No. of studies Search end date Sources PCOS criteria
Moran et al. (2010b)
IGT
DM2
MetS
35 (87)
Mar. 2009
(Jan.2015)
MEDLINE
CINAHL
EMBASE
NIH
Rotterdam
(AES)
Anderson et al. (2014)
Cardiovascular
diseases
9 Up to 2014
MEDLINE
EMBASE
WHO
NIH
Rotterdam
AES
Self-reported
Qin et al. (2013)
Pregnancy
complications
27 Jul. 2012
PubMed
MEDLINE
EMBASE
Cochrane
NIH
Rotterdam
AES
Barry et al. (2014)
Endometrial,
ovarian
and breast
cancer
11 Oct. 2013
MEDLINE
EMBASE
Most
Self-reported
1 Rotterdam
Lim et al. (2012) Obesity 106 Nov. 2010
MEDLINE
EMBASE
CINAHL
Cochrane
PSYCINFO
NIH
Rotterdam
Barry et al. (2011)
Anxiety
Depression
12 Dec. 2010
MEDLINE
EMBASE
Cochrane
PubMed
Mostly
Rotterdam
Self-reported
Li et al. (2011b)
Quality of
life
5 Dec. 2009
MEDLINE
EMBASE
CINAHL
EMBR
CNKI
Wanfang
Vip
2 NIH
3 Rotterdam
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Figure 2.2: Flow chart of search process of metabolic disorders associated with PCOS.
2.4.2 Qualitative analysis
Results of prevalence
Forty-one studies were identified evaluating the epidemiology of PCOS in the general population
but I only retrieved the full text for 39 of them, with the remaining 2 articles inaccessible: there
was no link to follow on the websites where these two articles were indexed and attempts to
contact the original authors also failed to receive responses. However, in the abstracts of these
articles, Jiao et al. (2013) clearly presented source of recruitment, sample size, age range, eth-
nicity, definition of PCOS, prevalence data and the corresponding crude number of PCOS cases;
Sung et al. (2010) provided source of recruitment, age range, definition of PCOS, prevalence
data, with the crude number of PCOS cases and sample size irretrievable.
Geographically speaking, there were 10 studies in America, 6 in Europe, 11 in Asia, 10 in the
Middle East and 4 in Oceania. All studies were cross-sectional, with 4 (Lo et al., 2006a; Okoroh
et al., 2012; Christensen et al., 2013; Sirmans et al., 2014a) in the US reported using databases
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and 3 (Jiao et al., 2013; Al Khaduri et al., 2014; March et al., 2010) using a retrospective
study design. The sample size of the studies ranged from 50 to 12,171,830. Most of the studies
included sample population within a reproductive age range (15-45 years). The weight status
of the sample population varied significantly for sample population in different studies. The
characteristics of each study (displayed by geographical locations) are listed in Appendix A.
The prevalence of PCOS ranged from as low as 0.56% (Christensen et al., 2013) using the
NIH criterion in the US population to as high as 22.5% (Joshi et al., 2014) using the Rotterdam
criterion in Indian population, as marked by the data labels in Figure 2.3.
Studies of PCOS-related morbidities
The results from seven meta-analyses for PCOS-related morbidities suggested that the preva-
lence of a range of disorders is higher in PCOS patients and women with PCOS are more likely
to suffer from psychological problems, thus having reduced quality of life compared with the
healthy controls (shown in Table 2.4).
The updated search for metabolic disorders associated with PCOS included 52 studies
in additional to previous reviews. The number of studies for IGT/DM2 and MetS distributed
across different geographical locations is displayed in Figure 2.4.
The detailed characteristics of studies assessing IGT/DM2 and MetS in women with and
without PCOS are presented in Appendix B and C, respectively. Of all the studies eligible for
inclusion, we found 11 assessing PCOS by all the 3 major diagnostic criteria. Seven studies
were identified to use more than one definition of metabolic syndrome. The majority of the
studies assessed women of reproductive age (15-45 years) with the exception of 15 studies where
sample population consisted of either adolescents only or post-menopausal women only. Most
studies included overweight and/or obese PCOS patients with a mean body mass index (BMI) ≥
25kg/m2. Only 15 studies reported including PCOS patients with normal weight as a subgroup
or the mean or median BMI of sample population smaller than 25kg/m2 or < 23kg/m2 for East
Asian countries.
There are 50 studies assessing prevalence or incidence of either IGT or DM2 or both. The
majority of the studies used the NIH criterion of PCOS and 5 studies were found to use more
than one definition of PCOS. In terms of the definition of IGT and DM2, 14 studies used World
Health Organisation (WHO) criteria of IGT (Alberti and Zimmet, 1998) and 16 used ADA
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definition (American Diabetes Association, 2010). Six studies used OGTT but did not state the
specific cut-off value for diagnosis of IGT and DM2. Fourteen used other definitions (National
Diabetes Data Group, 1979) or did not specifically state.
For the assessment of MetS, a total number of 50 studies were identified. Most of the
studies applied the Rotterdam criterion for PCOS. Ten studies used more than one diagnostic
standard of PCOS and 7 studies reported using more than one definition of MetS. Twenty-
eight studies used Adult Treatment Panel III or modifications (Williams et al., 2002) whereas
10 used International Diabetes Federation (IDF) or modifications (Alberti et al., 2005). Seven
studies used American Heart Association/National Heart Lung Blood Institute or modifications
(Grundy et al., 2005) and 4 used WHO criteria (Alberti and Zimmet, 1998). Fourteen studies
were found to apply other criteria (Cook et al., 2003; de Ferranti et al., 2004; Coviello et al.,
2006; Caliskan et al., 2007; Rotterdam and ASRM-Sponsored, 2004a,b) or not specifically state
the definition of MetS.
The majority of the studies reported higher prevalence of IGT, DM2 or MetS among women
with PCOS compared with controls. While most of the studies assessed the point prevalence of
metabolic disorders of interest, a few long-term follow-up studies were identified. Five studies
evaluated the incidence of IGT and DM2 comparing women with and without PCOS. Legro
et al. (1999) performed a 2- to 3-year follow-up, reporting an odds ratio of 2.7 (95% CI: 0.7,
8.0) for conversion from normal glucose tolerance to IGT/DM2 in 71 women with PCOS and
25 controls. Boudreaux et al. (2006) conducted an 8-year follow-up study, presenting an odds
ratio of 2.07 (95% CI: 0.68, 6.30) for incidence of DM2 in 97 PCOS patients and 95 controls.
Hudecova et al. (2011a) followed age-matched populations over a period of 13.9 years and found
that 9.5% of the women with PCOS developed IGT and 8.3% had DM2. The corresponding
proportions for controls were 2.3% for IGT and 1.1% for DM2, respectively. Schmidt et al. (2011)
conducted a prospective 21-year follow-up study using 35 PCOS patients and 120 age-matched
controls. By the end of study, 7 out of 32 (22%) PCOS patients and 13 of 95 (14%) controls
had diabetes although the difference was not statistically significant. Another study by Celik
et al. (2014) reported that among women with PCOS who had normal glucose tolerance (NGT)
at baseline, 11.5% were observed to develop IGT. For PCOS patients who had IGT at baseline,
33.3% had converted into DM2. In contrast, 2.3% of the controls with NGT at baseline had
IGT at follow-up and no controls with IGT at baseline were observed to convert into DM2 later
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on. One study by Hudecova et al. (2011b) was found to assess the incidence of MetS comparing
84 women with PCOS and 87 controls. This study reported that 23.8% of women with PCOS
and 8% of controls had developed MetS by the end of study period.
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Figure 2.3: Summary of prevalence results reported by studies identified through literature
review (categorised by geographical location). The results are presented based on the diagnostic
criteria of PCOS. The two studies with a data label are the ones that reported the lowest and
highest prevalence of PCOS.
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Figure 2.4: The distribution of studies across geographical locations. The bars in blue and red
represent the number of studies identified in each continent reporting data on impaired glucose
tolerance (IGT)/type 2 diabetes (DM2) and metabolic syndrome (MetS), respectively.
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Table 2.4: Summary of results from reviews for PCOS-related
morbidities.
Study Sample size Main results
Moran et al. (2010b)
IGT: 1403
DM2: 59064
MetS: 6386
Higher prevalence of IGT, DM2 and MetS in PCOS compared to controls:
Odds Ratios (95% CI):
IGT: 2.48 (95% CI: 1.63, 3.77)
DM2: 4.43 (95% CI: 4.06, 4.82)
MetS: 2.88 (95% CI: 2.40, 3.45)
Anderson et al. (2014)
Stroke: 3194
CHD: 3974
Higher prevalence of non-fatal stroke and coronary heart disease in women
with PCOS but is not significant
Odds Ratios (95% CI):
Stroke: 1.61 (95% CI 0.82, 3.15)
Coronary heart disease (CHD): 1.63 (95% CI 0.96, 2.78)
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Study Sample size Main results
Qin et al. (2013) 124674
Higher prevalence of pregnancy complications in women with PCOS:
Odds Ratios (95% CI):
Gestational diabetes: 3.43 (95% CI: 2.49, 4.74)
Pregnancy-induced hypertension: 3.43 (95% CI: 2.49, 4.74)
Preeclampsia: 2.17 (95% CI: 1.91, 2.46)
Preterm birth: 1.93 (95% CI: 1.45, 2.57)
Caesarean section: 1.74 (95% CI: 1.38, 2.11)
Babies delivered by PCOS patients have lower birth weight
(weighted mean difference 0.11g 95% CI: -0.19, -0.03),
and higher risk of admission to neonatal ICU (OR 2.32 95% CI: 1.40, 3.85)
Barry et al. (2014) 72973
Higher prevalence of endometrial cancer in women with PCOS
(OR 2.79 95% CI 1.31, 5.95)
Higher prevalence of ovarian and breast cancer in women with PCOS but
is not significant (both ORs include 1)
Lim et al. (2012)
Overweight: 7633
Obesity: 9045
The prevalence of overweight and obesity is significantly higher in women
with PCOS compared with controls
(RR 1.95 95% CI: 1.52, 2.50; RR 2.77 95% CI: 1.88, 4.10 respectively)
Barry et al. (2011)
Depression: 2257
Anxiety: 377
Higher depression (mean difference: 0.82 95% CI: 0.73, 0.92) and anxiety
(mean difference: 0.54 95% CI: 0.33, 0.75) measured in terms of score are
observed in women with PCOS compared with controls
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Study Sample size Main results
Li et al. (2011b) 708
Women with PCOS demonstrate a significant lower score in all SF-36
dimensions compared with controls, with a reduction in score as high as
-23.86 (95% CI: 27.51, 20.21) for emotional role function and as low as
-4.55 (95% CI: 7.99, 1.11) for body pain.
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2.4.3 Results from quality assessment
The results from the quality assessment for prevalence studies are presented in Table 2.5
(ordered by geographical location). It should be noted that most of the prevalence studies
scored 5 and above (n=27), with 8 studies rated very low score (i.e. ≤ 3).
Given that there is a large number of studies reporting data on metabolic disorders
associated with PCOS, the results of quality assessment for these studies from my updated
search are presented in Appendix D. In a nutshell, most of the studies identified are cross-
sectional using non-randomised sampling. Consequently, the majority of the studies included
were considered to be at least at some degree of selection bias and reporting bias. For diagnosis
of PCOS, the exclusion of related reproductive disorders that may mimic symptoms of PCOS
was absent in 23 studies and the medication use that might affect the outcomes was not assessed
in 32 studies. The majority of the studies included used adequate diagnostic criteria for IGT,
DM2 and MetS and all studies described the methods used to measure the outcomes. Eight
studies did not report whether the same methods were applied to case and control to measure
the outcomes of interest. Most studies did not state whether subjects had family history of
IGT, DM2 and MetS. Four studies excluded controls with family history of DM, potentially
introduce bias towards a more significant odds ratio. Comparability of subjects was evaluated
based on age and BMI. Only 14 studies were found to strictly use age- and/or BMI-matched
populations with an additional 24 reported non-significant difference in mean age and/or BMI
between PCOS and control group.
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Table 2.5: Summary of quality assessment of prevalence studies.
Study
Appropriate
sampling
PCOS measured
reliably and
objectively
Response
rate
Sample
size
Crude number
of cases
Age range Ethnicity Score
America
Knochenhauer et al. (1998) 0 1 1 1 1 1 1 6
Azziz et al. (2004) 0 1 0 1 1 1 1 5
Goodarzi et al. (2005) 0 0 1 1 1 1 1 5
Lo et al. (2006a) 0 0 0 0 0 1 0 1
Okoroh et al. (2012) 0 0 0 1 0 1 0 2
Christensen et al. (2013) 0 0 0 1 1 0 0 2
Sirmans et al. (2014a) 0 0 0 1 1 1 1 4
Moran et al. (2010a) 0 1 1 1 1 1 1 6
Gabrielli and Aquino (2012) 1 1 1 1 1 1 1 7
Faria et al. (2013) 0 0 0 1 1 0 0 2
Europe
Michelmore et al. (1999) 0 1 0 1 0 0 1 3
Diamanti-Kandarakis et al. (1999) 0 1 1 1 1 1 1 6
Asuncio´n et al. (2000) 0 1 1 1 1 1 1 6
Sancho´n et al. (2012) 0 1 1 1 1 1 0 5
Lindholm et al. (2008) 1 1 1 1 1 0 1 6
Lauritsen et al. (2014) 0 1 0 1 1 1 1 5
Asia
Chen et al. (2008) 0 1 1 1 1 1 1 6
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Study
Appropriate
sampling
PCOS measured
reliably and
objectively
Response
rate
Sample
size
Crude number
of cases
Age range Ethnicity Score
Ma et al. (2010) 1 1 1 1 1 1 1 7
Li et al. (2013a) 1 1 1 1 1 1 1 7
Jiao et al. (2013) 0 1 0 1 1 1 1 5
Zhuang et al. (2014) 1 1 1 1 1 0 1 6
Sung et al. (2010) 0 1 0 0 0 1 0 2
Nidhi et al. (2011) 0 1 1 1 1 0 1 5
Gill et al. (2012) 0 1 0 1 1 0 1 4
Joshi et al. (2014) 1 1 1 1 1 0 1 6
Kumarapeli et al. (2008) 1 1 1 1 1 1 1 7
Vutyavanich et al. (2007) 0 1 1 1 1 1 1 6
Middle East
Musmar et al. (2013) 0 1 1 1 1 0 1 5
Hashemipour et al. (2004) 1 1 1 1 1 0 1 6
Mehrabian et al. (2011) 0 1 0 1 1 0 1 4
Asgharnia et al. (2011) 1 1 1 1 1 0 1 6
Tehrani et al. (2011) 1 1 1 1 1 1 1 7
Esmaeilzadeh et al. (2014) 1 1 1 1 1 0 1 6
Rashidi et al. (2014) 1 1 1 1 1 1 1 7
Yildiz et al. (2012) 0 1 1 1 1 1 1 6
Al Khaduri et al. (2014) 0 0 0 1 1 1 0 3
Attlee et al. (2014) 0 0 1 1 1 0 1 4
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Study
Appropriate
sampling
PCOS measured
reliably and
objectively
Response
rate
Sample
size
Crude number
of cases
Age range Ethnicity Score
Australia
Lowe et al. (2005) 0 0 1 1 1 0 0 3
March et al. (2010) 0 1 0 1 1 0 1 4
Boyle et al. (2012) 0 1 1 1 1 1 1 6
Joham et al. (2013) 1 0 0 1 1 0 1 4
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2.5 Discussion
2.5.1 Prevalence studies identified
For prevalence studies identified from the literature, it is suggested that for the same study,
the prevalence under the NIH criterion is always the lowest, followed by that estimated using
the AES criterion and then the Rotterdam criterion. This verifies the inclusive and exclusive
relationship between the 3 major criteria in Table 1.1.
In term of sample size, there are 4 studies (Lo et al., 2006a; Okoroh et al., 2012; Christensen
et al., 2013; Sirmans et al., 2014a) in the US using fairly large sample sizes based on electronic
medical records. However, all these studies presented a much lower prevalence of PCOS com-
pared to community-based studies, underlying the fact that PCOS is a syndrome without much
awareness by both the public and the healthcare workers. As a consequence, women with PCOS
often do not seek for care and the diagnosis of PCOS is likely to be under-reported by clinicians.
However, there are some concerns about the quality of the studies included which may
limit the interpretation of results from this qualitative analysis. As there are few instruments
specifically designed (i.e. the Newcastle-Ottawa scale for case-control and cohort studies) for
prevalence studies, the formal evaluation of included studies was challenged. It is suggested
by Munn et al. (2014) that the followings are all essential factors to be considered for preva-
lence studies: sampling scheme, sample representativeness, recruitment strategy, sample size
calculation, description of study subjects and settings, response rate, standard criteria used for
measurement of a specific condition, reliable measurement instrument, appropriate statistical
analysis. However, few studies met all of the above criteria. For example, there were differences
in the outcomes due to hormonal assays and measurement techniques (Knochenhauer et al.,
1998; Asuncio´n et al., 2000). The understanding and application of the diagnostic criteria of
PCOS in distinct studies also varied as some studies reported using less stringent definitions
(Asuncio´n et al., 2000). Selection bias was also observed because not all studies used an entirely
randomised sampling scheme (Diamanti-Kandarakis et al., 1999). Other concerns with respect
to study design included low response rate (Azziz et al., 2004), self-rated questionnaire (Gabrielli
and Aquino, 2012), biases against the diagnosis of PCOS (e.g. a negative evaluation is easier
to be made compared with a positive one since a confirmed diagnosis of PCOS requires a full
blood test whereas there were potential cases with suggestive symptoms who did not complete
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the full evaluation) (Azziz et al., 2004). The above factors all have influence on the accuracy of
the prevalence estimates in individual studies.
2.5.2 Studies for PCOS-related morbidities
The results from the reviews suggested that the prevalence of common metabolic disorders and
cardiovascular diseases is generally higher in women with PCOS compared with the general
population. PCOS patients are also at elevated risk of pregnancy complications and their ba-
bies tend to have higher chance of suffering from neonatal complications. In addition, women
with PCOS are more likely to develop endometrial cancer due to irregular menstruation. The
consequences of PCOS exert significantly negative psychological impact on patients, which fur-
ther lead to an overall reduced quality of life. Methodological issues raised by these reviews
include that confoundings were not able to be controlled for when examining the association
between PCOS-related disorders and PCOS. For example, these confoundings may include age,
concomitant treatments, diet history, socio-economc status (Anderson et al., 2014; Lim et al.,
2012).
The results from the updated search for metabolic disorders associated with PCOS also
largely supported the main conclusions raised in the previous review on this aspect. However,
methodological quality is a concern, which limit the interpretation of results from studies in-
cluded in the systematic review. For example, the majority of the studies used non-randomised
sampling scheme and therefore, were found to be at high risk of bias. In view of study design,
most studies used cross-sectional design, with PCOS and metabolic risk factor status being
evaluated concurrently at a single time point, which raised the issue of ‘prevalence bias’. For
instance, PCOS patients who suffer from the disease for a longer time are more likely to de-
velop metabolic disturbances whereas the sample is taken at a single time point. Consequently,
the prevalence odds ratios tend to overestimate the true risk factor because for most studies,
PCOS patients with different durations of disease history are equally weighted, with the former
being over-represented. There is also concern about the optimal comparison group as the con-
trol population in many studies comprised of population controls or pre-determined clinically
examined individuals without PCOS or even subject with partial PCOS features. Evidence has
been found to support an unselected age-matched control population rather than predefined
non-PCOS population to be the optimal comparison group such that this prevalence bias can
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be minimised (Bloom et al., 2006). The previous review by Moran et al. (2010b) suggested a
prospective (or retrospective) cohort study design as it allows the timing and directionality of
event (incidence) to be clearly established.
Despite the challenges mainly related to study design, I was able to explore the associations
of PCOS with a range of diseases and found that PCOS is likely to worsen many health aspects of
women, urging the need for early screening and monitoring as well as an integrated health plan.
In the next chapter, I will introduce the modelling approach and results obtained from the
modelling for the prevalence of PCOS in different ethnic groups and the prevalence of morbidities
associated with PCOS. These are largely based on modelling the data identified in the systematic
literature review in this chapter.
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Chapter 3
ESTIMATING
ETHNICITY-SPECIFIC
PREVALENCE OF PCOS AND
THE RISK OF MORBIDITIES
ASSOCIATED WITH PCOS
3.1 Chapter summary
In this chapter, I firstly introduce background information of evidence synthesis and meta-
analysis given that these are the key concepts leading through the whole chapter. I then describe
the methods of prevalence estimation for both PCOS and its associated morbidities. After
that, I discuss the generalised models for meta-analysis using a Bayesian approach, which was
motivated by the need to integrate data from multiple sources for comparing the relative risk
of common metabolic disorders associated with PCOS. I then present results from evidence
synthesis and a package created for R named bmeta. The package is largely based on the
generalised meta-analytic models and various functions of this package are illustrated through
examples, with sample data from the published studies for PCOS. The web application of the
package (bmetaweb) is also presented, which was created to facilitate users without knowledge
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of R. It should be noted that a paper derived from prevalence estimation of PCOS among
different ethnic groups in this chapter has been published in Oncotarget (Ding et al., 2017).
3.2 Background
It is often the case that important medical questions are studied more than once by different
research teams at different locations and the outcomes from small studies can be diverse and
conflicting, which may result in difficulties in making clinical decisions (Haidich, 2010). For
example, as described in Figure 3.1 (a fictional example is used here), suppose that four studies
conducted in different countries have been found to provide odds ratio (OR) comparing the
relative risk of developing type 2 diabetes in PCOS and general population. In such case,
combining available information from multiple sources to generate an integrated result may
provide more indications for decision making.
Figure 3.1: A fictional example: synthesise evidence from individual studies conducted in dif-
ferent countries to compare the relative risk of diabetes in PCOS and general population. Here
four studies conducted in three countries all provided odds ratio and it is of our interest to
estimate the ‘true’ effect of PCOS on the risk of diabetes.
Meta-analysis is a commonly used statistical approach to achieve this goal by integrating
results from independent studies and is considered to play an essential role in evidence-based
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medicine (Sackett et al., 1996). While meta-analysis based on Frequentist methods has been
widely applied in medical research, the application of a Bayesian approach can be beneficial in
the context of meta-analysis for several reasons (Sutton and Abrams, 2001a; Spiegelhalter et al.,
2004; Gelman et al., 2014). The main advantage of a Bayesian approach is that the observed data
can be complemented by a formal representation of prior belief to produce posterior probability
distributions for parameters of interest, especially when there is little information provided by
the observed data. Incidentally, this is exactly the case for studies that estimated the prevalence
of PCOS in different ethnic groups as only a limited number of high quality studies has been
identified through the literature search. For example, the prevalence of many chronic diseases is
not expected to go beyond 50% in the general population and prior distributions based on this
information can be included in the models. This helps stabilise the estimates, e.g. if we know the
prevalence of a disease is expected to be around 5% and is unlikely to go beyond 10%, a small
variance associated with the parameter representing the prevalence of the disease can be defined.
This reduces the variances of the estimates we finally obtain, thus increasing the precision of the
estimates. Moreover, compared to the traditional Frequentist methods where the parameters are
often assumed to be fixed values (i.e. maximum likelihood estimation), the Bayesian approach
allows to take fuller account of the uncertainties related to models and parameter values by
producing a distribution of parameters (also called the posterior distribution) to sample from.
This is a crucial aspect in decision making as in such way, the uncertainties can be propagated,
e.g. in models that are used for health economic evaluation. These advantages motivate me to
use the Bayesian approach in prevalence estimation for both PCOS and its associated morbidities
as well as to develop a package including a set of Bayesian meta-analytic models.
3.3 Aim
In Chapter 2, 41 prevalence studies have been identified, with a few of high quality and po-
tentially eligible for modelling. Therefore, the first objective was to establish the prevalence of
PCOS among different ethnic populations. The second objective was to establish the prevalence
of PCOS-related disorders in PCOS population. Along with this, I also aimed at creating some
basic templates of meta-analytic models using Bayesian approach. This is because that although
the idea of performing meta-analysis within the Bayesian framework has been widely accepted
and recommended (Sutton and Abrams, 2001b; Higgins et al., 2009) due to obvious advantages
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as discussed previously, there is no package identified that designed for Bayesian meta-analysis
(e.g. a set of models with vague prior which can be modified later on according to users’ need)
and its relevant post-hoc analysis. In other words, by then, most applied implementation of
meta-analysis are conducted under the Frequentist paradigm. For example, standard packages
such as ‘RevMan’ developed by the Cochrane Centre (Collaboration et al., 2011), ‘meta’ or
‘metareg’ in STATA (Sterne et al., 2008) and the 3 existing packages ‘metafor’,‘rmeta’ and
‘meta’ in R (Viechtbauer et al., 2010; Lumley, 2009; Schwarzer, 2007) all compute maximum
likelihood estimates. Therefore, it would provide much more convenience if such a package that
can perform Bayesian meta-analysis is available.
3.4 Methods
3.4.1 Estimating prevalence of PCOS
Modelling approach
This section presents the Bayesian hierarchical model used for the prevalence estimation. The
underlying reason for using a Bayesian approach is discussed previously in the background of
this chapter. The software used to perform the analysis is Just Another Gibbs Sampler
(JAGS, Plummer et al., 2003). It is a software that can perform simulations from Bayesian
hierarchical models using Markov Chain Monte Carlo (MCMC) and the concepts related to
MCMC will be discussed later. The modelling approach is described through an explicit example
of the White population and the same method was applied to establish the prevalence of PCOS
for all the ethnic groups.
The model includes several modules. Suppose that there are I studies in total for a certain
ethnic group (e.g. Caucasian) and for each study i = 1, 2, . . . , I, the number of PCOS cases out
of the total female population was observed. A Binomial distribution was used to model data
in these studies:
yi ∼ Binomial(pii,mi),
where yi is the total number of women observed to develop PCOS in the ith study; pii represents
the probability of developing PCOS for the population in study i and mi is the total number of
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women in the study.
A logistic link (defined as log( p1−p), where p is the probability of a binary outcome, i.e.
success or failure) was used to model the probability of developing PCOS in this case. The
most obvious reason for applying a logit link is that it rescales a probability with values varying
between −∞ and ∞.
The model is specified as
logit(pii) = βi ∼ Normal(µ, σ2),
where βi is the study-level prevalence of PCOS on the logit scale and was further assumed to
follow a Normal distribution with a mean µ and variance σ2. The parameter µ represents the
pooled mean prevalence of PCOS (on the logit scale) for all the studies using population of the
same ethnicity. This can be transformed back to the natural scale and the overall prevalence p
was calculated as follows:
p =
exp(µ)
1 + exp(µ)
.
This module was completed by including some prior distributions for µ and σ and several
versions of priors were attempted. For example, the simplest model specification assumes:
µ ∼ Normal(µˆ, σ2)
σ ∼ Uniform(0, 2).
It is often the case that “off-the-shelf” vague priors are used for the parameters in the
model. This would mean that the probability of developing PCOS is 50% and one does not
favour any value between 0 and 1 (which can be represented by µˆ = logit(p) = log( 0.51−0.5) = 0
and a large value such as 10, on the logit scale, for σ). However, this was considered to be
inappropriate because we do not expect such high prevalence of PCOS in the general population
(e.g. >20%) associated with high uncertainties. Therefore, some common-sense information was
used on what the likely range of probability of the condition may be and the prior for µ was
informed accordingly. For example, values ranging from 2.5% to 15% for µˆ were considered to
be reasonable.
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It should be noted that for most ethnic groups, fewer than 5 studies met the inclusion criteria
for modelling (e.g. pooling is inappropriate for studies that used electronic databases and those
that sampled study population from the community). Given that the amount of information
present in the data is limited, the estimation for the parameter σ is likely to be associated with
high variability. In particular, if a very vague prior specification, i.e. Uniform(0,k), for some
relatively large value k was selected, it is possible that the data would not be able to update
this in a consistent way, resulting in a highly unstable posterior distribution for statistical
inference. To mitigate this problem, it is possible to include more information in the prior,
for example, here, a half-Cauchy distribution was specified as prior for σ. This distribution
can be expressed as: σ ∼half-Cauchy(B), where B is the population median residual standard
deviation (also called the scale parameter). The half-Cauchy distribution belongs to the half-t
family of distributions and is recommended when a more informative prior is needed (Gelman
et al., 2006). Its probability density function is defined as:
f(x) =
2
piB
1
1 + (x/B)2
, x > 0
Note that the scale parameter B, can be modelled assuming a vague prior, e.g. a uniform
distribution with lower and upper bound as 0 and 100. By assigning proper values for the scale
parameter B, a weakly but reasonably informative prior can be included. For example, although
having heavy tails, the half-Cauchy distribution is less likely to produce extreme values and
distort inferences in the area of high likelihood. Therefore, including a half-Cauchy distribution
for the variance is advantageous in terms of allowing for outliers and accommodating small
variances close to zero.
One technical complication is that the half-Cauchy distribution is not one of the standard
distribution in software such as JAGS. However, it can be proved that if
εσ ∼ Gamma(0.5, 0.5)
Zσ ∼ Normal(0, σ2Zσ)
σ2Zσ =
1
B2σ
,
where Bσ ∼ Uniform(0, k) for some upper limit k. Then σ = |Zσ |√εσ follows a half-Cauchy distri-
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Figure 3.2: Graphical representation of the half-Cauchy distribution with different scale param-
eters.
bution with a median of Bσ (Lunn et al., 2012). Using this coding trick allows us to implement
the half-Cauchy model in a relatively simple way.
In our case, we set B ∼ Uniform(0, 0.5) and Figure 3.2 shows different half-Cauchy distri-
butions for varying values of the scale B. As is possible to see, using an upper limit of 0.5 still
ensured that the prior for σ is concentrated closed to 0, while still allowing for large values (up
to around 20 — recall that σ is actually defined in the log scale).
The computation approach for this analysis is Markov Chain Monte Carlo (MCMC), which
is a widely used sampling method (Gamerman and Lopes, 2006; Gilks et al., 1996). A funda-
mental concept of MCMC methods is Markov chain. Consider a sequence of random variables
X0, X1, X2, . . . where we assume that the observation Xt+1 only depends on the current one Xt
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but does not depend on any observations before the previous one. This is equivalent to:
p(xt+1 | x0, x1, . . . , xt) = p(xt+1 | xt).
Note that MCMC methods largely depend on the construction of a Markov chain that can
converge to a target distribution p, from which one can simulate the distribution of interest,
e.g. a posterior for a set of parameters. The distribution p is formally called the stationary
distribution of the Markov chain. A stationary distribution can be described as that the prob-
ability distribution remains unchanged as time t progresses and is independent of the initial
value of X0, i.e. the distribution p no longer changes. In other words, the chain forgets where
it starts in the end and enters into an “equilibrium” state where there is no more change in the
distribution even we run the chain for a further number of iterations. In practice, under fairly
general regularity conditions (MCMC works if the chains are irreducible and aperiodic such
that convergence to the stationary distribution can be reached when the number of iterations
becomes larger) (Brooks et al., 2011), the chain will converge after a sufficient large number
of iterations (also called burn-in). Once convergence is reached, it is possible to compute any
statistics such as mean and standard deviation from this distribution using random sampling
(i.e. Monte Carlo).
One of the most commonly used algorithms for simulating Markov chains is the Gibbs
sampling (Geman and Geman, 1984). The idea of this sampling method is to generate posterior
samples by blocking one parameter each time to sample from its conditional distribution, with
the remaining parameters fixed to their present values. More specifically, suppose the parameters
of interest are defined as θ = (θ1, θ2, . . . , θk) and the observed data are represented by y, then
the sampling methods can be described as follows:
 Select arbitrary starting values for all the parameters of interest, e.g. θ
(0)
1 , θ
(0)
2 , . . . , θ
(0)
k ;
 Sample a new value, θ
(1)
1 , for θ1 from the conditional distribution p(θ1 | θ(0)2 , θ(0)3 , . . . , θ(0)k , y);
Sample a new value, θ
(1)
2 , for θ2 from the conditional distribution p(θ2 | θ(1)1 , θ(0)3 , . . . , θ(0)k , y);
Note that since a new value for θ1 has been sampled before, this most “recent” value is
included as an element to be conditioned upon.
This procedure continues until a new value of all the parameters has been sampled from
the conditional distribution, e.g. sample θ
(1)
k from p(θk | θ(1)1 , θ(1)2 , . . . , θ(1)k−1, y)
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 Repeat the previous step a sufficient large number of times until the chain converges and
then generate a sample from this distribution p.
MCMC is particularly important in Bayesian inference because it is often difficult to perform
analytic examination on the posterior distributions given its complexity. MCMC allows one to
take random samples from a distribution even without any knowledge of its mathematical prop-
erties.
Given the paucity of data, the estimates obtained from the posterior distribution are expected
to be largely driven by the priors. I attempted to address this by looking at the Deviance
Information Criterion (DIC, Spiegelhalter et al., 2002) of each model. The DIC is a common
measure for comparing Bayesian models and can be used to perform model selection. The
definition of DIC is described in the following steps. The model deviance, a likelihood-based
measure of the model fit, is defined as:
D(θ) = −2 log p(y | θ),
where θ represents the parameters of interest.
It is often the case that models with a large number of parameters are more likely to be
subjected to ‘over-fitting’. In other words, these models may fit the observed data (also called
training dataset) quite well, while perform much worse for other datasets of similar structure.
However, since these model fit the training dataset quite well, they are associated with smaller
values of D(θ) and therefore, it may be of interest to penalise the complexity of a set of different
models. This can be quantified by the following function:
pD = Eθ|y[D(θ)]−D(Eθ|y[θ])
= D −D(θ),
where D is the posterior mean deviance and D(θ) represents deviance evaluated at the posterior
mean of the parameters. pD measures the complexity of the model structure and the strengths
of the prior at the same time. The DIC is then defined as follows:
DIC = D(θ) + 2pD
= D + pD.
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Models with lower values of DIC are considered to perform better. However, only differences
in the DIC are of interest whereas its absolute value is not relevant. This is because that the
computation of model deviance depends on the observed data. A set of alternative models can
then be compared by DIC however it may be possible that none of the models in comparison
are correct.
It should be noted that the use of DIC may be a concern when the models are only populated
by limited amount of information. This is due to the fact that the posterior distribution of the
parameters of interest can be approximated to a Normal distribution only when the sample size
of the observed data is large enough.
Despite this limitation, the DIC is simple to be obtained in the MCMC procedures and it
can also be used to produce results by model averaging. Model averaging is a formal approach
to account for model uncertainties in the predictions from a series of competing models. From
a Bayesian perspective, the main interest of model averaging would be laid on the posterior
predictive distributions, which can be computed as a weighted average of the model specific
posterior predictive distribution (Hoeting et al., 1999). Suppose there is a set of models M =
(M1,M2, . . . ,MH), the weights attached to individual models can be defined using the following
formula (Baio, 2012):
wh =
exp(−0.5∆DICh)
ΣHh=1 exp(−0.5∆DICh)
, (3.1)
where ∆DICh =| minh(DICh)−DICh | and h = 1, ...,H, indicating the set of models.
For the current analysis, models with relatively small DIC were identified and the model
averaging methods introduced above was applied to combine results from these models. This
means that models with lower DIC were still favoured, however, instead of choosing a discrete
cut-off (the lowest DIC) and discarding information from all the other models, our assessment
is more continuous and effective by using the results from all the models in a principled way.
Data source and selection criteria for modelling
The source of data for prevalence estimation were from the literature review conducted in Chap-
ter 2. Studies rated less than 5 in the quality assessment were deemed as low quality studies
and therefore, were not included for further analysis (refer to Table 2.2). It should be noted
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that I also excluded studies that did not apply the same diagnostic criterion as the majority of
the studies reporting data for the same ethnicity (see Table 3.1). For example, Lauritsen et al.
(2014) applied the Rotterdam criterion of PCOS whereas the other studies conducted in the
Europe all followed the NIH criterion of PCOS. Another 5 studies were removed (Musmar et al.,
2013; Hashemipour et al., 2004; Mehrabian et al., 2011; Asgharnia et al., 2011; Zhuang et al.,
2014) due to that the age range of study population recruited was either narrower or wider than
the reproductive age range (e.g. 17-18 years, 14-18 years, 12-44 years). Similarly, given that
the age range of the study population are all different, statistical modelling was considered to
be inappropriate for certain ethnic groups, i.e. South Asians (from India and Sri Lanka) and
Australians. Likewise, modelling was not applied to ethnic populations such as Mexicans and
Thai since only one study was identified to report relevant data. This is because if the result
from a single study is unreliable, one would have no choice but to include it as the ‘best’ source
of data, which largely bias the estimation.
For studies that reported data for more than one ethnic group (i.e. White and Black pop-
ulation), data for subgroups were used to populate the model. In other words, data from all
eligible studies for a certain ethnic groups were included for modelling regardless of the country
origin of the studies. For example, studies conducted in the US and Europe providing data for
the Caucasians were synthesised together to generate estimates for the White population.
3.4.2 Modelling approach for comorbidities of PCOS
Meta-regression is an extension of standard meta-analysis in order to control for the moderator
effect such as age or ethnicity (Borenstein et al., 2009). However, it should be noted that meta-
regression accounts for the effect of study level covariates (e.g. mean age of the population in
one study) rather than those at individual level.
The random-effects meta-regression for binary outcome was used to establish the prevalence
of morbidities associated with PCOS, i.e. impaired glucose tolerance (IGT), type 2 diabetes
(DM2) and metabolic syndrome (MetS). Meta-regression rather than meta-analysis was used
because variation in the prevalence of IGT, DM2 and MetS in different geographical locations
was expected and therefore needed to be controlled for. The meta-regression model was fitted
using Bayesian methods such that the observed data were complemented by information from
empirical studies reporting prevalence estimates of metabolic disorders in the general population
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residing in different geographical locations. A random-effects model was selected as it is more
sensible to assume that the ‘true’ study effect varies across studies in a same region.
The prevalence of DM2 in PCOS patients (using the NIH criterion) in comparison with
controls was used as an illustrated example. The results for other combinations of metabolic
morbidities and diagnostic criteria of PCOS were obtained using the same method. The model
includes several modules.
Suppose that there are I eligible studies and each study i = 1, 2, . . . , I has 2 arms. The total
number of events out of the total number of PCOS patients and controls was observed. Let yi0,
yi1 denote the total number of events observed in case and control arm, respectively, for study
i. Similarly, ni0 and ni1 were defined as the total number of cases and controls. A Binomial
distribution was used to model these studies:
yi0 ∼ Binomial(pii0, ni0)
yi1 ∼ Binomial(pii1, ni1),
where pii0 and pii1 represent the probability of developing DM2 in the control arm and among
women with PCOS, respectively.
A logistic regression was used to obtain the pooled mean probability of developing DM2 in
women with PCOS and controls, respectively, in study i:
logit(pii0) = α+ β1Xi1 + β2Xi2 + β3Xi3
logit(pii1) = α+ β1Xi1 + β2Xi2 + β3Xi3 + δi,
where α is the baseline odds for controls in studies conducted in the Europe and the prevalence of
DM2 is reported to be 6.8% in this region; δi is the incremental risk of developing DM2 for women
with PCOS, in study i. Xi1,Xi2,Xi3 are indicators for region and were assumed to generate some
impacts on the study effect. Studies have suggested that the prevalence of DM2 is the highest in
North America (9.6%), then in a descending order by South East Asia (8.7%), South America
(8.2%), with the lowest prevalence reported in the Europe (IDF, 2013). Since Europe was
assumed to be the reference category, β1, β2, β3 were used to represent the incremental prevalence
of DM2 in North America, South East Asia and South America, respectively, compared with
that in the Europe, e.g. β1 was included to reflect the mean difference in prevalence of DM2
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comparing North America and Europe.
The model was completed by including prior distributions for all the parameters. For exam-
ple, the following distribution was included for α, which indicates that the prevalence of DM2 in
the general population residing in the Europe is expected to be 6.8% with some small variability:
α ∼ Normal(−2.62, 0.5).
Note that logit(0.068) = −2.62 and in this way, evidence from pilot studies was converted
to work as the prior distribution to inform our model. The variance of this prior distribution
for the reference group is small because the prevalence of DM2 is expected to be within some
reasonable range, e.g. 0-30% (Figure 3.3), with probabilities ranging from 0-15% more likely to
be favoured when the simulation procedure proceeds.
The incremental prevalence of DM2 for the remaining regions in comparison with Europe is
represented by the prior distribution of β1, β2, β3:
β1 ∼ Normal(0.375, 0.01)
β2 ∼ Normal(0.266, 0.01)
β3 ∼ Normal(0.202, 0.01).
Here the expected prevalence (mean) estimates correspond exactly to the regional estimates
mentioned previously, i.e. 9.6% in the North America, 8.7% in the South East Asia and 8.2%
in the South America. The variance of these prior distributions is small because these are all
population level estimates and therefore, high uncertainties are not expected. Note that when
two independent Normal distributions are summed up, the resulting distribution is also Normal
and the variance is equal to the sum of the variances of the two Normal distributions. Taking
studies evaluating the prevalence of DM2 in North America as an example, the regional indicator
β1 is equal to 1 so the probability of the disease is in fact based on the sum of the distribution of α
and β1. Since again the prevalence of DM2 in the general population residing in North America
is believed to lie within some reasonable range, the variance of the prior distribution included
for β1 is expected to be small. The resulting distribution after summing up the distribution of
α and β1 is shown in Figure 3.4. We can see that most of the bars lie within the range of 0
and 0.15, suggesting that the prevalence of DM2 is most likely to be in a range of 0-15% but
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Figure 3.3: Graphical representation of the prior distribution included for the prevalence on a
natural scale, which reflects the assumption made for the reference region (Europe) that the
prevalence of DM2 is centred at 6.8%. The horizonal bar in bold represents the 95% prior
interval.
unlikely to go beyond 25% for this given region. This figure reflects the assumptions made for
the prevalence of DM2 in North America.
The study-specific odds ratio (on log scale), δi, was assumed to follow a Normal distribution
with a mean of µ and a variance of σ2 and µ is the pooled odds ratio for all studies.
δi ∼ Normal(µ, σ2)
I selected a prior for µ following a Student t-distribution. This is because the data included
for this analysis are quite heterogeneous (e.g. some of the studies reported a high risk of diabetes
in the PCOS patients compared with the controls in contrast with other studies) and the Student
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Figure 3.4: Graphical representation of the prevalence of DM2 in North America, which is the
resulting distribution after summing up the distribution of α and β1. This is consistent with
the assumption made for North America that the prevalence of DM2 is centred at 9.6%. The
horizonal bar in bold represents the 95% prior interval.
t-distribution has heavy tails which can accommodate outliers. The degree of freedom of the
t-distribution is assumed to follow a uniform distribution within a range of 0 to 8. This is
because a degree of freedom of 4 is suggested to limit shrinkage too much (i.e. can generate too
extreme results). However using a Uniform(0,8) ensures on average a prior value for the degree
of freedom of 4, while allowing for some variability around it (Berger, 1990).
µ ∼ tv
v ∼ Uniform(0, 8)
Note that JAGS uses a “generalised” t-distribution where centrality and precision (i.e. inverse
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of the variance) need to be specified. In our case, a zero mean and a precision of 0.5 are included
and the variance can then be computed using the formula vτ(v−2) for v ≥ 0 where τ is the precision
(Lunn et al., 2012). This is more or less equivalent to a Student t-distribution with zero mean
and a variance of 4, which is reasonably vague given that this is on the log scale. The standard
deviation σ is assumed to follow a Uniform distribution with a lower and upper bound of zero
and one, respectively (also considered reasonably large on the log scale).
σ ∼ Uniform(0, 1).
The graphical representation of the prior distribution for this parameter obtained from for-
ward sampling (running the simulation without including the observed data) is illustrated in
Figure 3.5. The majority of the bars lie within a range of 2 to 6, suggesting that the risk of
diabetes comparing PCOS patients and the general population is most likely to be in this range.
This assumption was validated with some clinical experts: the graphical illustration of the prior
distributions was presented to clinicians, who considered these distributions sensible to work as
prior information to complement the observed data.
The data from literature review were used to populate the meta-regression model and the
results from quality assessment for all the studies considered are introduced in Chapter 2.
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Figure 3.5: Graphical representation of the prior distribution included for the pooled odds ratio
µ, which reflects the assumption that women with PCOS are generally 2-6 times more likely to
develop DM2 compared with the general female population.
3.4.3 Generalised models for meta-analysis using Bayesian approach
In this section, I introduce generalised meta-analytic models using Bayesian approach, which
forms the basis of all models included in the bmeta package for R (Ding and Baio, 2016). The
modelling approach for the binary outcomes in the previous section was extended to fit other
types of outcomes such as continuous and count outcomes.
The framework of models included can be summarised as follows. Suppose yik denotes the
number of events or mean (i.e. continuous data) observed in arm k of study i. This is generally
modelled as
yik ∼ p(yik | θik),
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where the possible distributional assumptions are
p =

Binomial, binary outcome
Normal, continuous outcome
Poisson, count outcome
and θik = (φik,ψik) is a vector of parameters, specific to the chosen distribution (i.e. the mean
and the variance, in the case of a Normal distribution). Here φik represents the parameter of
interest whereas ψik is a vector representing a list of other parameters in the model.
Model Parameter of interest (φik) Nuisance parameters (ψik)
Binomial piik arm-specific probability of the event nik sample size of arm k
Normal µik arm-level mean τik arm-level precision
Poisson λik arm-specific event rate tik person-time in the follow-up in arm k
A link function g(·) is then used to construct a linear predictor for the main parameter
of interest, possibly as a function of observed covariates. For binary, continuous and count
outcome, this is considered to be the logit, identity and log, respectively. In general terms, this
is constructed as
g(φik) =

α+Xiβ, if k=0 (control arm)
α+Xiβ + δi, if k=1 (case arm)
where α represents the ‘baseline’ information of parameter of interest for the control arm (e.g.
probability of an event on logit scale for the control arm when the outcome is binary). δi is
the study-specific impact of an exposure (for observational studies) or intervention effects (for
randomised control trials). Xi is a matrix with covariates information (i.e. binary, continuous or
categorical variables) for the i−th study and β is a vector of coefficients for regression parameters
of interest. Xi and β only exist when a meta-regression is performed.
For fixed-effects models, it is assumed that all studies estimate the same intervention effect.
While for the random-effects models, the assumption of exchangeability between studies is made
and therefore, the ‘true’ intervention effect is modelled probabilistically:
δi = µ Fixed-effects model
δi ∼ p(δi | µ) Random-effects models
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where µ is the pooled estimate and p is a probability distribution of µ.
The model is completed by including minimally informative prior for the model parameters.
For example, for binary outcome, a Normal prior is included, e.g. Normal(0,10000), for the
pooled estimate µ. This indicates that the probability of developing a certain disease is 50% but
is not likely to favour any particular value within the range of 0 and 1. This is a vague prior
with large variability to represent the uncertainties so the results would be driven by the data.
These generalised models can be applied to synthesise evidence from multiple sources for the
major data types in the medical research.
3.5 Results
3.5.1 Prevalence of PCOS in different ethnic populations
Using the modelling approach described in the Section 3.4.1, the following results were obtained
(see Table 3.1).
For the NIH criterion, the prevalence of PCOS for White women was estimated at 5.5%
and the 95% credible interval (CrI) is 4.8-6.3%. In other words, there is 95% chance that the
mean prevalence of PCOS for the White women lie in the range between 4.8% and 6.3%. The
corresponding figures for Black women and women residing in the Middle East are 7.4% (95%
CrI: 6.3-8.7%) and 6.1% (95% CrI: 5.3-7.1%), respectively.
Using the Rotterdam criterion, prevalence estimation is only feasible for Chinese women
(5.6%, 95% CrI: 4.4-7.3%) and women in the Middle East (16.0%, 95% CrI: 13.8-18.6%).
The prevalence for females in Middle East according to different criteria were estimated,
which is 6.1% (95% CrI: 5.3-7.1%) under the NIH criterion, 16.0% (95% CrI: 13.8-18.6%) under
the Rotterdam criterion, and 12.0% (95% CrI: 11.3-14.2%) under the AES criterion.
3.5.2 Prevalence of metabolic disorders in PCOS population
The odds ratios comparing the prevalence of impaired glucose tolerance (IGT), type 2 diabetes
(DM2) and metabolic syndrome (MetS) in women with and without PCOS are presented in the
Table 3.2. The prevalence of all the metabolic disorders examined is notably higher in women
with PCOS given that all the 95% credible intervals exclude 1, regardless of the diagnostic
criteria of PCOS applied. For example, under the NIH criterion, the risk of IGT is 3.86 times
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Table 3.1: Estimated prevalence of PCOS using 3 major criteria for different ethnic groups. The
results are presented as posterior mean with 95% credible interval (CrI) after weighted averaging
results from a set of models based on Deviance Information Criteria (DIC).
Ethnicity
Estimated Prevalence (%) of PCOS in general
population (95% CrI)
1990 NIH 2003 Rotterdam 2006 AES
White
(Caucasian)
5.5
(4.8-6.3)
- -
Black
(African-American
and Afro-Brazilian)
7.4
(6.3-8.7)
- -
Chinese -
5.6
(4.4-7.3)
-
Middle East
(Iranian and Turkish)
6.1
(5.3-7.1)
16.0
(13.8-18.6)
12.6
(11.3-14.2)
higher for women with PCOS compared with the general population and there is 95% probability
that the true odds ratio lie within the range of 2.28 and 6.47. It should be noted that for IGT
and DM2, the odds ratio is larger for studies that used the Rotterdam criterion compared with
the NIH criterion. While for MetS, the odds ratio is the largest for studies that applied the AES
criterion, followed by the NIH criterion and then the Rotterdam criterion.
Table 3.2: The estimated odds ratio of IGT, DM2 and MetS comparing women with and without
PCOS. The posterior means with 95% credible interval (CrI) are presented for each combination
of diagnostic criteria and PCOS-related comorbidity.
Prevalence of metabolic disorders in women with and without PCOS
(OR with 95% CrI)
1990 NIH 2003 Rotterdam 2006 AES
IGT 3.86 (2.28, 6.47) 4.17 (2.42, 6.77) -
DM2 3.95 (2.33, 6.40) 4.71 (1.85, 10.59) -
MetS 3.14 (2.04, 4.69) 2.81 (1.85, 4.11) 3.89 (2.15, 6.54)
3.6 Discussion
3.6.1 Prevalence of PCOS in different ethnic groups
In terms of disease risk, Caucasian women in the US and Europe are less likely to develop
PCOS compared with women residing in the Middle East. The Black women (the majority are
African-Americans and Afro-Brazilians) are at the highest risks of PCOS. The 95% CrI of the
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PCOS prevalence for White female and Black females do not overlap, indicating that White and
Black females are at substantially different risk of PCOS. For Chinese women, the prevalence
is merely 5.6% even when the Rotterdam criterion was applied. This figure is comparable with
the prevalence for White females under the NIH criterion. Although estimates for Chinese
women under the NIH criterion and the AES criterion was not modelled due to lack of data, it
is expected that the prevalence using these two criteria would be even smaller, had data been
available. The credible intervals of the estimates under the NIH criterion and the AES criterion
for women in Middle East indicate that the prevalence of PCOS for women residing in this
region differs according to these two criteria. It should be noted that the prevalence of PCOS
is quite high for women in the Middle East when using the Rotterdam criterion, i.e. 16% (95%
CrI: 13.8-18.6%). However, this finding is supported by a recent study where the prevalence
was found to be 20% in this ethnic group based on the same criterion (Dargham et al., 2017).
The prevalence of PCOS using different criteria for women in the Middle East supports the
inclusive and exclusive relationship of the 3 major diagnostic criteria (i.e. the AES criterion is
an extension of the NIH criterion and the Rotterdam criterion covers the broadest spectrum) as
discussed in Chapter 1.
Generally speaking, under the same diagnostic criterion, Asian women are at a lowest risk
of developing PCOS and then, in ascending order through Caucasians, Middle Eastern women,
with the highest prevalence reported in Black women.
The results from the current analysis may be interpreted by the genetic ancestry data (Louw-
ers et al., 2013). Evidence has suggested that the risk variants of PCOS in Korean women are
not replicated in female Caucasians (Kim et al., 2014) and there is wide variation in the clinical
presentations, hormonal and metabolic characteristics of PCOS across different ethnic popula-
tions (Wang and Alvero, 2013). As a consequence, the ethnic variation in terms of the diagnostic
criteria, disease monitoring and management needs to be considered carefully.
Our results also indicated that even for the same ethnic group (e.g. women in the Middle
East), there is large variation in the prevalence of PCOS when different diagnostic criteria
were applied. This potentially pointed out the issue of under- or over-diagnosis of PCOS at
present. Since the major concern for PCOS patients is the long-term metabolic risk, the clinical
management of PCOS is often suggested to be at the earliest possible when a confirmed diagnosis
is made because with proper interventions, the rapid conversion into complications such as type
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2 diabetes may be controlled or even avoided (Conway et al., 2014). However, on the other hand,
healthcare workers should be aware to avoid over-diagnosis of PCOS because it can negatively
affect the mood of potential cases, which may consequently worsen some major symptoms of
PCOS (i.e. menstrual dysfunction), thus increasing the chance for a potential case to be qualified
as a true case. A recent study supported this argument by stating that the occurrence of severe
dysmenorrhoea and irregular cycles can be induced by high stress (Kollipaka et al., 2013).
Admittedly, there are some limitations in this analysis, which is largely attributed to the
paucity of data identified from the literature. Given that the published studies only provided
limited prevalence data for different ethnic groups, the extrapolation of prevalence was largely
driven by the prior distributions. The prior included may have some influence on the pooled
estimates. However since experts’ opinions were consulted, they were considered to be sensible.
For example, the prevalence of PCOS was expected to be lie within a range of 2-20% and
this information was represented by some suitable prior distributions (i.e. the prevalence is
bounded within this range with certain degree of variability). Note that a prominent advantage
of Bayesian methods is that the prior distributions can be updated by the observed data to
generate posterior distributions of parameters of interest through the application of simulations.
For example, in our case, the posterior distributions of prevalence in different ethnic groups were
generated. Random sampling can then be proceeded by drawing a large sample size from the
posterior distributions and this is expected to provide much more reliable results. Moreover,
sensitivity analysis was conducted by attempting different versions of prior for our Bayesian
model to identify the ones with relatively lower DIC and pooled estimates were obtained from
model averaging based on Formula 3.1 in Section 3.4.1. Specifically, models with smaller DIC,
indicating a better fit to the data, were weighted up while those with larger DIC were weighted
down. In this way, information from models with a slightly higher DIC but provide reasonable
estimates was not discarded. This tends to improve the accuracy of the estimation.
It is also suggested that the prevalence of PCOS varies in individuals with different weight
categories (i.e. normal, overweight, obese) (Yildiz et al., 2008). However, the model used did not
account for this factor due to lack of high quality body mass index (BMI) data from individual
studies and the significant heterogeneity in the way of how BMI data were provided by different
studies (e.g. some studies provided mean BMI of the entire study population whereas the other
studies provided the proportion of patients who were overweight or obese).
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There is also evidence that lifestyle modification ameliorates presentations of PCOS (Domecq
et al., 2013). Consequently, the assumption that individuals of the same ethnicity have similar
risk of developing PCOS may not be sensible in reality (as they may have quite different lifestyles)
although we have accounted for individual level variability for prevalence estimates in our model.
3.6.2 Prevalence of morbidities associated with PCOS
In the current analysis, a larger number of studies were included compared with the previous
review, allowing the studies to be categorised by diagnostic criteria and geographical location.
The latter factor was controlled for in the meta-analytic model.
The results from our meta-analysis supported that significant greater prevalence of IGT,
DM2 and MetS is observed in women with PCOS compared with controls regardless of which
diagnostic standard of PCOS is applied: the odds ratios in Table 3.2 suggested that women with
PCOS are generally 2-6 times more likely to develop various metabolic abnormalities than the
general female population. Since the exact pathophysiology of PCOS remains largely unclear,
the metabolic disorders associated with PCOS is often considered to be attributed to a combi-
nation of factors. For example, the elevated risk of IGT and DM2 in PCOS may be caused by
peripheral insulin resistance, insulin hypersecretion and elevated β-cell function (Dunaif et al.,
1989; O’Meara et al., 1993; Holte et al., 1995; Ciampelli et al., 1997; Vrb´ıkova´ et al., 2002;
VrbIkova et al., 2004). It should be noted that insulin resistance appears in 50-70% of women
with PCOS (Legro et al., 2004), which augments androgen production and increases the level
of free androgens through reducing sex hormone binding globulin (Teede et al., 2010a). The
underlying hormonal imbalances form a vicious circle, which underpin PCOS.
Some studies have suggested that women with hyperandrogenic PCOS are more likely to
present a worse cardiometabolic profile (Daan et al., 2014). The results from the current study
tend to agree with this argument with respect to MetS as slightly higher ORs were observed
under both the NIH and the AES criterion where hyperandrogenism is a prerequisite for diagnosis
of PCOS. On the contrary, PCOS patients who met the Rotterdam criterion seem to be at a
higher risk of IGT and DM2 compared with those who met the NIH criterion. However, note that
there are uncertainties around estimates for IGT and DM2 (as suggested by the much wider 95%
CrI compared with that of estimates for MetS) because relatively more studies for MetS were
identified. Many studies investigating DM2 reported absence of DM2 in the control population,
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which potentially generates strong impact on the pooled estimates. The absence of DM2 in the
controls can be due to different reasons, e.g. selection bias, as discussed in the methodological
issues of the studies included in Section 2.5.2. Further research may need to be warranted to
investigate the metabolic features of PCOS population presenting different phenotypes.
Although the current model allowed to adjust for prevalence of IGT, DM2 and MetS in
populations living in different geographical locations, a range of other confounding factors were
not included. For example, it is well documented that obesity is a risk factor for glucose abnor-
malities and cardiovascular disorders, including metabolic syndrome and dyslipidaemia (Legro
et al., 1999, 2001; Ehrmann et al., 2006). There is also evidence that even the body weight or
BMI is controlled, central obesity may remain a contributing factor of increased cardiometabolic
risk in PCOS population (Escobar-Morreale and San Milla´n, 2007; Godoy-Matos et al., 2009;
Moran and Teede, 2009). Another example of confounding factor may be age as it is proposed
that glucose abnormalities often worsen gradually with aging (Aguiree et al., 2013). While the
confounding factors may bias the estimates, it was not possible to account for all of these vari-
ables due to lack of high quality data reported by empirical studies. In addition, the variation
across studies in terms of ethnicity, medication use, recruitment source of sample population,
family history of DM2 and definition of controls were also considered to substantially raise the
statistical heterogeneity in the current analysis. Further observational studies regarding these
aspects (e.g. matching by age, BMI and ethnicity) are in need to explore the causal relationship
between common metabolic disorders and PCOS.
3.7 The bmeta package for R
Based on the modelling approach introduced in Section 3.4.3, I also developed a specific R
package, named bmeta. The purpose of creating this package is to keep the users at least for
a selected range of model specifications by coding up a large set of predefined models. In this
way, all required for performing the Bayesian meta-analysis is a simple call to an R function and
a decision in terms of what type of model to fit the data. After model specification, the package
automatically calls JAGS and launches it in the background to conduct simulations. The results
obtained from simulations (e.g. estimates from posterior distributions) are then stored back to
R for post-hoc analysis. The package provides a relatively large class of models for conducting
Bayesian meta-analysis in R, which is an open source software and is easy to interface with
75
Bayesian/MCMC software, e.g. WinBUGS (Spiegelhalter et al., 2003) or JAGS (Plummer et al.,
2003), for simulations. The package includes functions for the calculation of various effect size
or outcome measures (e.g. odds ratios, mean difference and incidence rate ratio) for different
types of data and users are allowed to fit fixed- and random-effects models with different priors
for the parameters. When effects of additional covariates are observed, meta-regression (Dias
et al., 2013) can be performed to adjust for moderators. The sample data collected from the
literature review for PCOS were used to present functions of this package.
3.7.1 Models included
There are 22 fixed-/random-effects meta-analysis/meta-regression included in the bmeta pack-
age (see Table 3.3 below for more details), which can be used to model different types of data (i.e.
binary, continuous and count). Users can select fixed- or random-effects standard meta-analysis
or meta-regression in conjunction with different types of prior distributions for the pooled mean
outcome. In this way, users can compare the effect of different models (e.g. prior effect) fitted
to their data and use the results from the optimal ones based on the diagnostic statistics.
The t-distribution prior was included for modelling the pooled estimates for binary outcome
due to the fact that it has heavier tails and therefore was considered to be more suitable (com-
pared with a Normal distribution prior) for dataset with outliers. The half-Cauchy distribution
was included as prior for modelling the variance of the pooled estimate for count outcome. The
underlying reason is that it has heavy tails and therefore can allow for outliers and accommodate
small variances close to zero. The heavy tail of the half-Cauchy distribution can lead to less
shrinkage to the population mean (in our case, the pooled estimates from all studies). However,
this is considered to be appropriate for certain types of dataset where there are outlying data
points. In terms of continuous outcome, some studies may report mean and standard deviation
for both the case and control arm separately. Conversely, other studies may only report a mean
difference between the two arms and pooled standard deviation. Thus, models that can fit data
in different formats were created.
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Table 3.3: Models provided by bmeta.
Outcome Model Model explanation Type
Binary
std.norm meta-analysis with normal prior fixed/random
std.dt meta-analysis with t-distribution prior fixed/random
reg.norm meta-regression with normal prior fixed/random
reg.dt meta-regression with t-distribution prior fixed/random
Continuous
std.ta meta-analysis for studies reporting two
arms separately
fixed/random
std.mv meta-analysis for studies reporting mean
difference and variance only
fixed/random
reg.ta meta-regression for studies reporting two
arms separately
fixed/random
reg.mv meta-regression for studies reporting mean
difference and variance only
fixed/random
Count
std meta-analysis fixed
std.unif meta-analysis with uniform prior random
std.hc meta-analysis with half-Cauchy prior random
reg meta-regression fixed
reg.unif meta-regression with uniform prior random
reg.hc meta-regression with half-Cauchy prior random
3.7.2 Implementation
The models introduced in the above section can be selected by users and bmeta calls JAGS to
perform simulations with output stored back in R. However, before making model selection, the
user firstly needs to create or load the data. For example, data stored in the Excel spreadsheet
can be loaded using the following code:
> data=read.csv("IGT-NIH.csv")
Once the data are loaded into R, the user needs to format the data as required by bmeta
using the list command. Moreover, the user needs to name the input variables with specific
names (e.g. y1, n1, y0, n0) for the package to process and perform further analysis. The
recommended format of the input data is shown below.
Study Year y1 n1 y0 n0 Region X0 X1 X2
1 dos Reis 1995 7 29 0 19 1 1 0 1
2 Dunaif 2001 3 14 0 12 1 1 0 1
3 Yarali 2001 1 30 0 30 2 0 1 1
4 Faloia 2004 3 50 1 20 2 0 1 1
5 Phy 2004 4 7 2 18 1 1 0 1
6 Diamanti-Kandarikis 2005 1 29 0 22 2 0 1 1
7 Sawathiparnich 2005 3 6 0 6 3 0 0 1
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8 Alvarez-Blasco 2006 4 32 8 72 2 0 1 1
9 Echiburu 2008 17 159 1 93 1 1 0 1
10 Bhattacharya 2009 32 264 11 116 3 0 0 1
11 Kawai 2009 72 185 40 120 1 1 0 1
12 Wei 2009 27 356 28 974 3 0 0 1
13 Huang 2010 11 90 0 40 3 0 0 1
14 Luque-Ramirez 2010 12 112 2 86 2 0 1 1
15 Pall 2010 1 75 0 23 2 0 1 1
16 Wiltgen 2010 22 195 0 25 1 1 0 1
17 Huang 2010 13 128 0 40 3 0 0 2
18 Amato 2011 7 125 2 144 2 0 1 1
19 Wickham 2012 4 13 0 13 1 1 0 1
20 Guleria 2014 5 50 1 50 3 0 0 1
The first two columns show the study characteristics including author and year of publication.
Column 4-7 display the number of events and the total number of individuals in the case and
control arm. Column 8 contains the regional indicator and this categorical variable was further
converted into binary variables X0, X1, X2, which can only take either 0 (no) or 1 (yes), as
required by bmeta. Note that the data in Column 4-7 are the necessary information required
by bmeta to perform a standard meta-analysis and if a meta-regression model is selected,
then data from Column 9 and onwards are considered necessary depending on the number of
covariates included for the model. The variables (e.g. Study, year, y1) do not necessarily have
to be named as what are shown in the above table because the user will have to rename the
input variables to feed bmeta using the list command mentioned previously:
> data.list<-list(y0=data$y0,y1=data$y1,n0=data$n0,n1=data$n1,X=cbind(data$X0,data$X1,
data$X2))
After this, the user can proceed with model selection. Here, the random-effects meta-
regression model with normal prior for binary outcome was selected and the object x included
all the results.
> x<-bmeta(data=data.list,outcome="bin",model="reg.norm",type="ran")
The following output table is automatically generated by bmeta after the model specifica-
tion. The second column presents the posterior mean of each model parameter and the associated
standard deviation is presented in Column 3. Columns 4-5 are the lower and upper bound of
95% credible interval of the posterior mean. Notice that alpha[] represents the study-specific
baseline odds whereas delta[] and gamma[] are the study-specific odds ratio (comparing the
relative risk of events in case and control arm) on log scale and natural scale, respectively. The
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pooled odds ratio rho is high (6.02) with a wide 95% credible interval of (2.60, 13.39). It is
worth mentioning that n.eff (effective sample size) for certain parameters of interest is low,
indicating potential autocorrelation. Note that under the context of MCMC, autocorrelation
is a measure of the independence of different samples drawn from the posterior distribution
and lower autocorrelation indicates more independent results and conversely, if there is high
autocorrelation, the sample drawn does not accurately represent the posterior distribution.
Inference for Bugs model at "model.txt", fit using jags,
2 chains, each with 10000 iterations (first 5000 discarded), n.thin = 5
n.sims = 2000 iterations saved
mu.vect sd.vect 2.5% 97.5% Rhat n.eff
alpha[1] -3.718 1.261 -7.073 -2.094 1.093 55
alpha[2] -3.623 0.994 -5.713 -1.902 1.003 550
alpha[3] -6.062 1.484 -8.869 -3.489 1.063 31
alpha[4] -3.974 0.991 -6.237 -2.314 1.070 42
......
alpha[18] -4.422 0.594 -5.553 -3.297 1.013 120
alpha[19] -3.530 1.070 -5.860 -1.850 1.025 90
alpha[20] -3.986 0.712 -5.421 -2.667 1.073 27
delta[1] 2.394 1.265 0.721 5.413 1.020 88
delta[2] 2.050 0.946 0.449 4.145 1.001 1500
delta[3] 2.077 1.118 0.048 4.483 1.004 750
delta[4] 1.259 0.894 -0.287 3.200 1.059 34
......
delta[18] 1.542 0.642 0.318 2.841 1.010 1300
delta[19] 2.376 1.063 0.774 4.713 1.012 230
delta[20] 1.691 0.729 0.385 3.306 1.027 68
gamma[1] 178.820 1921.234 2.057 224.366 1.095 58
gamma[2] 13.654 27.510 1.567 63.125 1.001 1500
gamma[3] 15.484 24.030 1.049 88.506 1.004 750
gamma[4] 5.784 10.635 0.750 24.530 1.059 34
......
gamma[18] 5.786 4.355 1.375 17.140 1.010 1300
gamma[19] 24.141 75.662 2.169 111.374 1.012 230
gamma[20] 7.253 7.059 1.470 27.267 1.027 68
mu 1.695 0.433 0.956 2.595 1.003 520
rho 6.016 3.055 2.600 13.394 1.003 510
sigma 1.060 0.424 0.383 2.054 1.003 720
tau 1.587 2.298 0.237 6.805 1.003 720
deviance 141.753 8.141 127.402 159.204 1.014 110
For each parameter, n.eff is a crude measure of effective sample size,
and Rhat is the potential scale reduction factor (at convergence, Rhat=1).
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DIC info (using the rule, pD = var(deviance)/2)
pD = 32.9 and DIC = 174.6
DIC is an estimate of expected predictive error (lower deviance is better).
Apart from the output table, the JAGS file for the required model configuration (random vs
fixed effects; choice of outcome and prior distributions; presence of covariates) is saved in the
working directory. This is considered as a sort of “template” and can then be modified to extend
the modelling by changing priors in a way that is not automatically done by bmeta or saved for
future reference. For example, if the model convergence is poor, one may consider changing the
prior to be more informative as the prevalence of most diseases is likely to be restricted within
some reasonable range. The output table above suggests that more informative priors based on
pilot studies may need to be included in the analysis for this particular dataset.
3.7.3 Graphical functions
The bmeta package includes a range of graphical functions to produce not only standard plots
for output display but also diagnostics to assess heterogeneity between studies, publication bias
as well as model fit and convergence (Table 3.4).
Table 3.4: Plots produced by bmeta.
Plots Function
posterior.plot Posterior distribution plot of the summary estimate and between-
study standard deviation
forest.plot Graphical display of study-specific estimates and the pooled esti-
mate. Need to install package ‘forestplot’ from R library to
implement command
funnel.plot Scatter plot to present publication bias
diag.plot Diagnostic plot to present Gelman-Rubin statistic (Rhat) or effec-
tive sample size from MCMC simulations
traceplot.bmeta Trace plot to examine the model convergence for each node
acf.plot Autocorrelation plot to examine model convergence for each node
The function posterior.plot provides the posterior distribution of the summary estimate
and the between-study standard deviation (when a random-effects model is selected). As all
the models in bmeta employ the Bayesian approach, it is natural to look at the posterior
distributions of the parameters of interest. Figure 3.6 shows the posterior plot for the summary
estimate from the previous output table (Figure 3.6). We can see that all the bars lie to the right
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of the reference line x = 0, suggesting that the prevalence of DM2 is notably higher in PCOS
patients compared with the general population. The horizontal line in bold on the bottom of
the bars represents the 95% credible interval.
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Figure 3.6: Posterior plot for the overall estimate obtained from pooling results from all studies
included. The results are presented on a log scale and the reference line is therefore x=0. The
horizonal line in bold represents the 95% credible interval of the estimate.
The forest plot is commonly used to graphically illustrate the outcomes obtained from meta-
analysis. In a forest plot, a box or a circle is normally used to represent the study-specific
estimates, which is displayed somewhere on a line that represents the 95% Credible Interval
(CrI) of the estimate. The overall estimate obtained from pooling all studies is drawn like a
diamond and a vertical reference line is used to show whether the outcome favours intervention
or control. It should be noted that this function in bmeta is based on calling the R package
‘forestplot’ (note that bmeta automatically loads the forestplot package). A set of
arguments is provided to edit the plot according to the user’s preference. The user can change
81
the scale of the x-axis easily to make the estimates to be shown either on the log or natural
scale. The color of the boxes and diamond can be changed and titles and study details including
author and the year of publication can easily be added on the plot. For example, the following
command defines a log scale and all the study characteristics are added, with the colour of the
boxes and the diamond being specified as blue and orange, respectively.
> forest.plot(x,log=T,study.label=c(paste0(data$Study ,",", data$Year),"Summary estimate
"), box="blue", summary="orange")
Figure 3.7 is a forest plot generated from the previous output table for the relative risk of
IGT comparing the PCOS patients and controls. The boxes in blue represent study-specific
odds ratio and the diamond in orange represents the summary estimate obtained by pooling
all studies together. Note that the size of diamond is proportional to the uncertainties in the
pooled estimate. There are 20 studies and for each of them, the study-specific log odds ratio are
presented, with the pooled estimate at the bottom. We can see that all the boxes lie to the right
of the reference line x=0, indicating significant increased prevalence of IGT in PCOS patients
compared with controls.
Another important aspect when performing a meta-analysis is to examine the publication
bias and Figure 3.8 presents a sample funnel plot produced by bmeta for the previous sample
data of IGT. The function funnel.plot in bmeta displays study effect on log scale against
the standard error of the study effect. It is suggested that when bias and between-study het-
erogeneity are completely absent, the scatter resembles a symmetrical funnel and the triangle
area formed by connecting the centred summary estimate with its 2.5% and 97.5% quantiles on
either side includes about 95% of the studies if the fixed-effects model assumption holds (i.e. all
the studies estimate the same effect). Therefore, for the current plot, we can see that the scatter
is not quite symmetrical with several dots lying outside the triangle, suggesting some extent of
violation of the fixed-effects model assumption.
It is also worth commenting that bmeta allows to visualise diagnostics to assess model
convergence, i.e. diagnostic plot, trace plot and autocorrelation plot, and these diagnostics are
provided for all parameters in the output table.
Figure 3.9 presents the diagnostic plot for all nodes and we can see that the number of
effective sample size for many parameters is quite low (much smaller than the actual number
of simulated iterations as represented by the dash line at the top), suggesting issue of high
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Figure 3.7: Forest plot for studies comparing relative risk of IGT in women with and without
PCOS. The blue boxes represent the study-specific odds ratios and the lines are the corre-
sponding 95% credible intervals. The diamond on the bottom represents the summary estimate
obtained from pooling results from all the studies. The odds ratios are presented on a log scale
so the reference line is x=0.
autocorrelation.
This is confirmed by Figure 3.10 where a certain node gamma[18] in the output table
is presented. The autocorrelation plot often helps to check dependency among Markov chain
samples. The reason behind is that the distribution of the current observation always depends
on that of the previous one (a critical property of MCMC simulation), therefore the iterations
of a Markov chain are observed to be correlated. However, it is expected that the kth lag
autocorrelation (defined as the correlation between every draw and its kth lag) gets smaller as
k increases (i.e. the 5th and 100th draws should be less correlated than 5th and 10th draws).
Therefore, if autocorrelation continues to be high for larger values of k, we would suspect that
there is a slow mixing of chains and high degree of correlation between draws. The plot presented
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Figure 3.8: Funnel plot for studies comparing relative risk of IGT in women with and without
PCOS.
here shows moderate autocorrelation as although the correlation (represented by each vertical
line) between every draw of this node and its kth lag decreases when k increases, high correlation
was still observed for larger value of k (e.g. k=25), with the vertical lines exceeding the border
formed by the two dash lines.
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Figure 3.9: Diagnostic plot (display the number of effective sample size against the total number
of saved simulations after burn-in) for main parameters in the model.
The traceplot of the node gamma[18] is provided (Figure 3.11). The two chains in the
traceplot do not mix quite well and fluctuate around a certain horizontal line (represents a fixed
value) even after a large number of burn-ins. This indicates that the model convergence has
not been reached. It could be caused by the minimally informative prior in the model template
provided by the package. Therefore, more informative prior distributions for this dataset may
be considered or a larger number of iterations may need to be specified.
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Figure 3.10: Autocorrelation plot produced by bmeta.
Note that the bmeta package has been released to CRAN, the offcial repository of R packages.
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Figure 3.11: Traceplot produced by bmeta.
3.7.4 Web application of bmeta
A web application of bmeta has been created to facilitate users without direct knowledge of R.
By using bmetaweb, users only need to upload data in the required format in Excel spreadsheet
and specify the model to populate the data. bmetaweb runs the package in the background
and the outcomes are presented in fairly straightforward way on the website page. A structured
report in either PDF or Word can be downloaded with some pre-formatted texts aiming at
guiding users through the interpretation of the results. The official website of bmetaweb is:
https://egon.stats.ucl.ac.uk/projects/bmetaweb/.
Some screen shots of the bmetaweb are presented in Figure 3.7.4. The top graph in Figure
3.7.4 shows the welcome page of the website. This web page introduces the concepts of Bayesian
meta-analysis and gives instructions of the data format required by the website. The bottom
graph shows one of the function tabs where users can make model selection and upload data
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for analysis. The right side of the window presents the output table obtained from the model
specified by the user.
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Figure 3.12: Screen shots of bmetaweb. The top plot is the welcome page which gives some
general introduction about Bayesian meta-analysis and then instructs the user of the data format
required by the website. The bottom plot shows one of the function tabs where users can make
model selection and upload data for analysis. The output table is automatically generated on
the right side of the window.
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Chapter 4
EVALUATING THE
PREVALENCE, INCIDENCE AND
PRESCRIBING PATTERNS OF
PCOS UNDER THE UK
CONTEXT
4.1 Chapter summary
This chapter presents the results of incidence, prevalence and prescribing patterns of PCOS from
a database study conducted in the UK context. The motivation of this database study is firstly
discussed and then I give an overview of the UK primary care and the database used specifically
for the current research. The methods for patient identification from the database and the
analysis plan are introduced afterwards. The epidemiological and pharmaceutical results are
presented and compared with studies conducted under similar settings. Finally, I describe the
main conclusions from this database study and give some suggestions on the clinical management
of PCOS from a primary care perspective. The main findings in this chapter have been converted
into a paper published in the BMJopen (Ding et al., 2016).
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4.2 Background
In Chapter 3, I present results from statistical modelling for prevalence estimation of PCOS in
the general population. However, from the literature review, limited amount of information was
identified with significant heterogeneity between studies. Since there are many uncertainties
around the prevalence estimates in the previous chapter, I was motivated to find alternative
methods to investigate the prevalence or other epidemiological outcomes of PCOS. Aside from
this, the database study would allow me to explore the incidence, prevalence and prescribing
patterns of the condition under the UK-specific context as well as to include more covariates
(these may have influence on the epidemiological outcomes), which can hardly be achieved by
looking at data provided by published studies.
4.2.1 UK primary care
In the UK, in general, most of the patients’ experience is considered to be within primary care
and the majority of the general practitioners (GPs) record patient information by computer. In
the past, the main function of the information system in the general practices was to inform GPs
or other clinical members to provide care on a day-to-day basis. The patient information was
also used for registration and delivery of payments made to practices under a new GP contract.
The National Health Service (NHS) aims to provide care from cradle to grave through a uni-
versal coverage of services by GPs in the primary care and as early as in 1998, the Department of
Health’s strategy Information for Health (National Heatlh Service, 1998) attempted to establish
lifelong electronic health records for all the patients. The data collected in routine clinical prac-
tices are population-based, extending from birth information to details of diagnoses recording
as well as management and health outcomes. Therefore, by exploring primary care data, it is
possible to grasp a better understanding of the disease history including access to healthcare by
individual patients and the patterns of care (i.e. prescribing rates) in the general practices.
In 2006, the UK Department of Health has introduced a scheme termed the “Quality and
Outcome Framework” (QOF), whose objective was to encourage the delivery of high quality
primary medical services. Since the introduction of the QOF, GPs have been required to record a
wider range of data electronically. For example, GPs are required to record clinical management
following a diagnosis. Given that these data are also linked with payments to general practices, it
is expected that the accuracy and quality of electronic health records can be improved gradually
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in the primary care (Gnani and Majeed, 2006).
4.2.2 THIN database
History of the database
The primary care database used for this piece of analysis is The Health Improvement Network
(THIN). The idea of developing a database was firstly brought up in mid-1970s by a GP, Dr.
Alan Dean, who attempted to computerise the patient records and make these files paperless
(Health Service Journal, 1999). He managed to build this program with the help from some IT
staff and then began to sold it to other practices in 1979. By the end of the 1980s, an increasing
proportion of GPs in the UK started to work in computerised practices and the need for large
databases to conduct pharmaceuticoepidemiological research was raised (Hall, 1992).
In 1987, Dr. Alan Dean established a company — Value Added Information Medical Prod-
ucts (VAMP) and he aimed to include patient data from 950 practices. This first database
was named the Vamp Research Databank (VRD) however the way that GPs used computers
largely complicated its development. This is due to the fact that GPs generally needed to take
three steps to convert the paper records to computerised records. For example, they firstly
used the computer system to record prescriptions and then, to record details of consultations
and finally, other relevant information such as secondary care information or medical history
was recorded. Apparently, the analyses of the database were considered to be optimal by using
data contributed from practices that completed all these three steps. As a consequence, free
computers were offered to practices in order to incentivise more GPs to join this program.
In 1993, VAMP was sold to Reuters who later donated the VRD database to the Department
of Health for the purpose of public health research. After this, the VRD database was renamed
as the General Practice Research Database (GPRD, Ogdie et al., 2012) and regulated by the
Office for National Statistics (ONS). The database was further moved to the Medicines and
Healthcare products Regulatory Agency who is in charge of it nowadays. The name of the
database was changed again to Clinical Practice Research Datalink (CPRD) in 2012.
In 1994, Dr. Dean set up a new company called EPIC to regain the license of GPRD and at
the same time, VAMP was renamed as In Practice Systems Ltd (INPS) who bought back the
software platform (named Vision) for data management from Reuters. In 2002, EPIC, INPS and
Vision teamed up to establish The Health Improvement Network (THIN). It should be noted
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that although the data collection process of THIN was started in 2003, the patient records can
be retrieved back to 1980s for certain practices.
THIN at present
Nowadays, if a practice decides to join the THIN scheme, an initial process of full data collection
is carried out. In order words, the practice needs to provide all the retrospective data available
from the time point when the practice firstly began to use Vision or VAMP. The incremental
data collected each year are then automatically downloaded and stored in an electronic form.
This makes it less likely to incur disruptions to the daily activities of the practice while ensures
the data security.
It is estimated that THIN collects data on 3 to 5 million of patients on an annual basis
(Lewis et al., 2007). The latest data showed that the database included 559 practices covering
over 11,350,933 patients (among which over 3.8 million are active patients who are eligible to
be followed prospectively). It should be noted that the patient population accounted for 6.2%
of the total population in the UK (IMSHealth, 2015). Evidence has suggested that in 2011,
the number of patients on the NHS patient register record exceeded that of the population size
in the UK estimated by the Office for National Statistics (Office for National Statistics, 2014).
This could be due to the over and under coverage, e.g. patients registered in more than one area,
delays in birth or death notification.
Structure of THIN database
The information of patients in the THIN database is recorded in a range of different files as shown
in Table 4.1. There are seven files included in the database and some of the information may
be recorded in two files, e.g. additional health data may record the reason for death related to a
medical diagnosis indexed in the medical records. Due to the nature of the database structure,
when extracting data from separate files, it is essential to consider all the files that may contain
relevant information.
It should be noted that the symptoms and diagnoses are categorised using the so-called “Read
code” system, which is a unique hierarchical recording system developed by Dr. James Read
(Chisholm, 1990) and is widely used in the practices across UK. This classification codes disease
and its associated history and symptoms, findings and signs of the examination, diagnostic
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Table 4.1: Files that contain patient information in THIN database.
File name Information recorded in the file
Patient records
Age, sex, the date of registration and leaving the
practice
Medical records
Medical diagnosis and its associated date, the location
of the event and free text option
Therapy records
Prescription (indication not recorded) with formulation
and dosage information and the date issued, events
leading to withdrawal
Additional Health Data (AHD)
Records of vaccinations, other information such as
height, weight, smoking, birth, death, laboratory results
Postcode Variable Indicator (PVI)
The indices for postcode linked area-level socioeconomic,
ethnicity and environmental information
Consultation records Date, time and duration of consultation
Staff records Information of staff who entered the data
and test procedures, drugs prescribed as well as some social information. All the Read codes
are divided into chapters with a similar structure to the International Classification of Disease
(ICD). For example, Read codes starting with ‘C’ indicate endocrine and metabolic diseases
and “C11y200” is the Read code for impaired glucose tolerance. Over 100,000 Read codes are
currently included and the same condition can often be described by a range of Read codes
or the combination of different Read codes, e.g. ‘Stein-Leventhal syndrome’ is also used to
define PCOS.
Case identification from the database
In general, the primary step for research based on databases is case identification. This involves
extracting patient information from different files in the database to generate a big spreadsheet
containing individual level patient data (i.e. each line corresponds to a unique patient). This
spreadsheet can then be used to conduct more complicated analysis.
The data extraction process from THIN is graphically displayed in Figure 4.1 and can be
described as follows:
 The first step is to identify a list of Read codes relevant for a specific disease by looping
through the description fields of all the codes using ‘key’ words (Dave´ and Petersen, 2009).
These ‘key’ words are either definition of a disease or the descriptions of symptoms related
to a disease (see the rectangle with the terms ‘Read codes’ on the left side).
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 The code list is then merged with the medical records of patients for case identification.
 After identifying all the cases, this file is merged with other files such as patient record
(which contains the demographic information), therapy record (which contains the pre-
scription data), additional health data (which contains other variables) and postcode vari-
able indicator (PVI) records (which contains information on area-level social deprivation
level) depending on the research question and type of analysis needed. The final study
population file (see the bottom right rectangle) should contain all the disease and pre-
scription indicators as well as covariates of interest to facilitate the further analysis of the
dataset.
Figure 4.1: Overview of data extraction process from THIN. A list of Read codes defining a
disease or its major symptoms is identified to merge with the medical records of patients for
case identification. This file is then merged with all the other files (which contain other types
of patient information) to generate the final study population file for further analysis.
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4.3 Aim
The aim of this chapter was to firstly identify PCOS cases from the THIN database and then
estimate the incidence and prevalence of PCOS in the UK general population. The second
objective was to examine the impact of age, social deprivation level and time period on the
incidence rates. Finally, I aimed at investigating the prescribing patterns of PCOS in the UK
primary care.
4.4 Methods
4.4.1 Patient identification for PCOS
Specifically for PCOS, I primarily identified codes defining PCOS by looping through the de-
scription field including ‘key’ words such as ‘polycystic ovary syndrome’, ‘endoscopic drilling of
ovary’, ‘Stein-Leventhal syndrome’ or the symptoms of PCOS (i.e. irregular menstrual dysfunc-
tion, hirsutism, polycystic ovary). The code list of diseases that mimic PCOS was also developed
in the same way to be applied as exclusion criteria, including adrenal tumours, adrenal hyper-
plasia), Cushing’s syndrome, Nelson’s syndrome, pituitary disorders, prolactinoma. The reasons
for exclusion are presented in Table 4.2. The resulting code list is provided in the Appendix E.
This list was firstly developed based on the clinical guideline of PCOS and then was filtered and
modified through the discussion with clinical experts.
The THIN patient files were firstly restricted to only females who permanently registered.
The permanent patients refer to those who are residents in the practice area for more than 3
months. The identification process of the study population is graphically displayed in Figure 4.2.
Table 4.2: Diseases that mimic PCOS.
Disease Reason to exclude
Cushing’s syndrome
Make body produce excess cortisol hormone, leading to too much
hair in women and abnormal menstrual periods
Nelson’s syndrome Caused by operations that used to treat Cushings syndrome
Prolactinemia
Over production of prolactin, leading to oligomenorrhea or
amenorrhea, acne and excessive growth of facial and body hair
Adrenal disorders
Make body produce too little cortisol and too much male hormone,
leading to severe and early acne (before teenage),
facial hair in women and infrequent or absent menstrual periods
Pituitary disorders Can cause less frequent or no menstrual periods
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Figure 4.2: Identification of study population.
Two categories of PCOS cases were identified: diagnosed and probable cases. This is because
as described in Chapter 2, large data gaps between the prevalence rates estimated by community
studies and database studies were identified, suggesting that PCOS is a condition that is often
under-diagnosed. Since a combination of symptoms can also be indicative of PCOS, I included
probable cases in the analysis. It should be noted that the definition of probable cases was
validated through consultation with clinicians.
I now introduce how patients in these two categories were defined. The diagnosed case
group included PCOS patients with a record of either of the three Read codes: “Polycystic
ovary syndrome” (Read code C165.00), “Stein-Leventhal syndrome” (C164.12) and “Endo-
scopic drilling of ovary” (7E25300) recorded in their medical or additional health records. The
probable case group included patients with at least two Read codes from the following three
groups recorded in their medical or additional health records: Group A (menstrual or ovarian
dysfunction related PCOS features), Group B (androgen excess related PCOS features) and
Group C (Polycystic ovaries). Moreover, the Read codes must come from at least two different
groups, e.g. one from Group A and another from Group B or two from Group A and one from
Group C. The requirement for the (minimum) time between the 2 recorded features (or any 2
out of 3 features) for probable cases must not exceed 3 years. This time period was considered
to be long enough to capture half of the probable cases based on some pilot investigation of the
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study population (refer to Figure 4.5 in Section 4.5.2). The longer the time interval between
the two features, the less likely it is for a woman to be qualified as a case because one would
suspect that the woman may have developed some other conditions rather than PCOS.
Group B codes were further divided into two subgroups (I and II). Subgroup I included Read
codes for descriptive hyperandrogenic features (e.g. hirsutism, male pattern alopecia) whereas
subgroup II included Read codes for a range of laboratory tests for androgen related markers.
Subgroup I codes were considered if they were recorded in the medical or additional health
records. Subgroup II codes were only included if they were recorded in the additional health
records and have:
 A qualitative marker indicating that the test result was above the normal range (“high”,
“very high”, “significantly high”, “above high reference limit”);
 A quantitative marker indicating that the test result was above the normal range (where
the upper reference range for a quantitative result was not recorded in the additional health
records, the mode of the upper ranges for that practice in that year was used; where both
upper reference range and the mode of the upper ranges for that practice in that year
were not recorded, the mode of the upper reference ranges for all practices in that year
was used).
The following covariates were extracted, which may potentially be important factors affecting
epidemiological outcomes of interest in the current analysis:
 Age — age in 2014 was used here and women were categorised into 5-year age bands, i.e.
15-19, 20-24, 25-29, 30-34, 35-39, 40-44 years.
 Period — the whole study period was divided into 3 short periods, i.e. 2004-2007, 2008-
2011, 2012-2014.
 Townsend score — which describes the area-level social deprivation. The Townsend
score is a census-based index incorporating four variables (i.e. unemployment, non-car
ownership, non-home ownership, household crowding). Note that percentages rather than
absolute values are computed for each of the variables. For example, the percentage of
households without access to a car or van within an area (which is usually small geograph-
ical areas such as wards or local authorities across the whole country). These percentages
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are then standardised to a Z-score. The formulas for standardisation are shown below (the
first formula is for variables non-car ownership and non-home ownership and the second
formula is for variables unemployment and household overcrowding where log transforma-
tion is considered necessary):
Z scores = (percentage mean of all percentages)/ SD of all percentages
Z scores = (log percentage mean of log percentages)/ SD of log percentages
These standardised scores are then added up to be the final Townsend score, which ranges
from 1 to 5. Individuals with a score of 1 are considered to live in the least deprived areas
whereas those with a score of 5 reside in the most deprived areas (Townsend et al., 1988).
Similar to the wide accepted index of multiple deprivation (Department for Communities
and Local Government, 2015), Townsend score can be used to measure the deprivation
level of any geographical area where census data are available.
Since ethnicity information in THIN is incomplete and only reported by half of the patient
population, this variable was not included in the current analysis.
4.4.2 Analysis plan for PCOS
I performed analysis of both prevalence and incidence for the study population from 2004 to
2014. The start date was selected as 2004 because the second diagnostic criterion of PCOS
was established in 2003 and results from the literature review have suggested that very few
prevalence studies have been conducted before 2003. Therefore, it may be inferred that the
diagnostic criterion of PCOS was known by very few GPs and consequently hardly followed.
In other words, the recording rates of PCOS are expected to be lower before 2003, which may
bring in potential bias for the current analysis. In terms of the study end date, since the study
was performed in 2015, the end date was defined as the last date of 2014.
The incidence of PCOS records in the period from 2004 to 2014 were calculated for diag-
nosed cases, probable cases and both diagnosed and probable cases combined. The denominator
for the incidence calculation was the sum of all eligible follow-up time in the study population
with the start of each woman’s follow-up being defined as the latest of:
 5,478 days after a woman’s date of birth (i.e. 15 years of age);
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 1st January 2004;
 365 days after a woman’s registration date;
 The date when practices met the criteria for continuously acceptable computer usage
(ACU), i.e. one medical record, one additional health record per patient per year, and at
least two prescription per patient per year (Horsfall et al., 2013);
 The date when practices were determined to have acceptable mortality reporting (AMR),
i.e. a time point at which the observed death rate for a practice reaches the standard pre-
dicted numbers of deaths derived from national statistics given the practice’s demographics
(Maguire et al., 2009).
The end date of each woman’s follow-up was defined as the earliest of:
 16,436 days after a woman’s date of birth (i.e. 45 years of age);
 The date a woman transferred out of the practice;
 31st December 2014;
 The date data were last collected from a woman’s practice;
 The date of the first PCOS diagnosis (for the probable case group, the date the second
PCOS feature is recorded was used as the date of first diagnosis of PCOS regardless of the
time interval between the first and second PCOS feature).
If presented in formula format, the start and end date were then defined as:
start date = max {15 years, 1st Jan. 2004, registration date + 1 year, ACU date, AMR date}
end date = min {45 years, 31st Dec. 2014, transfer out date, date of the first PCOS diagnosis}
The underlying reason for only including women in reproductive age range is that the major
symptoms of PCOS (i.e. menses) only appear within this age range and it is uncertain whether
a woman has developed PCOS before menarche or after menopause.
The incidence rates (raw data) were computed using the following formula:
Incidence rates =
Total number of events (new PCOS cases)
Total number of person-year at risk from 2004 to 2014
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The annual rates were then graphed to investigate the time trends of the diagnosis of PCOS
(diagnosed cases, probable cases and both diagnosed and probable cases combined). More-
over, I graphed the incidence rates (also raw data) according to age bands to see the change
of rates across different age groups. Multivariable Poisson regression models were used to eval-
uate recordings of all PCOS cases by age (in 5-year age band), social deprivation (quintiles of
Townsend scores) and effects of year (given the changing definition of PCOS, the study period
was split into 3 periods, i.e. 2004-2007, 2008-2011, 2012-2014) as well as to account for clus-
tering effect of patients nested in different practices. A two-level Poisson regression model was
considered here. Suppose there are j = 1, 2, ..., N practices with each practice consisting of
i = 1, 2, ...,mj patients. I then model:
yij ∼ Poisson(λij)
log(λij) = xijβ + uj
where yij are counts and λij = exp(xijβ+uj); the vector xij , a 1×p row vector, represents the co-
variates for the fixed-effects part of the model with regression coefficients β; uj is the random ef-
fects components, which is a multivariate normal distribution with mean 0 and q×q variance ma-
trix
∑
. The variance matrix is a diagonal matrix structured as
∑
=

σ21 0 0 . . . 0
0 σ22 0 . . . 0
. . . . . . . . . . . . . . .
0 0 0 . . . σ2q
.
For the sake of simplicity and in view of the large amount of data (which would dominate in the
absence of particularly strong prior information on the model parameters), I have conducted this
exploratory analysis under a standard Frequentist approach. Note that this piece of analysis will
be fully expanded to a proper Bayesian model in Chapter 5 because the uncertainties associated
with both parameters and models can easily be propagated to the rest of the decision model
(e.g. Markov model) by using a Bayesian approach.
The period prevalence of PCOS records in calendar year 2014 was calculated for diagnosed
cases, probable cases and both diagnosed and probable cases combined (see formula below).
Prevalence =
Total number of PCOS cases in 2014
Total number of women eligible to be included in 2014
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The denominator of the prevalence study consisted of any woman with at least 12 months
of post-registration follow up, at least 6 months of which must have occurred in 2014. The
numerator consisted of all women in this denominator who were identified as PCOS cases defined
by the previous section. Secondary analysis in terms of post-registration period (i.e. 1 year, 2
years) and time registered within 2014 (i.e. 3, 6, 9 months) were also performed.
PCOS cases were then stratified by age (5-year age band) to investigate the age-specific
prevalence of PCOS for the study population.
The followings were also graphed to explore the characteristics of the patient cohort: (i) the
time distribution for a probable case to be formally indexed as a diagnosed case (diagnosed cases
with two or more features recorded before the date of their confirmed diagnosis were looked at);
(ii) the time between the index date of the first two diagnoses of PCOS features for probable
cases; (iii) the distribution of time between the date of PCOS diagnosis for cases and the end
of study period (31st Dec. 2014) stratified by age groups.
4.4.3 Analysis of drug treatment
Since there is variation in the symptoms of PCOS, it is expected that PCOS patients may
receive a wide range of prescriptions depending on their clinical presentations. Consequently,
different chapters of the British National Formulary were searched to identify drugs that are
most relevant to PCOS. e.g. oral contraceptives, metformin. I referred to the recommendations
of treatments in the PCOS guideline and other published studies on this aspect (Sheehan, 2004;
Conway et al., 2014).
The first record of a list of relevant treatments to PCOS was extracted both before and
after the diagnosis of PCOS. For each treatment included, the followings were computed:
 The proportion of PCOS patients who were on a certain type of drug before the diagnosis
of PCOS;
 The proportion of PCOS patients who newly (i.e. not on this drug before the diagnosis of
PCOS) initiate a certain type of drug following the diagnosis of PCOS.
Given the post-registration time of individual patients (1 year), the cumulative incidence
plots of different drug categories were restricted to 2004 to 2012 (censored two year before the
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end of study period in case those who started in 2012 do not have enough follow-up time as the
post-registration time requirement is 1 year).
4.5 Results
4.5.1 Prevalence and incidence outcomes
In total, over 14,000 individuals (amongst 2,087,107 eligible women) aged 15-45 years old had a
medical record indicative of potential PCOS between 2004 and 2014, which equated to 1.84 per
1000 person-year at risk (PYAR, 95% CI: 1.81-1.87). The rate for diagnosed PCOS cases was
0.93 per 1000 PYAR (95% CI: 0.91-0.96) whereas the rate for probable cases was 0.91 per 1000
PYAR (95% CI: 0.89-0.93).
The change of incidence rates over time and the age-specific rates are presented in Figure
4.5.1. The overall incidence of PCOS increased from 1.67 (95% CI: 1.58-1.77) per 1000 PYAR in
2004 to 2.00 (95% CI: 1.89-2.10) per 1000 PYAR in 2010, after which the rate remained relatively
constant at approximately 2 per 1000 PYAR. The incidence rates after 2007 are significantly
higher compared with that before 2007 for probable cases as shown in Table 4.3.
The incidence was the highest for those in the 20-24 age group (3.59 per 1000 PYAR, 95%
CI: 3.47-3.70) whereas the age group 40-45 reported the lowest incidence at a rate of 0.62 (95%
CI: 0.58-0.66) per 1000 PYAR. The age-specific trend of PCOS diagnosis was similar for both
diagnosed and probable cases. After adjusting for effects of year, social deprivation and practice-
level variability, significant differences still remained in the incidence of PCOS, i.e. the incidence
rates estimated are significantly lower for all the other age groups compared with the reference
group (Table 4.4).
In terms of social deprivation (measured by Townsend score), there was an increase in record-
ing of PCOS for individuals living in more deprived areas. The incidence of PCOS for individuals
who lived in the least deprived areas was 1.59 (95% CI: 1.53-1.65) per 1000 PYAR whereas those
in most deprived areas reported a rate of 2.23 (95% CI: 2.15-2.32) per 1000 PYAR. This was
statistically significant even after adjusting for effects of other covariates (i.e. age, year) and
practice-level variability (Table 4.4).
The random effects variance estimates suggest that there are some differences in the incidence
estimates across practices.
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The overall prevalence of PCOS in 2014 was approximately 2.27% (95% CI: 2.23-2.31%),
with diagnosed and probable cases reporting 1.34% and 0.93%, respectively. The age-specific
prevalence was the highest for the 30-34 age group and decreased for older age groups. Preva-
lence estimates were not sensitive to the varying post-registration period and the minimal time
registered in 2014, remaining consistently at about 2%.
Figure 4.3: Time trends in PCOS diagnosis record (top) and age-specific PCOS diagnosis record
(bottom) for diagnosed, probable and total cases.
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Table 4.3: Recorded rates (raw rates without modelling) of
PCOS by definition of PCOS, social and demographical char-
acteristics.
Diagnosed PCOS Probable PCOS Overall
Rate per 1000 PYAR (95%CI) Rate per 1000 PYAR (95%CI) Rate per 1000 PYAR (95%CI)
Townsend quintile
1
0.80
(0.76-0.84)
0.80
(0.76-0.84)
1.59
(1.53-1.65)
2
0.90
(0.85-0.95)
0.79
(0.75-0.84)
1.69
(1.62-1.75)
3
0.94
(0.90-0.99)
0.91
(0.86-0.96)
1.85
(1.78-1.92)
4
1.02
(0.97-1.07)
0.97
(0.92-1.02)
1.98
(1.91-2.05)
5
1.07
(1.01-1.13)
1.17
(1.11-1.23)
2.23
(2.15-2.32)
Age, years
15-19
1.20
(1.14-1.27)
0.54
(0.50-0.59)
1.75
(1.67-1.83)
20-24
1.72
(1.64-1.80)
1.87
(1.79-1.96)
3.59
(3.47-3.70)
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Diagnosed PCOS Probable PCOS Overall
Rate per 1000 PYAR (95%CI) Rate per 1000 PYAR (95%CI) Rate per 1000 PYAR (95%CI)
25-29
1.51
(1.44-1.58)
1.49
(1.42-1.56)
2.98
(2.88-3.08)
30-34
1.03
(0.98-1.09)
0.86
(0.81-0.91)
1.88
(1.81-1.96)
35-39
0.45
(0.42-0.49)
0.55
(0.51-0.59)
0.99
(0.94-1.05)
40-45
0.17
(0.15-0.19)
0.45
(0.42-0.48)
0.62
(0.58-0.66)
Period
2004-2007
0.91
(0.87-0.94)
0.82
(0.79-0.86)
1.73
(1.68-1.78)
2008-2011
0.94
(0.91-0.98)
0.95
(0.92-0.99)
1.89
(1.84-1.94)
2012-2014
0.96
(0.92-1.01)
0.98
(0.93-1.02)
1.92
(1.86-1.98)
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Table 4.4: The incidence rate ratios (IRR) and the random-
effects variance estimates obtained from multilevel Poisson
regression model are provided.
Diagnosed PCOS Probable PCOS Overall
Adjusted IRR (95%CI) Adjusted IRR (95%CI) Adjusted IRR (95%CI)
Townsend quintile
1 1 1 1
2
1.14
(1.06-1.23)
0.99
(0.92-1.07)
1.08
(1.02-1.14)
3
1.12
(1.04-1.21)
1.07
(0.99-1.15)
1.10
(1.05-1.16)
4
1.15
(1.06-1.24)
1.06
(0.98-1.15)
1.11
(1.05-1.17)
5
1.15
(1.05-1.25)
1.21
(1.11-1.32)
1.19
(1.11-1.26)
Age, years
15-19
0.69
(0.64-0.74)
0.29
(0.27-0.32)
0.49
(0.46-0.51)
20-24 1 1 1
25-29
0.86
(0.80-0.91)
0.78
(0.73-0.83)
0.81
(0.78-0.85)
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Diagnosed PCOS Probable PCOS Overall
Adjusted IRR (95%CI) Adjusted IRR (95%CI) Adjusted IRR (95%CI)
30-34
0.58
(0.54-0.62)
0.46
(0.42-0.49)
0.51
(0.49-0.54)
35-39
0.26
(0.24-0.28)
0.30
(0.27-0.32)
0.27
(0.26-0.29)
40-45
0.10
(0.08-0.11)
0.24
(0.22-0.26)
0.17
(0.16-0.18)
Period
2004-2007 1 1 1
2008-2011
1.00
(0.95-1.06)
1.13
(1.07-1.19)
1.06
(1.02-1.10)
2012-2014
0.98
(0.92-1.04)
1.13
(1.07-1.20)
1.04
(1.00-1.09)
Random-effects
variance estimates
0.52
(0.44-0.61)
0.32
(0.27-0.38)
0.25
(0.22-0.29)
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4.5.2 Features of patients
The proportion of diagnosed cases who had a PCOS feature of menstrual dysfunction, hyper-
andrgenism and polycystic ovaries (PCO) recorded was 28.4%, 39.2% and 2.8%, respectively
(Table 4.5). The results suggested that 8.3% of the diagnosed cases used to be a probable case
and the probability for a probable case to be formally indexed as a diagnosed case within 1 years
was about 7% (Figure 4.4). On the other hand, menstrual dysfunction, hyperandrogenism and
PCOS were captured in 88.8%, 88.2% and 23.2% of the probable cases, respectively.
Table 4.5: Number and proportion of diagnosed and probable cases with major PCOS features.
Features
No. (%)
Diagnosed cases
(n=7233)
Probable cases
(n=7057)
Menstrual
dysfunction
2055 (28.4) 6265 (88.8)
Hyperandrogenism 2836 (39.2) 6221 (88.2)
Polycystic overies 199 (2.8) 1636 (23.2)
≥2 features 597 (8.3) 7057 (100)
Figure 4.4: Histogram displaying the time distribution for a probable case to be formally indexed
as a diagnosed case.
The time between the index date of the first two diagnoses of PCOS features for probable
cases is presented in Figure 4.5. It suggests that approximately half of the probable cases
have their second PCOS feature recorded within 3 years after the index date of their first PCOS
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feature. This 3-year interval was used as the maximum inter-feature period for the identification
of probable cases as discussed in the methods section.
Figure 4.5: The time between the index date of the first two diagnoses of PCOS features for
probable cases.
As presented in Figure 4.6, older women with PCOS were more likely to have their diagnosis
recorded longer time ago (10-15 years ago) whereas for young women with PCOS, their PCOS
recordings were unlikely to be indexed more than 10 years ago.
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Figure 4.6: Distribution of time between the date of PCOS diagnosis and the end of study period
(31st Dec. 2014) stratified by ageband. Older women with PCOS generally have their date of
diagnosis recorded longer time ago compared with younger women with PCOS.
4.5.3 Prescribing patterns
As presented in Table 4.6, the results have demonstrated that before the diagnosis of PCOS, a
large proportion (over 40%) of women were on combined oral contraceptives (COC), followed
by acne-related drugs (about 30%) and then progestin oral contraceptives (POC, about 20%).
Approximately 18% of the women had previously been prescribed with at least one of the re-
maining drugs, i.e. intrauterine devices, clomiphene, metformin, gonadotrophins, spironolactone,
cyproterone, flutamide, eflornithine, weight control/loss drugs, lipid regulators. The cumulative
percentage of patients who newly initiated acne-related drugs, COC and metformin was the most
common drugs prescribed in the 24 months after a diagnosis of PCOS. The cumulative incidence
plots show that while there is an initial increase in prescribing on or within a short period after
the PCOS index date, this is greater for metformin, acne-related drugs compared with others
(COCs, POCs). Prescription results stratified by case definition indicated that acne-related
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drugs and POCs were more commonly prescribed for probable than diagnosed cases whereas
COCs, metformin, clomiphene, cyproterone, eflorinithine and weight loss drugs were prescribed
more commonly in diagnosed than probable cases (Figure 4.7).
Table 4.6: Number and percentage of PCOS women on relevant drugs for PCOS both
prior to and following the diagnosis of PCOS.
Types of drugs
No. (%)
Before
After
2004-2007
After
2008-2011
After
2011-2014
COC 12349 (40.22) 901 (17.01) 912 (18.87) 459 (17.88)
POC 5806 (18.91) 474 (6.45) 691 (10.22) 272 (7.80)
IUDs 733 (2.38) 44 (0.51) 64 (0.75) 25 (0.52)
Clomiphene 518 (1.69) 210 (2.46) 165 (1.92) 70 (1.43)
Metformin 1278 (4.16) 1212 (14.77) 1102 (13.25) 495 (10.52)
Gonadotrophins 435 (1.42) 29 (0.34) 13 (0.15) 13 (0.26)
Spironolactone 235 (0.77) 109 (1.26) 111 (1.28) 43 (0.87)
Cyproterone 91 (0.30) 28 (0.32) 19 (0.22) 3 (0.06)
Flutamide 6 (0.02) 4 (0.05) 1 (0.01) 0
Eflornithine 530 (1.79) 354 (4.10) 407 (4.81) 172 (3.58)
Weight control/loss drugs 1330 (4.33) 403 (4.84) 364 (4.43) 91 (1.95)
Lipid regulators 194 (0.63) 69 (0.79) 46 (0.53) 8 (0.16)
Acne-related drugs* 9000 (29.31) 1182 (19.52) 1234 (20.78) 582 (18.32)
COC: combined oral contraceptives; POC: progestin oral contraceptives; IUDs: intrauterine
devices; *Acne-related drugs also include a range of topical treatments, e.g. benzoyl peroxide
cream
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Figure 4.7: Cumulative incidence of women with a prescription for each drug type over the 24 months following their index date
stratified according case definition (dashed line for diagnosed case, solid line for probable case). Results shown for the eight most
commonly prescribed drugs. COC, combined oral contraceptive; POC, progestin oral contraceptive.
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4.6 Discussion
4.6.1 Summary of main findings
For the current analysis, over 14,000 potential PCOS cases in women of reproductive age were
identified in practices across UK during the 10-year period from 2004 to 2014. More than half of
the cases identified have received a confirmed diagnosis of PCOS (diagnosed cases) whereas the
remaining women only have features indicative of PCOS (probable cases). This corresponds to
an incidence rate of 0.93 per 1000 PYAR (95% CI 0.91 to 0.96) and 0.91 per 1000 PYAR (95%
CI 0.89 to 0.93) for the diagnosed and probable cases, respectively. The prevalence of PCOS in
2014 was estimated to be 2.27%. A wide range of treatments have been initiated in the primary
care for women with PCOS and the prescribing pattern varies for diagnosed and probable cases.
The results suggested that oral contraceptives have been frequently used by women with PCOS
both prior to and after the diagnosis of PCOS was recorded. A greater proportion of diagnosed
cases received metformin on the day, or after the diagnosis has been recorded while a greater
proportion of probable cases received treatments tailored to the external symptoms of PCOS
such as acne.
4.6.2 Comparison with literature
The prevalence of PCOS in the UK primary care in 2014 was comparable to that obtained from
studies using other databases with a range from 0.56% to 2.22% (Lo et al., 2006a; Okoroh et al.,
2012; Christensen et al., 2013; Sirmans et al., 2014a). However, the rates are significantly lower
than those from community-based studies in Europe where rates generally ranged from 5.4% to
8% were observed using the NIH criterion (Michelmore et al., 1999; Diamanti-Kandarakis et al.,
1999; Asuncio´n et al., 2000; Sancho´n et al., 2012).
The proportion of women with PCOS who had been using oral contraceptives prior to their
PCOS diagnosis is comparable to other studies (Okoroh et al., 2012; Glintborg et al., 2015).
The proportion of PCOS patients who initiated metformin following a diagnosis is also similar
to a Danish study that reported the percentage of the PCOS population in their sample who
have received metformin to be about 12% (Glintborg et al., 2015).
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4.6.3 Interpretation
The incidence of PCOS increased slightly over the study period although no significant changes
were observed in any consecutive year. This may suggest that there was increasing awareness
of this syndrome after the gradual establishment of major criteria of PCOS. However, the fact
that the database has been improved over the time could also be an underlying reason for the
increasing rates.
Results from the multilevel Poisson regression model suggested that women who lived in
more deprived areas had a larger incidence of PCOS compared with those living in the less
deprived areas. This could be due to that obesity is more prevalent among women living in
more deprived areas. Alternatively, women living in these areas may have more complications
and therefore visit their GPs more frequently to have PCOS diagnosed and recorded.
The incidence of probable cases was comparable to that of diagnosed cases, indicating that a
large number of women who present with features of PCOS (within a 3 year period) in primary
care do not receive PCOS diagnosis subsequently. However, it is possible that some of these
probable cases have been referred to the secondary care for a confirmed diagnosis whereas a
diagnosis has not been recorded in the primary care. While a confirmed diagnosis may not
be relevant for some of the probable cases, it is likely that some of the women with features
of PCOS actually meet the criteria of PCOS and should receive further assessment. Failure
to refer such women may result in that these women are not offered the proper care for the
treatment of PCOS such as lifestyle modification or medications. Considering the relative low
cost of screening/diagnosis and the high cost of care for the associated disorders (Azziz et al.,
2005), further work is needed to inform women and health care providers about this condition.
There is considerable variation in the treatments prescribed to diagnosed and probable cases,
for example, a greater proportion of diagnosed women received metformin as medication whereas
many probable cases received medication tailored to the features they present with. This sug-
gests that diagnosed and probable cases indeed received different care for this syndrome and
some of the probable cases may not receive the most effective treatments. The wide variation in
prescribing pattern could also be explained by the fact that the clinical presentations of PCOS
not only varies by individual but also by age, i.e. younger women are more likely to initiate
drugs to regulate their menses while older women may ask for drugs to prevent rapid conversion
to diabetes.
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The most common drugs prescribed for women with diagnosed PCOS were metformin and
oral contraceptives, possibly reflecting the major long-term metabolic concerns of this syndrome
as indicated by the PCOS consensuses. However, even among women with diagnosed PCOS, the
treatments prescribed varied, indicating the lack of consensus for the ideal treatment of PCOS.
Therefore, there is much potential for future research to investigate the most cost-effective
treatments for this condition.
4.6.4 Strengths and limitations
To the best of our knowledge, this piece of analysis is the first to investigate the diagnosis and
management of PCOS in the primary care setting in the UK. THIN contains patient information
from more than 500 practices and our study population included more than 2,000,000 women.
Therefore, the current analysis is advantageous in terms of sample size and because the data
were contributed from practices across the UK, the sample was also considered to be broad
representative for the UK population. The trends of PCOS recording was examined over a 10-
year period, which has not been explored by any previous epidemiological studies where study
population was often sampled at a single time point.
The results in the current study are largely likely to reflect the true burden of PCOS for
the healthcare system since the data were coming from the routine clinical practice. However,
notice that since only data considered relevant at a consultation are recorded, underdiagnosis
was a major concern for this analysis. Consequently, it is not surprising to observe a low
proportion (i.e. 8%) of diagnosed cases with 2 or more features of PCOS recorded because once
a confirmed diagnosis has been made by a specialist, general practitioners are unlikely to record
anything further. Attempts have been made to identify and include women with features of
PCOS (interfeature within 3 years) as probable cases to address the under-reporting issue. This
may introduce case misclassification since some of the probable cases may not be true cases.
On the contrary, it could also be that some of the probable cases indeed have developed the
condition but were not captured and recorded for some reasons.
Another issue is considered to be the incomplete information of ethnicity (less than 50% of
the patients have this variable recorded in THIN) and the incidence rates can be influenced by
the unobserved differences in ethnicity distributions across the other variables such as age and
deprivation level.
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The indication of drugs is not specified in the prescription files of each patient and therefore
it is uncertain if the drugs prescribed following a diagnosis or even on the day of a record were
indeed for the treatment of PCOS. The results suggested that approximately 30% of the PCOS
patients prescribed metformin had a diagnosis of type 2 diabetes before their PCOS diagnosis.
By excluding these patients, it is more certain that metformin was prescribed at least partly
for the treatment of PCOS, with the proportion of patients initiated the drug lying somewhere
between 8% (on the day of diagnosis) and 20% (cumulative proportion within 24 months).
The advantage of using a 24-month window is that it allowed to capture prescriptions initiated
by specialists in secondary care that are transferred back to primary care. This is supported
by the cumulative incidence curves because the initiation of drugs that are more commonly
prescribed in secondary care (e.g. spironolactone) was further away from the origin (the day of
PCOS diagnosis).
In the next chapter, I will explore the healthcare burden of PCOS and the quality of life for
PCOS population in the UK by synthesising evidence from previous chapters using modelling
approach.
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Chapter 5
MODELLING THE BURDEN OF
PCOS IN THE UK
5.1 Chapter summary
The previous chapters suggested that PCOS is associated with a range of morbidities, however
the major concern for PCOS patients raised by most endocrine societies is the elevated risk of
type 2 diabetes. Based on the evidence identified in the previous chapters, it is likely that a
substantial proportion of PCOS patients may develop type 2 diabetes later in life (e.g. after
the age of 35 or 40), exerting large economic impact on the National Health Service (NHS)
in the UK. Therefore, it is of great interest to project the prevalence/incidence of diabetes in
the PCOS population and evaluate the potential burden of disease as well as the quality of life
(QoL) of individual patients in the near future. In such way, one is likely to have a clear view
of the public health impact of PCOS and can attempt to propose some ways to improve the
current situation. This chapter introduces the economic evaluation of disease burden and the
analysis of QoL associated with PCOS under the UK context. I firstly gives an overview of the
methods commonly used for the health economic evaluation. After this, the specific methods for
modelling the population dynamics of PCOS (i.e. a multistate Markov model) and the sources
of data used to populate the model are described. I then present outcomes from simulations
(based on a virtual PCOS cohort estimated from the UK census data) in terms of the number of
patients ending up in different states of the model, the healthcare burden of disease and the QoL
for the entire PCOS population in the UK over a relatively long period of follow-up. The results
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of QoL were compared with the simulated outcomes for a virtual healthy cohort of the same
population size. The main findings in this chapter have been converted into a paper submitted
to Human Reproduction and is currently under revision.
5.2 Background
In clinical decision making, a decision tree can often model the prognosis of patients and help
to guide the choice of management strategy for the condition (Elwyn et al., 2001). Figure 5.1
presents a possible decision tree for PCOS patients who come to see the clinician for treatment
consultation. A woman with PCOS may already have developed diabetes and therefore, treat-
ments for diabetes such as metformin should be prescribed to such patients. However, if the
woman have not developed diabetes yet, the clinician may prescribe treatments tailored to the
most prominent external symptoms of the patient. For example, as suggested in Figure 5.1, a
non-diabetic but obese patient may receive orlistat and is asked to take a diet. Conversely, a
non-diabetic and non-obese patient may only need drugs such as oral contraceptives to regulate
menstrual dysfunction. It should be noted that although drugs for disease management are
prescribed for all the non-diabetic patients, an adverse event may still occur, e.g. non-obese
patient who receive oral contraceptives may still develop diabetes. For each clinical scenario,
the associated cost and utility can be measured. For example, for obese patients who received
orlistat and take a diet but still develop diabetes later in life, the overall cost is calculated as
the cost spent on orlistat and a diet plus the cost of treating diabetes. Similarly, the utilities
can be attached to patients under each clinical scenario, e.g. we would expect that patients
who eventually develop diabetes have lower quality of life compared with those who do not
develop diabetes.
However, there are a few shortcomings for this model. The most obvious one is that the
time when an event occur is not clearly indicated. Moreover, an adverse event may occur more
than once. For example, some women with PCOS may lose weight and have normal BMI after a
period of diet management while become obese again. The decision tree can be very complicated
to depict if there are too many branches and one may find it difficult to assign utilities for each
of the outcomes, e.g. non-obese PCOS patients without diabetes.
Consider another scenario where there are only four possible health states: Healthy, Disease,
Recovery, Death. If we use a decision tree to describe this, then a patient starts in healthy state,
119
Figure 5.1: A possible decision tree for PCOS patients who come to see the clinician for drug
consultation. The recommended prescriptions for patients with different phenotypes of the
condition are indicated in green.
may develop the disease, stay healthy or die. However, apart from staying in death state (transit
from either healthy or disease state) forever, the patient can transit from healthy to disease state
(or back) recurrently. Consequently, the decision tree would get too many branches (see Figure
5.2) and become very complicated to analyse.
However, this situation can be much better depicted and analysed using Markov models
(MM, Sonnenberg and Beck, 1993). In a MM, a finite set of states (assumed to be mutually
exclusive and exhaustive) are used to represent possible health status of a progression disease.
It is assumed that patients can transit from one state to another with some probabilities which
may be based on patient characteristics such as age and sex or time point. For example,
Figure 5.3 presents the structure of a MM including the four health states defined previously.
Arrows indicate that individuals can move between the two states from the one where the arrow
originates to the one where it ends. The absence of an arrow indicates that the movement
between the two states is not possible. The healthy and disease state are recurrent states. The
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Figure 5.2: A decision tree for a scenario that only includes four possible health states: Healthy,
Disease, Recovery, Death. A patient starts in healthy state may develop the disease, stay
healthy or die. Apart from staying in death state (from either healthy or disease state) forever,
the patient can transit from healthy to disease state (or reversely) recurrently.
death state is an absorbing state such that once individuals move there, they will remain there
forever. In this way, one can easily get rid of the large number of branches of the decision tree.
Given that MM provides a much more convenient and efficient way to model the likely outcomes
of a disease, particularly for recurrent events occurring over time, they are widely used for health
economic evaluation.
Once the structure of the model is specified (e.g. the number of health states), we need to
define the time horizon (e.g. 15 years) and then estimate the transition probabilities. The time
horizon (also called the follow-up period) can often be modelled by discrete cycles (e.g. months,
years). This “virtual” follow-up period can be determined depending on the specific disease or
outcome of interest examined and we would expect that if the follow-up period is long enough
(e.g. 100 years), all the individuals coming into the model would end up in the absorbing state
of death. After defining all these quantities, we can use the MM to simulate the likely outcomes
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Figure 5.3: The structure of a basic Markov model involving four possible states. The circle
represents each possible health state. Arrows indicate that individuals can move between the two
states from the one where the arrow originates to the one where it ends. If an arrow connecting
the two states is absent, then a transition is not possible. The blue thick arrows represent that
individuals remain in the original state without transiting to another state in the model. The
state of death is considered to be an absorbing state such that individual moving from all the
states to there remain forever. The transition probabilities between the states are indicated as
“pij” where i, j = 1, 2, 3, 4. Since death is an absorbing state, p44 is equal to 1.
for a “virtual” cohort over a period of time. The outcomes (e.g. the number of individuals in
the disease state at endpoint) can then be summarised from these simulations. Note that it
is possible to evaluate the impact of some given interventions. For example, suppose that a
new drug is available on the market which largely increases the probability of recovery (this is
equivalent to the assumption that p23 in Figure 5.3 suddenly increases). Moreover, by attaching
costs and quality of life data to each state in the model, we can also perform economic evaluation
and utility analysis.
In reality, uncertainties are often expected because sometimes it is difficult to collect exper-
imental data to inform some of the parameters, e.g. the transition probabilities from PCOS to
diabetes for menopausal women. For these parameters, assumptions based on limited evidence
and/or clinical expert consultation are typically applied. A Bayesian approach can formally
incorporate existing evidence from several sources to construct a probabilistic MM (Baio, 2012).
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By using a simulation method, it is possible to characterise the uncertainties about all the pa-
rameters and further propagate these uncertainties to the MM. In fact, the Bayesian procedure
produces a large number of simulations from the joint distribution of all the parameters. These
can be used to simulate for a bunch of potential “futures” with respect to population dynamics
as determined by the transitions between either two states of the MM.
Suppose that for a given discrete time MM, there are S states and the simulations are
performed for K cycles. We use mk = (m1k,m2k, . . . ,mSk) to represent the total number of
patients who enter into each state, where the element msk included is defined as the number
of patients in state s at time k. Let Pk denote the matrix that includes all the transition
probabilities between states over the discrete time (i.e. k ∈ N = {0, 1, 2, . . . }). Then the
element pss′k arranged in Pk is defined as the probability for a patient to transit from state s
to s′ between the consecutive cycles k − 1 and k. The total number of patients at a given time
point for a given state can then be computed as follows:
mk = mk−1 × Pk.
In other words, the total number of patients distributed over the states at cycle k equals the
total number of patients at cycle k − 1 times the transition probabilities between cycles k − 1
and k.
The associated costs and utilities for each state at a given time point can be computed by
the multiplication of unit cost/utility and the absolute number of patients in that state. For
example, assuming that the cost of treatments for an individual patient who remains in State 1
is constant over time (represented by c1), then the overall cost for patients in this health state
at time k is estimated as m1k × c1. The utilities attached to each state at a given time can be
estimated in the same way.
Note that the time horizon of a MM is often large (e.g. 25 years) whereas people are likely to
value more for the benefits that can be received closer to the present time compared with those
that they will get in the later future. As a consequence, it is essential to apply discounting when
measuring the costs and utilities in the future (Torgerson and Raftery, 1999). Discounting dif-
ferentiates outcomes that occur at different time point and accounts for people’s time preference
by devaluing the costs and benefits that will be seen in the future. It is generally accepted that
if the time horizon for an economic evaluation is greater than 1 year, then a discounting factor
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(1 + d)k needs to be applied for the costs or other outcomes measured where d is the discount
rate and k is the time when the costs/outcomes occur (Drummond et al., 2015). It may also
be of interest to compute the present value (PV) of costs or other outcomes that occur over the
entire time horizon examined. For example, the PV of the total costs over the follow-up period
examined for a MM can be specified as
PV =
K∑
k=0
S∑
s=1
ck ×msk
(1 + d)k
,
where ck represents the costs of the treatment at time k and K is defined as the number of
time points included in the analysis. This is equivalent to summing up the discounted costs
at each time point for all the states included in the model. Similarly, this formula also applies
for the calculation of the PV of benefits. Note that NICE suggests a discount rate of 3.5%
(i.e. d = 0.035) for all the costs and outcome measurements (National Institute for Clinical
Excellence, 2004).
To conclude, the general steps required to conduct a health economic evaluation using the
MM include:
 Specify the model structure including the number of possible states through the disease
progression;
 Define the time horizon of the model;
 Construct the matrix including transition probabilities between either two of the possible
states at each time point evaluated;
 Define the cohort matrix which includes the number of patients in each possible state at
each time point evaluated for the purpose of simulation;
 Run the MM model (multiplication of the cohort matrix and matrix of transition proba-
bilities) to get a large set of simulated “futures”;
 Summarise results from simulations and record the economic and utility outcomes associ-
ated with each state at each time point;
 Discounting should be applied if the time horizon of the MM exceeds one year.
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5.3 Aim
The objective of this chapter was to firstly estimate the prevalence of type 2 diabetes among
PCOS population in the UK over a 25-year follow-up period from 2014 to 2039. This would
further allow me to establish the economic burden related to healthcare for PCOS and evaluate
the quality of life for the entire PCOS population in this country over the period examined.
5.4 Modelling approach
5.4.1 Overview of the model
For PCOS, it is assumed that there are four possible states for the disease progression (as shown
in Figure 5.4) and the descriptions for each state are described below:
 State 1 (Probable PCOS ): Women with PCOS in this state are assumed to have developed
PCOS but remain clinically undiagnosed. From the previous chapters, we have seen that
there is a large number of women with symptoms indicative of PCOS but have not received
a confirmed diagnosis.
 State 2 (Diagnosed PCOS ): Women with PCOS in State 2 have been clinically diagnosed
and this population consists of prevalent cases and incidence cases (newly emergent cases
each year).
 State 3 (PCOS with diabetes): This state includes PCOS patients who have developed
diabetes. The number of patients in this state would increase if the accumulative number
of patients who gradually develop diabetes (coming from both State 1 and 2) exceeds those
who have died (transit into State 4).
 State 4 (Death): This state includes individuals who are dead from all states.
The assumptions for this proposed model include:
 Each year, a certain proportion of probable cases convert into diagnosed cases with a
transition probability p12. Women who remain undiagnosed after the age of 45 are assumed
to be unable to receive a diagnosis for this syndrome since the most prominent external
presentation (i.e. menses) disappears after reproductive age.
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Figure 5.4: The structure of Markov model for modelling the population dynamics of PCOS.
It is assumed that there are four possible states for the disease progression of PCOS: Probable
PCOS (State 1), Diagnosed PCOS (State 2), PCOS with diabetes (State 3) and Death (State
4). Rounded rectangles represent a single health state. Arrows indicate that women can move
across two states (from the one at which the arrow originates, to the one where it ends). If the
arrow is absent between the two states, then the assumption is that a particular transition is
not possible. The state of death is an absorbing state and individuals from any state can move
there and stay forever.
 The total number of cases in State 2 in a calendar year is then assumed to be equal to
the number of newly emergent cases plus the prevalent cases (defined as cases that have
already been diagnosed in the previous year).
 For women who have developed PCOS (either probable or diagnosed cases), some propor-
tion will transit into State 3.
 Once a patient with PCOS have developed diabetes, she is assumed to remain in State 3
until death and can never recover given the nature of diabetes.
 PCOS itself does not increase mortality but mortality for PCOS patients who have devel-
126
oped diabetes differs significantly from that for individuals in other states. This is a strong
assumption considering that cardiovascular diseases (CVD) can largely increase the mor-
tality rates and PCOS patients are found to at elevated risk of CVD compared with the
general population as suggested in Chapter 2. However, a review by Legro et al. pointed
out that while existing data suggested that PCOS is likely to adversely affect the cardio-
vascular risk profile, its impact is limited for pre-menopausal age group (Legro, 2003). This
is supported by the findings from a study conducted in the UK where the CHD-related
mortality among 786 women with PCOS (evaluated after 30 years of diagnosis) was not
found to be significantly higher than the national rates (Pierpoint et al., 1998). Therefore,
the current analysis only considered diabetes as the main cause of elevated mortality for
PCOS population.
The list of parameters in Figure 5.4 with their definition and sources of ‘real-world’ evidence
are presented in Table 5.1.
Table 5.1: Model inputs
Parameter Definition Source
p12
Transition probability from probable PCOS
to diagnosed PCOS
Estimated from THIN
p13
Transition probability from probable PCOS
to diabetes
Estimated from THIN
p24
Transition probability from diagnosed PCOS
to diabetes
Estimated from THIN and published
literature
p14, p24
Transition probabilities from probable and
diagnosed PCOS to death
Assumption based (assume that PCOS
does not increase mortality and
therefore is estimated using rates in
general population)
p34 Transition probability from diabetes to death
Based on mortality rates in published
studies
5.4.2 Estimating the transition probabilities
I started by estimating the transition probabilities between different disease states (State 1,
2 and 3) in the Markov model for PCOS cohort. A Poisson regression model fitted using a
Bayesian approach and its hierarchical version (to account for practice-level variability) were
used to obtain the incidence rates. Recall that in Chapter 4, the Frequentist method was used
to model the incidence rates of PCOS and in this Chapter, the model was fully expanded to
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a Bayesian version. This is particularly relevant as the Bayesian framework allows to easily
propagate uncertainty in the transition probability to the ultimate estimates through the MM.
This enables a better characterisation and quantification of the burden of the disease. The
incidence rates were converted into transition probabilities. The formula for conversion and its
associated assumptions will be discussed later on.
Age group specific incidence rates were estimated due to the fact that: (i) results in the
previous chapter suggested that younger women are more likely to be diagnosed and most women
with PCOS received a diagnosis before the age of 35; (ii) age is a factor strongly associated with
the onset of type 2 diabetes (Sharma et al., 2016).
The standard Poisson regression model used to estimate the age group specific incidence
rates was specified below:
yi ∼ Poisson(λi) (5.1)
log(λi) = β0 +Xiβ + log(ti), (5.2)
where yi is the event indicator representing a Poisson process for individual patient during the
entire follow-up period. The parameter β0 is the baseline incidence rate and β is the incremental
effects of other variables on the baseline rate. For the current analysis, age was included as a
categorical variable with 6 levels and β0 is the incidence rate for individuals aged 40-44. The
parameters β1, β2, . . . , β5 represent the effect of age on the incidence rates in age group 15-19,
20-24, 25-29, 30-34, 35-39 compared with the reference group. Note that ti is the time of follow-
up and was included as a log offset in the linear predictor. This model was applied to estimate
the parameters λ12, λ23 and λ13.
For the estimation of λ12 and λ13 (incidence rates for probable cases to receive a confirmed
diagnosis of PCOS and diabetes, respectively), minimally informative priors were used, e.g.
β0 ∼ Normal(0, 100). This is due to the fact that no studies have been identified that provide
some insights into such transition rates in women with symptoms indicative of PCOS. Therefore,
little is known (even after discussion with the clinician in the team) to allow me to make strong
assumptions for statistical inference. In terms of estimating λ23 (incidence rates for diagnosed
cases to convert to diabetes), different versions of prior were attempted due to the availability
of published studies. This is likely to help minimise the impact of bias (e.g. referral bias,
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incompleteness of patient information, recording errors of the database, etc.) that may exist in
the data I used and the published studies.
Three scenarios were considered.
 Scenario 1: minimally informative priors for baseline incidence rate and incidence rate
ratio in comparison with other age categories were included:
β0, β1, ..., β5 ∼ Normal(0, 100).
As all the parameters are on a log scale, the prior Normal(0, 100) is very vague. In this
scenario, no formal knowledge on the range of rates was included and consequently, the
results would be driven only by the data.
 Scenario 2: informative priors for baseline incidence rate and incidence rate ratio were
included based on external evidence from published literature. Firstly I referred to the
incidence of diabetes in the general female population aged 40-44, denoted by βpop on the
log scale. It is suggested that the incidence rate for this age group is 3 per 1000 person-
year (PY) (Sharma et al., 2016). This can be translated into a mean on the log scale of
ln(0.003) = −5.809. Thus the parameter βpop was modelled using a Normal distribution
centred at −5.809 with some variability that reflect the uncertainties of this estimate:
βpop ∼ Normal(−5.809, 0.01).
Figure 5.5 is a graphical representation of the distributional assumption made for the
parameter βpop. We can see that the mean is centred at 3 per 1000 PY with a small 95%
interval of (2.95, 3.05). This is consistent with what is reported in the study by Sharma
et al. (2016).
The relative risk of diabetes comparing PCOS patients and the general population was
then defined and represented by ρ. Therefore, the incidence of diabetes in PCOS patients
in the reference group (defined as β0) can be calculated as.
β0 = βpop × ρ.
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Figure 5.5: Graphical representation of the prior distribution of βpop on the natural scale, which
reflects the assumption that the incidence of diabetes in the general female population aged
40-44 is 3 per 1000 PY with a small variance (the horizonal bar in bold represents the 95%
interval: 2.95-3.05 per 1000 PY). This reflects the estimate in the published study by Sharma
et al. (2016).
Note that there is evidence that the relative risk of developing diabetes for women with
PCOS are 3.02 (95%: 2.73-3.33) compared with the general female population (Morgan
et al., 2012). Therefore, the incidence of diabetes in the PCOS patients aged 40-44 is
expected to be around 9 per 1000 PY (3 per 1000 PY times the relative risk of 3), with
some variability (95% interval: 8.1-10.2 per 1000 PY). After converting this rate to the log
scale, it corresponds to a value of −4.71 with a 95% interval of (−4.82 to −4.59). In other
words, the product of βpop and ρ (represented by β0) is expected to follow a distribution
shown as below:
βpop × ρ = β0 ∼ Normal(−4.71, 0.06).
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The resulting distribution of β0 on the natural scale is presented in Figure 5.6. We can
see that the mean is centred at 9 per 1000 PY. The 95% interval also largely corresponds
to the rates obtained in the previous calculation.
Figure 5.6: Graphical representation of the prior distribution of β0 on the natural scale, which
reflects the assumption that the incidence of diabetes in the PCOS population aged 40-44 is
9 per 1000 PY with a small variance (the horizonal bar in bold represents the 95% interval:
8.1-10.2 per 1000 PY). This is produced based on estimates in the published studies.
I further referred to the relative risk of diabetes (represented by β1, β2, ..., β5 on the log
scale) across different age groups compared with the reference age group in the study by
Sharma et al. (2016). The prior distributions for β1, β2, ..., β5 were included to encode
the assumption that, compared with the reference group, women aged 15-19, 20-29 and
30-39 are 0.09, 0.37 and 0.63 times less likely to develop diabetes. These relative risks
were converted to the log scale. For each parameter, the log mean is consistent with the
estimate on the natural scale and a relatively small variance was included to reflect the
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uncertainties of these estimates as reported by Sharma et al. (2016):
β1 ∼ Normal(−2.408, 0.001)
β2, β3 ∼ Normal(−0.994, 0.001)
β4, β5 ∼ Normal(−0.462, 0.001).
 Scenario 3: similarly, the priors included in this model were informed by external evidence
but in a slightly different manner. A case-control matched study using the General Practice
Research Data (GPRD) in the UK was identified that examined the incidence rate of type
2 diabetes in PCOS population from 1990 to 2010 (Morgan et al., 2012). The structure
of GPRD is similar to that of THIN. For example, GPRD also collects primary care data
across practices in the UK with a higher coverage (e.g. covering 7% of the total population
in the UK) and 50-60% of the practices contributing data to THIN also provide data to
GPRD. Note that the two databases also share the same coding system. Therefore, results
from this study were considered to be relevant to inform the model I used and help to
limit bias that may exist both in the THIN data and the previous study.
Equation 5.2 suggests that β0 is the baseline incidence rate (on a log scale) for the reference
group (i.e. women aged 40-44) and β1, β2, ..., β5 represent the relative risk of diabetes
across age groups compared with the baseline group. Therefore, the incidence rate on
the natural scale for women in the comparison groups can be computed as exp(β0 + βh)
where h = 1, 2, 3, 4, 5 represent women in age group 15-19, 20-24, 25-29, 30-34 and 35-
39, respectively. The overall incidence rate βprev then can be calculated by proportional
weighting using the following formula:
exp(β0 + β1)w1 + exp(β0 + β2)w2 + ...+ exp(β0 + β5)w5 + exp(β0)w6 = exp(βprev),
where w1, w2, ..., w5 are the proportion of women in each age group estimated from the
THIN cohort, e.g. the percentage of women aged 15-19 in the study population included
from THIN. Consequently, the assumption here is that the age distribution of the cohort
from THIN is the same as that of the GPRD study. This was considered to be reasonable
since the source of data and the structure of GPRD is quite similar to the THIN database.
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By rearranging the above formula, the following equation was obtained that can be used
to compute the baseline rate:
β0 = βprev − log
{ 5∑
n=1
[wh × exp(βh)] + w6
}
.
The model was completed by including informative prior distributions to encode assump-
tions that reflect estimates in the published studies. For example, the overall rate of
diabetes (represented by βprev and is on log scale) was estimated to be 5.7 per 1000 PY in
the PCOS population in the GPRD study, with a 95% interval of (5.17, 6.29). This was
converted to the log scale:
βprev ∼ Normal(−5.167, 0.05).
The same assumptions in Scenario 2 were still applied for women in the remaining age
groups: women aged 15-19, 20-29 and 30-39 are 0.09, 0.37 and 0.63, respectively, less likely
to develop diabetes compared with women aged 40-44. This is represented by the following
distributions on the log scale:
β1 ∼ Normal(−2.408, 0.001)
β2, β3 ∼ Normal(−0.994, 0.001)
β4, β5 ∼ Normal(−0.462, 0.001).
It should be noted that for Scenario 2 and 3, the variances of all the prior distributions
included are small and are consistent with the variability of the estimates provided in the
published studies by Sharma et al. (2016) and Morgan et al. (2012). In addition, sensitivity
analyses were performed to assess the impact of increasing the variance of some of the parameters
(e.g. increase the variance from 0.001 to 1 for relative risk of diabetes across different age groups).
Apart from the above standard model, a multilevel Poisson regression model was also fitted
to account for the variances that may exist across different practices. The hierarchical version
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of the model can be specified as below:
yij ∼ Poisson(λij)
log(λij) = β0 + βXij + log(tij) + uj ,
where yij was defined as the event indicator representing a Poisson process for the ith individual
in the jth practice; tij is the time of follow-up for the ith individual in the jth practice; uj is
the random components of the model indicating variability between practices and the following
prior distribution was included for this parameter:
uj ∼ Normal(0, σ2)
σ ∼ Uniform(0, 10).
This prior is quite vague and the underlying assumption is that the difference in the incidence
rates across practices in the UK is centred at zero whereas is associated with large variability.
The priors included for the regression coefficients (i.e. β) are exactly the same as those
discussed previously for the standard Poisson regression model because the purpose for this
hierarchical model was to assess whether there is variation in the incidence rates across practices.
The model convergence was assessed using the Gelman-Rubin statistics and the statistics
were provided for all the model parameters. The Gelman-Rubin statistic is designed specifically
to assess the output of MCMC algorithm by looking at differences between multiple Markov
chains (Gelman and Rubin, 1992). By comparing the estimated between- and within-chains
variances for each of the model parameters, the convergence can be examined and large differ-
ences between these two variances would indicate issue of non-convergence. Note that there is a
numerical cut-off value of 1.1 for Gelman-Rubin statistic, values below which indicate the Monte
Carlo Markov model procedure converges to the target posterior distribution.
The incidence rates estimated from the Poisson regression model (and its hierarchical version)
were then converted to annual transition probabilities using the following formula (Gidwani,
2014):
pij = 1− e−λij , i, j = 1, 2, 3.
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The underlying assumption is that the incidence rate is constant for a given age group over a
Markov cycle of 1 year. This was considered reasonable as PCOS and type 2 diabetes are chronic
disease and therefore, the population-level incidence rate is unlikely to change drastically over
a short period of time such as 1 year.
Mortality rates in the general population were referred to UK life table (Office for National
Statistics, 2016) whereas those in the diabetic patients were based on empirical studies on
diabetes, i.e. female patients with type 2 diabetes are 2.13 times more likely to die compared
with the general female population (Mulnier et al., 2006). These rates were directly applied as
the transition probabilities from disease states to death (p14, p24 and p34) without using any
modelling approach.
Note that a healthy cohort was simulated to work as the comparison group for the PCOS
cohort with respect to the reduction in quality of life over the follow-up period (which will be
discussed later in Section 5.4.5). Similarly, a Markov model with three health states (healthy,
diabetes and death) was specified and the transition probabilities between either two of the three
states were estimated. The incidence rates of diabetes in the general population suggested by
Sharma et al. (2016) were used to compute transition probabilities between the healthy and
diabetic state. Likewise, mortality rates in the general population and the diabetic patients
were referred to UK life table and Mulnier et al. (2006), respectively.
5.4.3 Cohort simulation
A virtual PCOS cohort estimated using the prevalence rates in 2014 (refer to Chapter 4) and UK
census data from the Office of National Statistics (Office for National Statistics, 2014) were used
to simulate the population dynamics of PCOS from 2014 to 2039. The transition probabilities
estimated in the previous section were applied. Two scenarios were considered:
 Closed cohort model: women aged 15-44 were included and the number of patients who
start in each state at the baseline year (2014) was assumed to be consistent with previous
estimates from THIN, i.e. 18.2% of the PCOS patients had a prior diagnosis of type 2
diabetes and therefore, these women start in State 3 (PCOS with diabetes). Another
assumption is that there is no death for the entire cohort simulated at the baseline year.
Given that a limited number of deaths occur in women aged below 45 (i.e. mortality
rates smaller than 0.13%), this assumption is not expected to have massive impact on the
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overall simulation.
 Open cohort model: while others remain the same as the closed cohort model, women
aged 1-14 at the baseline year were also simulated in a way such that this cohort enters
the study population gradually when they reach the age of 15. The number of probable
and diagnosed cases was calculated based on the prevalence rates estimated from THIN
for the age group 15-19. Therefore, women aged 1-14 were assumed to be diagnosed at
the same rates as the youngest age group once they are eligible to be included in the
study population.
Likewise, for the virtual healthy cohort, both closed and open cohort model were simulated.
Some of these women start in diabetic state and the number of women with diabetes was assumed
to be consistent with the report by Diabetes UK (2015) where age-specific prevalence of diabetes
is provided.
5.4.4 Economic analysis
In this section, the methods used to evaluate the healthcare-related economic burden of PCOS
is introduced. This is mainly based on summing up the costs of a range of possible treatments
to PCOS and care for patients who have developed diabetes. The treatments selected for the
analysis were those that tailored to the major symptoms of PCOS (i.e. menstrual dysfunction,
obesity, pre-diabetes, acne), with a proportion of patients receiving the treatments greater than
2% after the diagnosis of PCOS (refer to Table 4.6). Otherwise, the treatments were considered
to be rarely prescribed to the patients and therefore, are likely to contribute only a small amount
of costs to the overall burden of the condition. The total costs of an individual treatment were
computed as the multiplication of the unit price, the daily dose, treatment duration and the
proportion of patients who require that treatment. The recommended dose and duration of
treatment for each drug considered are displayed in Table 5.2. The unit price of treatments
was referred to the British National Formulary (BNF, 2014), conference abstracts and pub-
lished reports by the NHS. The prior distributions included for the calculation of drugs costs
are presented in Table 5.3. The range of drug dose for each treatment considered forms the
boundary of the prior distribution, e.g. suppose that m represents the daily dose for metformin
and consequently, m would follow a uniform distribution: m ∼ Uniform(1828, 1914). The total
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costs of metformin can then be computed as £0.19 (the unit price) times m and the duration of
the treatment as well as the total number of patients who require this treatment.
Table 5.2: The recommended dose and treatment duration for each drug considered.
Treatment Dose and instruction
Oral contraceptives
One tablet daily for 21 days and repeat for each menstrual cycle
until menopause
Metformin
500-1000mg daily for the first week and then 1000-1500mg daily
for the second week and 1500-2000mg daily if tolerated
thereafter for 3-6 month
Eflornithine
Apply twice daily and should be discontinued in the absence
of improvement after treatment for 4 months.
Weight loss/control drugs
Orlistat: 120mg for maximum 3 times daily and continue
treatment beyond 12 weeks only if weight loss since start of
treatment exceeds 5%.
Acne drugs
Most are topical cream or gel,including erythromycin, benzoyl
peroxide, tretinoin and isotretinoin. Apply 1-2 times daily and
review at 8 weeks. Treatment may take up to 6 months or beyond
depending on severity.
Table 5.3: The distributional assumptions of mean dose and duration of treatment for drug
considered.
Item Mean Distribution Note/source
Drug dose
Oral contraceptives 1 tablet daily Constant BNF
Metformin 1828-1914mg daily Uniform Daily average for 3-6 months (BNF)
Eflornithine 4 cream tubes Constant Expert interviews
Orlistat 120-360mg daily Uniform Daily average for 3 months (BNF)
Acne drugs 0.5-2g daily Uniform
Daily average for 2-6 months
(National Health Service, 2015)
Drug costs
Oral contraceptives £124.33 per year Constant
3-year average costs applied
(Praet and D’Oca, 2014)
Metformin £0.19 per gram Constant BNF
Eflornithine
£56.87
per cream tube
Constant BNF
Orlistat £3.14 per gram Constant BNF
Acne drugs
£0.047-0.398
per gram
Uniform National Health Service (2015)
Diabetic care £6400 per year Constant Published study (Hex et al., 2012)
The cumulative proportion of patients who receive a relevant treatment within one year
after their diagnosis was estimated from THIN using the methods introduced in Chapter 3. The
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overall healthcare burden was discounted at a rate of 3.5% as suggested by the National Institute
for health and Clinical Excellence (NICE) (National Institute for Clinical Excellence, 2004).
5.4.5 Utility analysis
Quality of life (QoL) data from published studies were used for this analysis. It is assumed that
the QoL of both probable and diagnosed cases are the same based on estimates reported by
Coffey et al. (2006). The assumption is likely to be reasonable since many probable cases may
be true cases but failed to receive a confirmed diagnosis due to the imperfection of the current
screening system for this condition. The QoL of diabetic patients were used to approximate that
of PCOS patients with diabetes because it was not able to identify any study reporting relevant
information for this specific cohort. Although EQ-5D is recommended by the NICE to facilitate
comparisons across economic evaluations (National Institute for Clinical Excellence, 2004), I
only identified studies that report the QoL estimates for PCOS patients based on the 36-Item
short survey form (SF-36). Therefore, the methods introduced by Ara and Brazier (2008) was
applied as the conversion method between the two score measurements. In a nutshell, this article
introduces a method to derive the mean EQ-5D score of a cohort using mean statistics of the
eight dimension scores of SF-36 of the same cohort. Specifically speaking, the EQ-5D score is
regressed on the eight dimension scores of the SF-36 form (e.g. physical function, mental health,
social function) to obtain coefficients for each dimensional considered. Although the estimation
is based on individual level patient data (sample data) but predictive abilities are assessed using
the summary statistics from both subgroups in the sample data and some published studies.
The regression coefficients (for each health component examined by SF-36) obtained from the
model in this study was applied for conversion in the current analysis.
As mentioned previously, the population dynamics of a healthy cohort of the same population
size as the PCOS cohort was also simulated. The purpose was to examine the reduction in
quality of life (QoL) comparing the PCOS cohort and the healthy cohort over the follow-up
period. This time, the MM only includes 3 states: healthy (State 1), diabetes (State 2), death
(State 3). Individuals start in State 1 can transit to State 2 and 3 and once individuals develop
diabetes, they were assumed to remain in State 2 or die (transit into State 3). I referred to QoL
suggested by Kind et al. (1999) and the QoL for diabetic patients was still applied for healthy
women who develop diabetes later in life.
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A discounting rate of 3.5% was also used for all the utility analyses.
5.5 Results
5.5.1 Characteristics of patient cohort selected from THIN
A total number of 14,135 eligible patients with PCOS selected from THIN were used for esti-
mating the incidence rates from one disease state to another. Among these patients, 776 (5.5%)
had a diagnosis of diabetes before the date when the diagnosis of PCOS was recorded. The
recording of an HbA1c test was reported in 2.4% of PCOS patients within one year after they
received their diagnosis of PCOS, which increased to slightly above 4% after 3 years of diagnosis.
5.5.2 Incidence rates estimated from the Poisson model
The incidence rates estimated from both the standard and multilevel Poisson regression model
are presented in Table 5.4. In general, the rates are smaller for the hierarchical model (bottom
line in the table) and associated with a narrower 95% credible interval (CrI) compared with the
standard model (top line in the table). The plots for rate comparison are presented in Figure
5.7 and 5.8.
Table 5.4: Incidence rates estimated from the Poisson model using Bayesian approach. The top
line in each row represents results from the standard model and the bottom line represents those
from the hierarchical model.
Age, years
Incidence rates, per 1000 person years (95% Credible Intervel, CrI)
Probable PCOS to
diagnosed PCOS
Probable PCOS to
diabetes
Diagnosed PCOS to diabetes
Scenario 1 Scenario 2 Scenario 3
15-19 121 (82-163) 26 (9-28) 27 (12-41) 3 (3-3) 3 (2-3)
94 (63-132) 17 (6-35) 18 (9-31) 2 (1-2) 2 (1-2)
20-24 58 (45-70) 11 (3-13) 22 (15-26) 13 (12-14) 10 (9-12)
48 (37-61) 5 (3-9) 15 (11-21) 6 (5-8) 7 (6-9)
25-29 24 (19-28) 8 (3-8) 23 (18-25) 13 (12-15) 11 (9-13)
18 (14-22) 4 (2-6) 16 (12-20) 7 (5-8) 7 (6-9)
30-34 17 (12-18) 6 (3-7) 30 (25-33) 22 (20-24) 18 (15-20)
12 (9-15) 4 (2-6) 22 (18-26) 11 (9-13) 12 (10-14)
35-39 10 (7-11) 8 (5-10) 28 (22-32) 22 (19-24) 17 (14-19)
7 (5-10) 5 (3-8) 20 (16-25) 11 (9-13) 11 (9-13)
40-44 6 (3-7) 7 (3-8) 32 (25-36) 33 (30-36) 26 (24-29)
3 (2-5) 4 (2-6) 24 (19-29) 17 (14-20) 17 (14-21)
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The incidence rates from probable to diagnosed PCOS obtained from both models suggest
that younger women more likely to receive a confirmed diagnosis of PCOS compared with
older women. For example, the rates for women aged 15-19 are as high as 121 per 1000 PY
whereas are below 20 per 1000 PY for women aged 30 and above as suggested by the standard
model. In terms of probable cases converting to diabetes, both of the models suggest that the
younger women are associated with higher rates in contrast to older women. The estimated
incidence rates of diagnosed cases converting to diabetes are presented by scenarios (based on
different assumptions as discussed in the methods section). When minimally informative prior
was included (Scenario 1), the rates remain constant across different age groups for both of the
models. However, when informative prior (Scenario 2 and 3) was included, variation arises in
the rates across age groups and the rates increase from young to older age groups, i.e. from 3
per 1000 PY in women aged 15-19 to around 30 per 1000 PY for women aged 40-44 for the
standard model. The results obtained from inflating the variances (from 0.001 to 1) in the prior
distributions for the relative risk of diabetes (across different age groups) are generally in line
with Scenario 1 with slightly lower rates for the younger age groups compared with Scenario 1.
For example, the incidence rates were estimated to be 19 per 1000 PY (95% CrI: 9-33 per 1000
PY) for the youngest age group whereas older women (aged 30 and above) are associated with
higher rates at around 28 per 1000 PY (95% CrI: 22-33 per 1000 PY). The model convergence was
reached for all the analyses and the plots of diagnostic statistics are presented in Appendix G.
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Figure 5.7: The plots are for model comparison in terms of age-specific incidence rates estimated under different scenarios: (i)
transition from probable to diagnosed PCOS (left plot); (ii) transition from probable PCOS to diabetes (right plot).
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Figure 5.8: The plots are for model comparison in terms of age-specific incidence rates estimated under different scenarios: (i)
transition from diagnosed PCOS to diabetes by including minimally informative prior in the model (left plot); (ii) transition from
diagnosed PCOS to diabetes by including informative prior (Scenario 3) in the model (right plot).
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5.5.3 Results from population dynamics simulation
The age distribution of the PCOS population estimated from the UK census data is presented
in the Table 5.5. There is a higher proportion of women in the older age groups (i.e. age above
25) compared with the younger age groups.
Table 5.5: Age distribution of PCOS population in the UK for baseline year (2014). The
number of patients who aged 1-14 in 2014 was estimated based on the assumption that they
will be diagnosed at the same rate as women aged 15-19 once they reach the age of 15.
Age in 2014, years Population size (%)
1-4 9,270 (2.91)
5-9 11,021 (3.46)
10-14 10,056 (3.16)
15-19 10,957 (3.44)
20-24 40,166 (12.62)
25-29 69,061 (21.70)
30-34 69,873 (21.96)
35-39 52,801 (16.59)
40-44 45,029 (14,15)
The projected number of patients ending up in each state from 2014 and onwards at a
consecutive 5-year interval is presented in Table 5.6. It should be noted that the results in this
table are based on the most conservative estimates in Table 5.4 (Scenario 3). Results from both
closed cohort and open cohort model are presented. The figures on the top and bottom line
in each row represents the number of patients estimated from the standard Poisson regression
model and the hierarchical version of the model, respectively.
For the standard model, at the baseline year, 12.3% of the PCOS patients had a diagnosis
of diabetes. The closed cohort model indicates that proportion of PCOS patients who are likely
to convert to type 2 diabetes is 26.3% (95% Credible Interval, CrI: 25.2-27.6%) after 25 years of
follow-up whereas the corresponding proportion estimated from the open cohort model is 26.5%
(95% CrI: 25.4-27.8%). The rainbow plot (Figure 5.5.3) graphically displays the distribution
of patients over states (same legend for both plots). It should be noted that these results are
generally robust even when different transition probabilities from diagnosed PCOS to diabetes
(Scenario 1, 2 and 3) were applied. For example, for the base case scenario, the proportion of
patients who end up in the diabetic state by the end of follow-up was estimated to be 30.4%
(95% interval: 29.2-31.9%).
The results obtained from the hierarchical model are slightly smaller but do not differ much
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from those using the standard model. For example, the closed cohort model estimates that
22.0% (95% CrI: 20.7-23.5%) of the patients are likely to end up in the diabetic states after the
follow-up period and corresponding estimates from the open cohort model are 22.1% (95% CrI:
20.8-23.7%).
The results from simulating the healthy cohort suggest that the prevalence of type 2 diabetes
in this population increases from 1.5% in the baseline year 2014 to 8.3% by the end of follow-up.
Table 5.6: The predicted distribution of cases over states in the follow-up period (estimates for
both closed and open cohort model presented). The figures on the top line in each row were
simulated based on estimates from standard Poisson regression model and those on the bottom
line were simulated using estimates from the hierarchical version of the model.
Year
Probable PCOS Diagnosed PCOS PCOS with diabetes Death
Closed Open Closed Open Closed Open Closed Open
2014 139,659 139,659 112,609 112,609 35,620 35,620 0 0
139,659 139,659 112,609 112,609 35,620 35,620 0 0
2019 122,628 126,588 115,750 120,318 48,704 50,229 806 809
127,235 132,126 115,411 119,098 44,442 45,916 800 803
2024 114,236 120,830 112,206 123,060 59,805 63,423 1,640 1,653
120,143 129,542 114,062 122,293 52,064 55,500 1,619 1,630
2029 109,599 117,135 107,267 124,128 68,529 74,450 2,494 2,520
116,192 128,340 111,135 123,846 58,111 63,573 2,450 2,475
2034 107,356 112,744 103,220 120,975 73,957 81,111 3,356 3,403
114,212 124,390 108,501 122,319 61,889 68,194 3,286 3,330
2039 106,486 111,096 101,073 118,232 76,110 84,617 4,220 4,287
113,378 122,380 107,023 121,152 63,364 70,515 4,122 4,186
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Figure 5.9: Distribution of women over states in the follow-up: (i) closed cohort model (on
the top); (ii) open cohort model (on the bottom). The graphs are based on simulations using
estimates from the standard model.
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5.5.4 Pharmaceutical outcomes
The cumulative proportion of patients who receive a relevant prescription within one year after
their diagnosis is shown in Table 5.7. A higher proportion of diagnosed cases received oral
contraceptives (either combined or progestogen, 23.4%), metformin (17.8%) and eflornithine
(4.6%) compared with probable cases. In contrast, a notable higher proportion of probable
cases received acne drugs (24.9%), which more than doubles that of diagnosed cases. This is
consistent with results shown in Table 4.6.
Table 5.7: Cumulative proportion of cases receiving relevant prescription for PCOS by case
definition (between 2012 and 2014).
Treatment
Percentage of patients receiving prescription
Probable cases Diagnosed cases
Combined oral contraceptives 12.8% 17.5%
Progestogen oral contraceptives 4.8% 5.9%
Metformin 1.7% 17.8%
Eflornithine 1.8% 4.6%
Weight loss/control drugs 0.63% 2.3%
Acne drugs 24.9% 11.1%
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5.5.5 Economic burden
The economic burden of PCOS was estimated to be £237 million (95% CrI: £237-238 million)
in 2014 and it continues to increase, with a present value of overall economic burden of over £7
billion (95% CrI: £6.8-7.3 billion, these are conservative estimates from the standard model).
The overall burden of the disease estimated from the hierarchical model is slightly lower (£6.2
billion). Figure 5.10 presents the trend of the country level healthcare burden of PCOS over the
25-year follow-up (results from standard model). The average costs for an individual patient
per year were estimated to be within a range of £723 and £950 during the 25-year follow-up
(e.g. £723 in 2014 and increase to a discounted value of £950 in 2023). This corresponds to
an overall average costs per patient on an annual basis of £876 for the entire follow-up period.
A significant proportion (over 96%) of healthcare burden for PCOS population is attributed to
treating diabetes.
Figure 5.10: The estimated healthcare-related economic burden of PCOS over the follow-up
period (based on simulations using estimates from the standard model).
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5.5.6 Quality of life
The quality of life (QoL) measured by EQ-5D for women with PCOS (both diagnosed and
probable cases) was estimated to be at a mean score of 0.76. The EQ-5D score is 0.7 (SD 0.3)
for PCOS patients with type 2 diabetes. The results from the model suggested that over the
period of follow-up, there is a reduction in QoL from 0.75 (95% CrI: 0.67-0.79) to 0.31 (95%
CrI: 0.24-0.34) for the entire PCOS population in the UK (similar results were obtained from
the hierarchical model). This is significantly lower compared with the results simulated for the
healthy cohort, as represented by the shaded area in grey formed by the two lines in different
colours in Figure 5.11. The magnitude of quality deficits is within a range of 0.04-0.1 over the
follow-up period. Note that since discounting was applied in both PCOS and healthy cohort, the
quality deficits represent the loss of quality of life measured by EQ-5D score for PCOS cohort
compared with the healthy population. The results presented here were obtained from the open
cohort model and similar results were obtained from the closed cohort model.
Figure 5.11: Quality of life (QoL) simulated for the PCOS cohort (yellow line) and a healthy
cohort (blue line) in the UK over the follow-up period (2014-2039). The shaded area in grey
representes the loss of QoL of PCOS cohort compared with the healthy cohort. Results are
based on simulations using estimates from standard model (open cohort scenario).
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5.6 Discussion
5.6.1 Summary of main findings
In this chapter, I modelled the population dynamics of PCOS, the healthcare-related costs and
the quality of life for the entire patient cohort in the UK. The indication from this simulation-
based analysis is that approximately 26% of the PCOS patients are likely to develop type 2
diabetes over the next 25 years starting from 2014. This remains robust for transition rates
estimated based on different assumptions. The quality of life of PCOS patients is generally
lower compared with the general population throughout the follow-up period examined. The
costs to the NHS for this condition were estimated to be at least £237 million on an annual basis.
5.6.2 Interpretation
The results from the Poisson regression model suggested that only a very small proportion of
potential cases (the incidence rate is as high as 120 per 1000 PY for the youngest age group) is
expected to receive a confirmed diagnosis. This points out the issue of lack of public awareness
of this syndrome as indicated by previous chapters and also reflects the nature of primary care
recording: GPs are likely to record symptoms rather than making a confirmed diagnosis when
they are less certain about patients’ condition; the recording of some of the patients who are
referred to secondary care may be lost if care is not transferred back to the GPs. However,
high conversion rates from PCOS to diabetes were estimated from our model. The failure of
screening (to make a confirmed diagnosis of PCOS) and the rapid conversion from PCOS to
diabetes result in the fact that over a quarter of the PCOS population was projected to develop
diabetes by the end of the follow-up. This is likely to incur large amount of costs to the NHS (an
estimated present value of the overall economic burden of at least £6.2 billions) and significantly
impact the quality of life for individual patients (the magnitude of quality deficits ranges from
0.04 to 0.1 compared with the general population). All these urge the need for a more efficient
screening approach for PCOS given that an earlier diagnosis would allow interventions to reduce
the impact of the condition in this cohort (approximately three quarters of a million women in
the UK).
Screening with an HbA1c test has been found cost effective for other high risk populations
at diabetes, as the test is inexpensive (£4.04) (National Institute for Clinical Excellence, 2011)
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and facilitates intervention to prevent diabetes. The term HbA1c is used to refer to glycated
haemoglobin, which develops when haemoglobin (a protein in the red blood cells that carries
oxygen throughout one’s body) joins with glucose in the blood and becomes ‘glycated’. By
measuring glycated haemoglobin (HbA1c), the clinicians will be able to know the average blood
sugar level over a period of time. However, although an HbA1c test is recommended by the
guideline of PCOS (Legro et al., 2013), this is hardly followed at present: only 2.4% of the
PCOS patients eligible to be included from the THIN database for analysis had a recording
of HbA1c test within one year after the date of their diagnosis of PCOS, which increases to
slightly over 4% after 3 years of diagnosis (recall results in Section 5.5.1). Note that the HbA1c
test is already incorporated in the NHS health check and the National Diabetes Prevention
Programme (National Health Service). These programmes target those aged 40-74 with BMI>30
(or BMI>27.5 for South Asian population) in whom the incidence of diabetes ranges from 14.3
to 23.8 per 1000 PY (Tillin et al., 2015). Therefore, apart from improved screening for PCOS,
our finding of conversion rates of diabetes in women with PCOS also suggests a possible role for
screening PCOS patients for diabetes.
It is possible that expanding the current targeted population of these programmes to include
women with PCOS or symptoms indicative of this condition may be cost effective. For example,
this may help improve the detection of symptoms indicative of diabetes (e.g. pre-diabetes as
suggested by results from an HbA1c test ranging from 42 to 47 mmol/mol) and consequently,
more patients with PCOS can benefit from early intervention to prevent rapid conversion to
diabetes. From a country perspective, this is likely to produce massive amount of savings in
healthcare costs associated with PCOS.
5.6.3 Strength and limitation
This is the first study that applied modelling approach to simulate the population dynamics of
PCOS using the real world evidence. Modelling is often considered to be cost-effective to explore
what-if scenarios and allow data from multiple sources to partially inform the model to examine
more complicated research questions, which is unlikely to be achieved by an individual study.
The individual patient data (IPD) from THIN were used to estimate some of the transition
probabilities between possible states included in the Markov model. As the IPD are from routine
clinical practice, the estimated transition rates are likely to reflect the true conversion between
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the disease states. However, referral bias may exist which meant that women with severe PCOS
(e.g. obesity, prediabetes) are more likely to visit general practitioners (GPs) and receive a
diagnosis consequently. For these women, the duration between the consecutive consultations
also tends to be shorter. All these factors may introduce bias into our estimates. I attempted
to address this issue by using the Bayesian approach to allow the IPD to be complemented
by external evidence from other comparable observational studies conducted in similar context
(Morgan et al., 2012). While there may be bias in both our data and published studies, the
formal machinery of the Bayesian approach is likely to make a compromise and provide more
realistic estimates based on more sources of information.
The Poisson regression model and its hierarchical version were applied to estimate the tran-
sition probabilities and the results obtained from the two models largely agree with each other.
The estimates from the hierarchical model are generally more stable (with smaller variances)
due to the nature of the hierarchical structure. Specifically speaking, individual estimates that
are based on less information can borrow strengths from other estimates to be pooled closer to
the group mean and this is called the “shrinkage” property (Gelman et al., 2014). Both models
controlled for the age variable and the hierarchical version of the model further accounted for
the variability across practices.
Nevertheless, other factors may need to be considered in the Poisson regression model. There
is evidence that obesity may be a factor affecting the transition from PCOS to diabetes (Legro
et al., 1999; Zhao and Qiao, 2013). For example, obesity can worsen PCOS and thus result in a
faster conversion to diabetes (Sam, 2007). However, since part of the risk of developing PCOS
is obesity, it is not possible to separate the effect of obesity and PCOS on the higher conversion
rates from PCOS to diabetes. The previous chapters also suggested that the prevalence of
PCOS varies across different ethnic groups and a study by Zhao and Qiao (2013) indicated that
Southeast Asian women with PCOS are at higher risk of diabetes compared with PCOS patients
with other ethnic background. Therefore, higher conversion rates may be expected for certain
ethnic groups and this would further lead to higher prevalence of diabetes in patients with certain
ethnic backgrounds by the end of follow-up. Nonetheless, this may not have strong influence
on our estimates given that over 85% of the population in UK are White Caucasian (Office for
National Statistics, 2011) and THIN is considered to be a true reflection of the mixture of various
ethnic groups across different regions of the country. Another reason for not including obesity
151
status and ethnicity into the current model is the incompleteness of data on these variables from
THIN database, i.e. the information of weight/BMI and ethnicity were only recorded in less
than 40% and less than 50% of the patients, respectively. The proportion of patients with both
weight/BMI and ethnicity information reported would be even lower (≤40%). Further analysis
considering these aspects needs to be warranted.
A further concern regarding the methods applied in this piece of analysis is that modelling
is often a simplification of the complex situation in reality. The current Markov model only
included four states however it is possible that other states may exist. For example, a state of
PCOS with pre-diabetes may be reasonable given that pre-diabetes is an independent state often
considered in modelling the population dynamics of diabetes (Thurecht et al., 2007; Bernier,
2012). Note that the state of resolved PCOS was not included due to the fact that PCOS is
believed to be generically inherited and is largely incurable (Bernier, 2012).
As for the economic analysis, the list of drugs considered as the major burden of care for
PCOS is supported by a recent European survey where a group of specialists in PCOS were
interviewed. The results from this survey suggested that obesity and diabetes were the major
concern by over 60% of the interviewees. Metformin was selected as the top line treatment by a
third of the interviewees, followed by lifestyle modification (25%) and oral contraceptives (22%)
(Conway et al., 2014).
However, the estimate for the overall healthcare costs of PCOS in the UK was considered to
be conservative due to several reasons. The primary reason is that the current analysis did not
include the costs associated with other comorbidities of PCOS such as cardiovascular diseases
(CVD), obstetrical complications and infertility due to lack of supporting evidence. For example,
Azziz et al. (2005) suggested that the annual cost of infertility care for PCOS patients in the
US is $533 million each year. While this may contribute a certain proportion to the overall
disease burden, it is less plausible to apply strong assumptions for the economic evaluation
of infertility given the fact that not all women desire pregnancy. Some studies reported that
women with PCOS are at elevated risks of CVD compared with the general population (Wild
et al., 2000; Dahlgren et al., 1992). Nevertheless, the review by Legro (2003) argued that the
premenopausal age group did not appear to be at higher risk of presenting clinical signs of CVD.
As a consequence, limited data with respect to these aspects are currently available to draw
definite conclusions. It is also suggested that women with PCOS are more likely to experience
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depression (Barry et al., 2011) and antidepressants and counselling or cognitive behavioural
therapy for psychological disorders may be costly. Besides, it is often the case that prescribing
rates in primary care are under-reported due to various reasons (e.g. patient records are not
transferred back from the secondary care). I attempted to address this issue by extracting the
first drug record within 12 months following a diagnosis of PCOS and this period was considered
to be relatively long to examine the treatments initiated in the secondary care, which made it
less likely to bias the estimate for overall healthcare costs.
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Chapter 6
SUMMARY AND CONCLUSIONS
6.1 Chapter summary
This thesis explored the prevalence of PCOS from both a global and country-specific perspective
and established the healthcare related economic burden of the disease in the UK. It addressed
these objectives coherently through both empirical studies and individual level patient data from
primary care database in the UK, using a wide range of suitable methodologies for each of the
specific research questions. Each piece of analysis mirrored the aims and objectives of the thesis,
as represented by the flow of the chapters. This chapter starts by drawing together the main
findings from previous chapters. I then discuss the methodological strengths and weaknesses
and finally present the implications of the work in this thesis for practice and further research.
6.2 Main findings
There are several major findings from the analyses in this thesis. Firstly, there is a large gap
between the prevalence rates estimated from community studies and database studies (which is
often based on primary care database or medical insurance database), highlighting the issue of
under-diagnosis of PCOS. The under-diagnosis could be due to the wide variation in the clinical
presentations of the condition across individual patients and different populations, resulting in
difficulties for the clinicians to make a confirmed diagnosis. Another possible reason is the lack
of awareness of this syndrome by both the public and the healthcare workers given that the
major criteria of PCOS were established relatively recently. For example, the first criterion
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of PCOS (the NIH criterion) was established in 1990 and it may take years for clinicians to
start following the guideline for diagnosis. This is reflected by the limited number of studies
conducted in 1990s and the low recording rates in early 21st century.
The prevalence of PCOS varies across different ethnic groups and even for the same eth-
nic group, there is significant variation in the prevalence estimates under different diagnostic
standards. This raised the concern for the accuracy of current measurement techniques and the
applicability of current diagnostic criteria to populations with different ethnic backgrounds. Em-
pirical studies suggested that women with PCOS are at significantly higher risk of a wide range
of morbidities such as type 2 diabetes and infertility. Therefore, the failure of screening may lead
to serious health consequences for PCOS patients, which severely affect the daily activities and
quality of life for women with PCOS. On the other hand, while under-diagnosis remains a big
issue, over-diagnosis of the condition may exert negative psychological impact on women with
PCOS, which can worsen the major symptoms of PCOS such as menstrual dysfunction and thus
increase the chance for potential cases to be qualified as true cases. This further emphasises the
importance of diagnostic accuracy of this condition.
The prescribing patterns of PCOS in the primary care supported the previous argument be-
cause a wide range of treatments tend to be initiated for patients following a diagnosis of PCOS.
This also reflects the fact that currently, there is lack of most effective treatment for PCOS and
patients generally receive treatments tailored to the external symptoms they present with.
Given there is limited supporting evidence on the causal relationship between a range of
cardiometabolic diseases other than type 2 diabetes provided by the long-term follow-up studies,
a full economic evaluation by including costs of care for all the morbidities potentially induced by
PCOS was challenged. The current economic analysis estimated the costs of treating external
symptoms presented by patients and the care required by those who have converted to type
2 diabetes over a course of 25-year follow-up. The results suggested that the disease burden
associated with care for PCOS population in the UK is significant and the costs of treating type
2 diabetes account for an overwhelming proportion of the overall burden.
6.3 Methodological strengths and weaknesses
The work presented in this thesis had a number of strengths and some acknowledgeable weak-
nesses. Firstly, I systematically reviewed the published literature to collect evidence relevant
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to the main research questions and at the same time, to identify the aspects of disease that
had not been well explored (e.g. prevalence of PCOS in populations with different ethnic back-
grounds). Alongside the data collection process, the generalised models for evidence synthesis
using Bayesian approach were developed through the creation of an R package. The Bayesian
methods allow the observed data to be complemented by some formal representation of prior
belief based on empirical evidence or pilot studies when the available data are limited. The
model templates provided by the package can be applied to a wide range of disease areas and
therefore, are considered to be an important methodological highlight derived from the first
part of this thesis. However, it should be noted that the current models designed for evidence
synthesis fitted to observational studies or randomised trials can only account for confounding
factors at study level, which is likely to be inadequate. The heterogeneity in the way that
information is provided by individual studies also largely limited our ability to include some po-
tential factors. For example, the body mass index of patients are often observed to be provided
in different ways, e.g. mean BMI for the study population, range of BMI for subgroups. The
number of confounding factors to be considered in meta-regression models is limited because
model convergence may be an issue when a large number of parameters are included.
Apart from literature review, I also conducted analysis using real-world evidence from a pri-
mary care database in the UK, which largely formed the second part of this thesis. The database
analysis is advantageous in terms of sample size and is considered to be broadly representative
for the UK population. As the routine clinical data are collected, the results reflected the reality
in primary care. However, due to the nature of data recording in ‘real’ world setting of UK
primary care, under-reporting is expected because the general practitioners are likely to record
only the main diagnosis in the coded patient records but unlikely to code all the features related
to a diagnosis or all the other patient information. Moreover, due to the issue of missing data,
complete information cannot be obtained on variables such as ethnicity or drug indication, which
may potentially influence the epidemiological and pharmaceutical outcomes in this analysis.
Based on the aggregate data identified from empirical studies and the individual level patient
data extracted from THIN, I evaluated the economic burden and quality of life for PCOS popu-
lation in the UK over a relatively long period of follow-up by using a simulation-based method.
The modelling approach allowed me to explore what-if scenarios and synthesise evidence from
multiple sources to inform the model for examining more complicated research questions, which
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is unlikely to be achieved by an individual study. Nonetheless, modelling is almost always a
simplification of the complex real world situation and many factors were not able to be consid-
ered at the moment due to lack of supporting evidence, e.g. the costs of treating infertility and
cardiovascular diseases. This may lead to an underestimation of the true healthcare burden of
the disease for this country.
6.4 Implications of the findings
The findings in this thesis have significant public health impact and important implications for
practice and further research. The work presented is quite novel and add much to the current
state of science for this disease area. For example, by the time when the literature review
was conducted, there had been no studies attempting to investigate the prevalence of PCOS
in different ethnic groups by combining information from single observational studies using a
meta-analysis approach. Similarly, modelling approach was firstly introduced to simulate the
population dynamics of PCOS based on evidence from multiple sources. The specific implications
with respect to each of the main findings are discussed below.
Firstly, the significant difference in the prevalence rates estimated using medical recordings
and through systematic screening in designed studies suggested that the public awareness of
PCOS still remains to be improved. Health campaigns can be a potential way to allow the
public and general practitioners to learn more aspects of PCOS. Early screening may also be
recommended given the relatively low costs of care for PCOS itself compared with the high costs
of diabetic care required after disease progression. However, considering the frequent issue of
under- and over-diagnosis of PCOS, further work is still expected to enhance the accuracy of
current screening approach for PCOS. This could possibly be achieved through the establishment
of a more detailed ethnicity-specific diagnostic criteria, as suggested by the large variation in
prevalence rates and metabolic features of the condition across different ethnic groups.
The results from the current evaluation for the prevalence of type 2 diabetes in the PCOS
cohort indicated that PCOS or possibly menstrual dysfunction (major symptom of PCOS)
may be a marker for the detection of type 2 diabetes as a high proportion of women with
PCOS was estimated to develop diabetes by the end of the 25-year follow-up. Therefore, the
current targeted population of the Diabetes Prevention Programme may be recommended to
be expanded to include women with PCOS or symptoms suggestive of PCOS. This is likely
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to massively improve the detection of symptoms indicative of diabetes in PCOS patients and
prevent rapid conversion to diabetes for this selected population. In this way, significant amount
of healthcare costs associated with PCOS can be saved for the NHS in the UK.
The wide variation in the prescribing patterns of PCOS in the primary care suggested the
issue of lack of most effective treatment for this condition currently, urging the need for further
research to explore this area. While there are many trials comparing the efficacy of different
treatments on ameliorating the metabolic presentations of PCOS patients, longitudinal studies
are recommended to investigate the long-term effect of various treatments in terms of reducing
the risk of conversion from PCOS to diabetes as well as the improvement in quality of life for
individual patients. Data from this type of longitudinal studies are expected for conducting
further cost-effectiveness analysis based on the current model structure, e.g. the public health
impact of improved screening offered to PCOS patients. It is expected that if more effective
screening is available, a larger number of potential cases is likely to receive a confirmed diag-
nosis and proper care thereafter. Although this increases the number of diagnosed cases, the
actual number of cases transiting into diabetic state tend to be reduced given that appropriate
treatments are initiated following a diagnosis. The economic burden can then be re-evaluated
to see the effect of the new intervention from a country perspective. Similarly, the public health
impact of other interventions or the combination use of a range of interventions can be modelled
in the same way.
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Table 1. Summary of studies evaluationg the prevalence of PCOS in women of reproductive age.
Article Country
Sample
size
Age BMI Prevalence of PCOS (%)
NIH Rotterdam AES Other
Americas
Knochenhauer et al. (1998) US 277 18-45yrs 26.9+/-7.4 4.0 - - -
Azziz et al. (2004) US 400 18-45yrs 27.8+/-7.7 6.6 - - -
Goodarzi et al. (2005) US 156 34+/-8.6yrs 29.9+/-7.9 - - -
13(self-reported
NIH)
Lo et al. (2006a) US 644166 15-44yrs
50% of the
population
reported BMI
19.4%, 29.0%
overweight for
PCOS and
control,
respectively;
67.0%, 31.4%
obese for
PCOS and
control,
respectively
- - - 2.2(ICD-9)
Okoroh et al. (2012) US 12171830 18-45yrs
0.6%, 1.3% obese
for PCOS and
control,
respectively
1.11 1.59 1.20 -
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Article Country
Sample
size
Age BMI Prevalence of PCOS (%)
NIH Rotterdam AES Other
Christensen et al. (2013) US 137502 15-19yrs
21.2% overweight,
57.3% obese
for PCOS;
20.3% overweight,
16.5% obese
for control
0.56 - - -
Sirmans et al. (2014a) US 143413 15-45yrs
39.5%, 10.1%
obese for
PCOS and
control,
respectively
- - - 0.88(ICD-9)
Moran et al. (2010a) Mexico 150 20-45yrs 27.5+/-4.6 6.0 6.6 - -
Gabrielli and Aquino (2012) Brazil 859 18-45yrs
Median (IQR)
PCOS:
24.2(17.7-30.7)
control:
24.1(18.1-30.1)
8.03 8.5 - -
Faria et al. (2013) Brazil 485 15-18yrs
Median(min-max)
PCOS:
20.2(16.7-27.6)
control:
20.4(16.3-27.1)
- - -
6.2(medical
diagnosed
PCOS)
Europe
Michelmore et al. (1999) UK 230 18-25yrs
Median(IQR)
PCOS:
23.7(21.3-25.6)
PCO only:
20.7(19.7-22.0)
control:
22.3(20.4-24.7)
8.0 - - -
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Article Country
Sample
size
Age BMI Prevalence of PCOS (%)
NIH Rotterdam AES Other
Diamanti-Kandarakis et al. (1999) Greece 192 17-45yrs
27.2+/-0.7,
28.7+/-2.7
for 1 feature
group
28.9+/-1.6
for PCOS
25.9+/-0.6
for control
6.8 - - -
Asuncio´n et al. (2000) Spain 154 18-45yrs 23.8+/-3.2 6.5 - - -
Sancho´n et al. (2012) Spain 592
≥ 18yrs
Median:17-33*
25+/-5,
24+/-5
for women
from Spain
and Italy,
respectively
5.4 - - -
Lindholm et al. (2008) Sweden 147 25-40yrs
29.5+/-5.7
for PCOS;
25.1+/-6.9,
28.0+/-4.4
for 1 feature
group;
24.8+/-4.4
for control
- - -
4.8(self-reported
NIH)
Lauritsen et al. (2014) Denmark 447 20-40yrs 23.1+/-3.5 - 16.6 - -
Asia
Chen et al. (2008) China 915 19-45yrs 20.9+/-3.0 - 2.4 2.2 -
Ma et al. (2010) China 2111 19-45yrs - - 6.11 - -
Li et al. (2013a) China 15924 19-45yrs
22.2+/-4.2,
22.1+/-3.4
for PCOS
and control,
respectively
- 5.6 - -
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Article Country
Sample
size
Age BMI Prevalence of PCOS (%)
NIH Rotterdam AES Other
Jiao et al. (2013) China 1600 19-45yrs
25.8% obese
for PCOS
control not
known
- 8.25 - -
Zhuang et al. (2014) China 1645 12-44yrs - 7.1 11.2 7.4 -
Sung et al. (2010) Korea - 16-39yrs - 4.4 6.3 5.1 -
Nidhi et al. (2011) India 460 15-18yrs
14.3% overweight,
7.14% obese
for PCOS;
control
not known
2.61 9.13 -
Gill et al. (2012) India 1520 18-25yrs
21.7+/-5.5
for PCOS,
19.5+/-3.0
for control
3.7 - - -
Joshi et al. (2014) India 600 15-24yrs 19.4+/-3.7 - 22.5 10.7 -
Kumarapeli et al. (2008) Sri Lanka 2915 15-39yrs
Median(IQR)
PCOS:
24.2(16.1-32.3)
control
not known
- 6.3 - -
Vutyavanich et al. (2007) Thailand 1095 18-40yrs
23.8+/-5.1
for PCOS,
control
not known
5.7 - - -
Middle East
Musmar et al. (2013) Iran 137 18-24yrs 22.2+/-3.1 7.3 - - -
Hashemipour et al. (2004) Iran 1000 14-18yrs 9.1% obese - - - 3(clinical PCOS)
Mehrabian et al. (2011) Iran 820 17-34yrs
19% overweight
9% obese
7.0 15.2 7.92 -
Asgharnia et al. (2011) Iran 1850 17-18yrs
21.1+/-3.6
for PCOS,
control
not known
11.34 - - -
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Article Country
Sample
size
Age BMI Prevalence of PCOS (%)
NIH Rotterdam AES Other
Tehrani et al. (2011) Iran 929 18-45yrs
Median (IQR)
PCOS:
27.0(25.8-37.3),
25.0 (21.6-29.2),
25.6 (23.0-31.2)
control:
26.4(23.1-29.4)
7.1 14.6 11.7 -
Esmaeilzadeh et al. (2014) Iran 1549 16-20yrs 21.9+/-4.1 - - -
8.3 (criteria
not stated)
Rashidi et al. (2014) Iran 602 18-45yrs
36.9% overweight,
22.1% obese
4.8 14.1 12.0 -
Yildiz et al. (2012) Turkey 392 18-45yrs
Obese:
10.2% for total
25% for NIH
15.4% for
Rotterdam
15% for AES
6.1 19.9 15.3 -
Al Khaduri et al. (2014) Oman 3644 12-45yrs 25.5+/-4.7 - 7.0 - -
Attlee et al. (2014) UAE 50 17-23yrs 22.9+/-3.5 - - -
20(criteria
not stated)
Oceania
Lowe et al. (2005) Australia 100 -
23.4+/-3.8
for women
reported (11%)
- 12 - -
March et al. (2010) Australia 728 27-34yrs
Median 25.7
(22.5-30.9)
8.7 11.9 10.2 -
Boyle et al. (2012) Australia 248 15-45yrs
Median 27.0
(22.5-32.6)
15.3 - - -
Joham et al. (2013) Australia 8612 28-33yrs
28.0+/-7.2
25.1+/-5.6
for PCOS,
control,
respectively
- - -
5.8(self-reported
PCOS)
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Table 2. Summary of studies assessing impaired glucose tolerance (IGT) and type 2 diabetes (DM2) in women with and
without PCOS.
Study
Total
case/control
Age(yrs) BMI(kg/m2)
PCOS
definition
IGT/DM2
definition
Europe
Rajkhowa et al. (1996) 72/39
Mean:
cases: 26
controls: 30
Mean:
cases: 31.6
controls: 25.9
Rotterdam WHO
Ciampelli et al. (1998) 35/11
cases: 21-36
controls: 28-30
Not stated NIH NDG
Cibula et al. (2000) 28/752 45-59
Mean(SD):
cases: 28.0(4.2)
controls: 28.2(5.2)
NIH
Fasting glucose
≥ 7mmol/L
current medical
treatment
Yaralı et al. (2001) 30/30
Mean(SD):
cases: 27.9(6.1)
controls: 31.4(6.5)
Mean(SD):
cases: 27.3(6.0)
controls: 25.0(3.3)
NIH WHO
Faloia et al. (2004) 50/20
Mean(SD):
cases: 23(5)
controls: 12 lean,
8 overweight
cases: 23 lean,
27 overweight
controls: 12 lean,
8 overweight
NIH WHO
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Study
Total
case/control
Age(yrs) BMI(kg/m2)
PCOS
definition
IGT/DM2
definition
Diamanti-Kandarakis et al. (2005) 29/22
Mean(SD):
cases: 25.8(5.0)
controls: 28.1(4.0)
Mean(SD):
cases: 27.2(7.7)
controls: 23.3(5.7)
NIH
OGTT,
not stated
A´lvarez-Blasco et al. (2006) 32/72
Mean(SD):
cases: 26(7)
controls: 32(8)
Mean(SD):
cases: 34.8(6.6)
controls: 35.2(6.2)
NIH Not stated
Attaoua et al. (2008) 207/100
Mean(SD):
cases:
lean: 23.1(0.5)
obese: 26.3(0.6)
controls: 31.4(1.1)
Mean(SD):
cases: 23.0(0.3)
controls: 22.2(0.4)
Rotterdam ADA(2006)
Alvarez-Blasco et al. (2009) 141/102 Not stated
Mean(SD):
cases: 30(8)
controls: 31(8)
NIH ADA
Vrbikova et al. (2009) 228/643
cases: 18-39
controls: 20-39
cases:
121 obese
or overweight,
107 lean
controls:
not stated
Rotterdam WHO
Karaer et al. (2010) 31/31 18-45 Mean: 28.9 Rotterdam OGTT
Luque-Ramı´rez et al. (2010) 112/86
Mean(SD):
cases: 27(6)
controls: 28(6)
Mean(SD):
cases: 31(8)
controls: 30(8)
NIH ADA
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Study
Total
case/control
Age(yrs) BMI(kg/m2)
PCOS
definition
IGT/DM2
definition
Pall et al. (2010) 75/23 14-45
Mean(SD):
54 obese,
52 lean
controls: 22(2)
NIH
OGTT, glucose level
100-126mg/dL
and/or 2-hr glucose
level of 140-199mg/dL
for IGT,
glucose level
≥ 126mg/dL and/or
2-hr glucose level
≥ 200mg/dL
Amato et al. (2011)
125/144
220/144
177/144
13-43
Mean(SD):
cases: 30.6(7.7)
controls: 31.3(7.7)
NIH
Rotterdam
AES
OGTT, ADA
Hudecova et al. (2011a) 84/87
Age at follow-up:
> 35yrs
mean follow-up:
13.9yrs
Mean(SD) at
follow-up:
cases:
29.2(5.7), 26.2(5.2)
controls: 25.6(4.2)
Rotterdam WHO
Schmidt et al. (2011) 25/95 40-59 at baseline
Mean(SD) at
follow-up:
cases: 27.1(5.0)
controls: 26.4(4.8)
Rotterdam
Medical or dietary
treatment for diabetes
and/or diagnosis of
diabetes
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Study
Total
case/control
Age(yrs) BMI(kg/m2)
PCOS
definition
IGT/DM2
definition
Celik et al. (2013) 252/117
Mean(SD):
cases: 24.8(5.5)
controls: 25.9(5.7)
Mean(SD):
cases: 26.1(5.7)
controls: 24.9(4.3)
Rotterdam OGTT, ADA
Dalamaga et al. (2013) 316/102 18-35
Mean(SD):
cases:
28.7(8.0), 24.9(6.3)
controls: 24.6(4.9)
Rotterdam WHO
Celik et al. (2014) Celik 84/45
Mean(SD) at
baseline:
cases: 24.7(6.5)
controls: 27.4(5.6)
Mean(SD) at
follow-up:
cases: 27.5(6.9)
controls: 24.6(5.0)
Rotterdam ADA
North America
Dunaif et al. (2001) 14/12 19-41
Mean(SD):
cases: 40.5(1.9)
controls: 40.5(1.6)
NIH WHO
Phy et al. (2004) 7/18
Mean(SD):
cases: 30.9(4.5)
controls: 31.1(2.6)
Mean(SD):
cases: 30.9(10.2)
controls: 25.0(5.8)
NIH ADA
Apridonidze et al. (2005) 106/-
cases: 29.1-31
controls:
not stated
cases: 33.7-39.2
controls: not stated
NIH ADA 1997
Legro et al. (2005) 71/23
Mean:
cases: 27, 29.6
controls: 36.2
Mean(SD):
cases:
35.7(7.5), 38.7(8.3)
controls: 29.3(6.5)
NIH ADA, WHO
Boudreaux et al. (2006) 97/95
Mean:
cases: 38.0
controls: 40.0
Mean:
cases: 31.6
controls: 26.2
NIH
Fasting glucose
≥ 7.0mmol/L or
doctor diagnosis
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Total
case/control
Age(yrs) BMI(kg/m2)
PCOS
definition
IGT/DM2
definition
Leibel et al. (2006) 36/21 12-19
Mean(SD):
cases:
30.3(7.6), 37.9(8.2)
controls: 24.9(4.5)
Rotterdam ADA
Lo et al. (2006b) 11035/55175
Mean:
cases: 30.7
controls: 30.8
cases: 67% obese
controls: 31.4% obese
NIH
Hospital discharge
or ≥ 2 outpatient
diagnosis
Shaw et al. (2008) 104/286
Mean(SD):
cases: 62.5(10)
controls: 65.8(9)
Mean(SD):
cases: 31.1(7)
controls: 28.4(6)
NIH
Fasting glucose
≥ 7.8mmol/L or
medication
Kawai et al. (2009) 185/120
Mean(SD):
cases:
30.8(6.3), 28.4(6.1)
controls:
41.6(10.6), 32.3(10.9)
Mean(SD):
cases:
38.2(7.3), 36.3(8.0)
controls:
31.6(8.4), 26.8(6.8)
NIH OGTT, ADA
Nur et al. (2009) 101/40 10-21
Mean(SD):
cases: 33.2(5.9)
controls: 32.4(5.3)
Rotterdam ADA
Wang et al. (2011) 53/1074
20-32 at baseline
34-46 at follow-up
At baseline:
cases:
22.6% obese
controls:
19.7% obese
NIH
Fasting plasma
glucose ≥ 126mg/dL
or use of diabetic
medications
Wickham et al. (2011) 13/13 18-40
Mean:
cases: 30.7
controls: 30.0
NIH OGTT, ADA
Roe et al. (2013) 148/57
cases: 13-20
controls: 14-20
cases: 38% obese
controls: 9%
AES (majority
also met NIH)
Glucose
≥ 100mg/dL
Sirmans et al. (2014b) 1689/5067 15-45
cases: 39.5% obese
controls: 10.1% obese
NIH (ICD-9) ICD-9
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Total
case/control
Age(yrs) BMI(kg/m2)
PCOS
definition
IGT/DM2
definition
South America
Dos Reis et al. (1995) 29/19 18-37
cases:
14 lean, 15 obese
controls:
10 lean, 9 obese
NIH WHO
Sir-Petermann et al. (2004) 146/97
cases: 15-35
controls: 15-35
Median:
cases: 29.0
controls: 24.8
NIH WHO
Echiburu´ et al. (2008) 159/93 15-36
Mean(SD):
cases: 28.7(6.1)
controls: 25.5(4.3)
NIH WHO
Ma´rquez et al. (2008) 50/70
cases: 16-43
controls: 20-45
Mean(SD):
cases: 33.3(8.1)
controls: 23.4(2.7)
NIH
Fasting glucose
≥ 7.8mmol/L or
history of DM2
Wiltgen and Spritzer (2010)
195/25
240/25
14-35
Mean(SD):
cases:
31.1(8.0), 27.0(6.4)
controls: 27.0(3.6)
NIH
Rotterdam
OGTT
East Asia
Sawathiparnich et al. (2005) 6/6
Mean:
cases: 14.1
controls: 14.5
Mean:
cases: 37.4
controls: 34.2
NIH ADA
Lee et al. (2009) 194/162
cases: 16-41
controls: 20-39
Mean(SD):
cases:
26.8(4.5), 22.3(3.8)
controls:
22.2(2.7), 23.7
Rotterdam WHO (1999)
Wei et al. (2009) 356/974 19-44
Mean(SD):
cases: 22.4(4.2)
controls: 20.6(2.4)
NIH OGTT, WHO
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Total
case/control
Age(yrs) BMI(kg/m2)
PCOS
definition
IGT/DM2
definition
Huang et al. (2010)
90/40
128/40
Median:
cases: 18
controls: 19
Median:
NIH cases: 20.2
Rotterdam cases: 20.0
controls: 19.6
NIH
Rotterdam
ADA
Zhao et al. (2010)
647/717
818/717
678/717
cases: 18-41
controls: 20-45
NIH cases:
21.8% obese
Rotterdam cases:
19.7% obese
AES cases:
21.1% obese
controls: 8.8% obese
NIH
Rotterdam
AES
ADA
Li et al. (2012) 56/26 15-19
Mean(SD):
cases: 22.0(4.9)
controls: 19.7(1.6)
Rotterdam
OGTT
2-h PG
≥ 140mg/dL
but ≤ 200mg/dL
LIANG et al. (2012) 220/70
Mean(SD):
cases: 26.9(5.8)
controls: 28.3(4.4)
Mean(SD):
cases: 25.9(6.1)
controls: 28.3(4.4)
Rotterdam OGTT
HU et al. (2014) 234/39
Mean(SD): cases:
29.2(3.3), 30.6(3.4)
31.5(4.0)
controls: 31.8(4.3)
Mean(SD): cases:
26.6(10.9), 26.4(4.6)
25.5(9.1)
controls: 21.3(3.2)
Rotterdam OGTT
South Asia
Bhattacharya and Jha (2011) 264/116
cases: 16-39
controls: 16-35
Mean(SD): cases:
26.5(4.7), 28.6(4.2)
controls: not stated
NIH WHO
Guleria et al. (2014) 50/50 18-35
Mean(SD):
cases: 24.6(4.9)
controls: 23.9(3.8)
NIH OGTT
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Total
case/control
Age(yrs) BMI(kg/m2)
PCOS
definition
IGT/DM2
definition
Middle East
Moini and Eslami (2009) 273/276
Mean(SD):
cases: 27.9(4.2)
controls: 31.1(5.8)
Mean(SD):
cases: 27.9(2.8)
controls: 25.6(4.4)
Rotterdam self-reported DM2
Australia
Chan et al. (2013) 109/133 18-60
Mean(SD):
cases:
29.5(1.4), 29.8(1.1)
32.1(1.5), 35(1.7)
controls:
22.2(0.6), 24.5(1.0)
27.7(0.9), 27.8(0.8)
Rotterdam
Self-reported DM2
history
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Table 3. Summary of studies assessing metabolic syndrome (MetS) in women with and without PCOS.
Study
Total
case/control
Age(yrs) BMI(kg/m2) PCOS definition MetS definition
Europe
Faloia et al. (2004) 50/20
Mean(SD):
cases:
23(5), 21(5)
controls:
age-matched
Mean: cases:
22 for lean,
32 for overweight
controls:
20 for lean,
37 for overweight
NIH ATP III
VrbI´kova´ et al. (2004) 69/73
Mean(SD):
cases: 25.2(4.7)
controls:
age-matched
Median:
cases: 23.0
controls: 21.9
Rotterdam ATP III
A´lvarez-Blasco et al. (2006) 32/72
Mean(SD):
cases: 26(7)
controls: 32(8)
Mean(SD):
cases: 34.8(6.6)
controls: 35.2(6.2)
NIH ATP III
Carmina et al. (2006) 282/85
cases: 18-40
controls: 18-35
Mean(SD):
cases: 27.2(0.3)
controls: 23.3(0.6)
Rotterdam ATP III, WHO
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case/control
Age(yrs) BMI(kg/m2) PCOS definition MetS definition
Attaoua et al. (2008) 107/100
Mean(SD): cases:
lean: 23.1(0.5)
obese: 26.3(0.6)
controls: 31.4(1.1)
Mean(SD): cases:
lean: 23.0(0.3)
obese: 34.9(0.4)
controls: 22.2(0.4)
Rotterdam ATP III
Fulghesu et al. (2010) 71/94
cases: 13-18
age-matched controls
Mean(SD):
cases: 24.0(0.7)
controls: 22.6(0.5)
Rotterdam
Adolescent-specific
3 out of 5
Gambineri et al. (2009) 200/200 14-49
Mean(SD):
cases: 31.7(7.4)
controls: 31.0(7.6)
Rotterdam
ATP III, IFD,
AHA
Tan et al. (2010) 186/73
Mean(SD):
cases: 28.4(6.7)
controls: 28.4(8.4)
Mean(SD):
cases: 31.5(8.3)
controls: 23.0(3.1)
AES Not stated
Veltman-Verhulst et al. (2010) 456/240
Mean(SD):
case: 30.6(4.4)
controls: 29.0(4.9)
Mean(SD):
cases: 26.6(7.0)
controls: 26.1(5.5)
Rotterdam ATP III
Hudecova et al. (2011a) 84/87
Age at follow-up: > 35
mean follow-up: 13.9yrs
Mean at follow-up:
cases:
29.2(5.7), 26.2(5.2)
controls: 25.6(4.2)
Rotterdam WHO
Amato et al. (2011)
125/144
220/144
177/144
13-43
Mean(SD):
cases: 30.6(7.7)
controls: 31.3(7.7)
NIH
Rotterdam
AES
ATP III
Rizzo et al. (2011) 350/185 18-40
Mean(SD):
cases: 27(7)
controls: 23(5)
AES AHA
VrbI´kova´ et al. (2011) 43/48
Mean(SD):
cases: 16.8(2.0)
controls: 17.5(1.9)
Mean(SD):
cases: 23.6(6.2)
controls: 23.4(5.3)
Rotterdam IDF adolescent
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Total
case/control
Age(yrs) BMI(kg/m2) PCOS definition MetS definition
Panidis et al. (2013)
905/277
1223/277
≤ 39
Mean(SD):
NIH cases: 28.1(7.0)
Rotterdam cases:
27.5(6.9)
controls: 26.6(6.7)
NIH
Rotterdam
ATP III, AHA,
IDF, Joint
definition
Albu et al. (2015) 398/126
Mean(SD):
cases: 24(7)
controls: 28(10)
Mean(SD):
cases: 26.1(10.9)
controls: 25.6(12)
Rotterdam ATP III
North America
Glueck et al. (2003) 138/1887
Mean(SD):
cases: 31(7)
controls: not stated
Not stated NIH ATP III
Apridonidze et al. (2005) 106/-
Mean:
cases: 29.1-31
controls: not stated
Mean:
cases: 33.7-39.2
controls: not stated
NIH
ATP III: BMI 31
as a surrogate
for WC 88cm
Dokras et al. (2005) 127/1887
cases: 18-49
controls: not stated
Not stated NIH WHO
Leibel et al. (2006) 36/21 12-19
Mean(SD):
cases:
30.3(7.6), 37.9(8.2)
controls: 24.9(4.5)
Rotterdam
Modified ATP III,
modified AHA
Coviello et al. (2006) 49/165
cases: 14-19
controls: 12-19
Mean(SD):
cases: 32(9)
controls: 23(5)
NIH Modified ATP III
Welt et al. (2006) 418/64
cases: 18-45
controls: 18-37
Mean(SD): cases:
32.0(8.6), 27.0(6.8),
24.7(5.4)
controls: 27.3(6.8)
Rotterdam Not stated
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Total
case/control
Age(yrs) BMI(kg/m2) PCOS definition MetS definition
Shroff et al. (2007a) 24/24 21-50
Mean(SD):
cases: 36(5.4)
controls: 35(3.3)
NIH AHA
Shroff et al. (2007b) 258/110 18-45
Mean(SD): cases:
35(9), 36.6(10.9)
35.5(9.1), 29.4(9.3)
controls: 29(6)
Rotterdam
3 out of 5:
BMI>30,
TG≥1.7mmol/L,
HDL-C<1.3mmol/L
BP≥130/85,
FPG≥6.1mmol/L
or DM2 presence
Shaw et al. (2008) 104/286
Mean(SD):
cases: 62.5(10)
controls: 65.8(9)
Mean(SD):
cases: 31.1(7)
controls: 28.4(6)
NIH ATP III
Gulcelik et al. (2008) 60/60
Mean:
cases: 24.6
controls: 26.1
Mean:
cases: 28
controls: 26.7
Rotterdam ATP III
Nandalike et al. (2012) 28/28 13-18
Mean(SD):
cases: 44.8(8.8)
controls: 40.2(4.7)
Rotterdam Weiss criteria
Roe et al. (2013) 148/57
cases: 13-20
controls: 14-20
cases: 38% obese
controls: 9% obese
AES (majority
also met NIH)
Modified cook
criteria
South America
Wiltgen and Spritzer (2010)
195/25
240/25
14-35
Mean(SD): cases:
31.8(8.0), 27.0(6.4)
controls: 27.0(3.6)
NIH
Rotterdam
Not stated
Melo et al. (2011)
150/146
226/146
175/146
Mean(SD): cases:
26.6(5.1), 26.2(5.7),
25.9(5.3), 27(4.5)
controls: 28.9(0.5)
Mean(SD): cases:
31.3(8.7), 28.5(8.8),
34.1(8.7), 29.5(9.9)
controls: 24.4(4.9)
NIH
Rotterdam
AES
Modified ATP III
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Total
case/control
Age(yrs) BMI(kg/m2) PCOS definition MetS definition
Ramos and Spritzer (2015) 199/99 Mean(SD): 22.7(7.1)
Mean(SD):
cases: 29.6(6.4)
controls: 27.0(6.0)
Rotterdam
Joint Interim
criteria
East Asia
Cheung et al. (2008) 288/98
Mean(SD):
cases: 30.2(6.4)
controls: 33.4(5.9)
Mean(SD):
cases: 25.8(5.9)
controls: 21.3(2.6)
Rotterdam ATP III, AHA
Zhang et al. (2009)
248/85
719/85
344/85
Mean(SD): cases:
26(4.9), 25(5.1),
27(3.7), 26(4.5)
controls: (27(5.3))
Mean(SD): cases:
36.5(8.6), 35.8(9.3)
30.9(8.3), 28.6(6.5)
controls: 27.3(5.2)
NIH
Rotterdam
AES
IDF
Huang et al. (2010)
90/40
128/40
Median:
cases: 18
controls: 19
Median:
NIH cases: 20.2
Rotterdam cases: 20.0
controls: 19.6
NIH
Rotterdam
IDF
Zhang et al. (2009)
254/342
406/342
279/342
17-40
Mean(SD):
cases: 22.9(4.2)
controls: 20.8(2.6)
NIH
Rotterdam
AES
ATP III
LIANG et al. (2012) 220/70
Mean(SD):
cases: 26.9(5.8)
controls: 28.3(4.4)
Mean(SD):
cases: 25.9(6.1)
controls: 23.4(5.2)
Rotterdam ATP III
Li et al. (2013b)
397/2732
833/2732
708/2732
19-45
Mean(SD):
cases: 22.2(4.2)
controls: 22.1(3.4)
NIH
Rotterdam
AES
ATP III
Chen et al. (2015) 224/198 Mean(SD): 27.5(6.4) Mean(SD): 24.6(5.8) AES ATP III
HU et al. (2014) 234/39
Mean(SD):
cases: 29.2(3.3),
30.6(3.4), 31.5(4.0)
controls: 31.8(4.3)
Mean(SD):
cases: 26.6(10.9),
26.4(4.6), 25.5(9.1)
controls: 21.3(3.2)
Rotterdam
China Diabetes
Association criteria
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Total
case/control
Age(yrs) BMI(kg/m2) PCOS definition MetS definition
South Asia
Bhattacharya and Jha (2011) 51/45
Mean(SD):
cases: 17.1(1.6)
controls: 16.7(1.7)
Mean(SD):
cases: 26.4(4.6)
controls: 25.4(4.6)
AES
Joint Interim
criteria
Wijeyaratne et al. (2010) 395/205
Median:
cases: 25
controls: 29
Median:
cases: 25
controls: not stated
Rotterdam ATP III
Karoli et al. (2013) 54/55
Mean(SD):
cases: 28.5(6.2)
controls: 27.8(7.5)
Mean(SD):
cases: 27.2(5.4)
controls: 26.8(6.7)
Rotterdam ATP III
Guleria et al. (2014) 50/50 18-35
Mean(SD):
cases: 24.6(4.9)
controls: 23.9(3.8)
NIH IDF
Thathapudi et al. (2014) 204/204 17-35
Mean(SD): cases:
29.3(4.2) for obese,
22.0(1.7) for lean
controls: 23.4(3.2)
AES ATP III, IDF
Middle East
C¸alıs¸kan et al. (2007) 182/182
Mean(SD):
cases: 23.2(4.5)
controls: 23.6(4.6)
Mean(SD):
cases: 25.0(5.1)
controls: 23.5(2.9)
Rotterdam
APT III, WHO,
AHA, IDF,
Rotterdam
Yilmaz et al. (2011)
85/44
127/44
103/44
Mean(SD): cases:
25.5(6.4), 25.3(5.2),
25.5(6.5), 25.3(5.8)
Mean(SD): cases:
25.4(5.6), 23.4(4.7),
21.7(3.2), 25.3(5.2)
controls: 22.0(2.5)
NIH
Rotterdam
AES
Study-specific
3 out of 5 criteria
Lankarani et al. (2009) 55/59 15-40
Mean(SD):
cases: 24.9(5.3)
controls: 21.6(2.6)
NIH ATP III
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Total
case/control
Age(yrs) BMI(kg/m2) PCOS definition MetS definition
Rahmanpour et al. (2012) 30/71
Mean(SD):
cases: 17.7(1.0)
controls: 17.7(1.3)
Mean(SD):
cases: 23.4(3.1)
controls: 21.2(2.9)
Rotterdam
IDF for
adolescent
Hosseinpanah et al. (2014) 134/414 18-45
Mean(SD):
cases: 26.8(5.8)
controls: 26.8(4.9)
Rotterdam
Joint interim
statement
Tehrani et al. (2014)
30/517
85/517
72/517
18-45
Mean(SD): cases:
25.4(5.0), 26.4(4.8),
27.2(4.4), 24.1(5.5)
controls: 26.6(5.0)
NIH
Rotterdam
AES
Clinical diagnostic
criteria applied
for Iranian adult
(3 out of 5)
Australia
Cussons et al. (2008) 168/883
cases: 25-54
controls: 25-53
Mean(SD):
cases: 32.3(8.1)
controls: 25.8(5.8)
NIH ATP III, IDF
Hart et al. (2011)
34/169
61/143
14 Mean(SD): 22.8(3.8)
NIH
Rotterdam
ATP III, IDF,
WHO, EGIR
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Table 4. Summary of critical appraisal of studies reporting PCOS-related metabolic
disorders using the Newcastle-Ottawa Scale for case-control studies.
Study
Selection
(max 4 stars)
Comparability
(max 2 stars)
Exposure
(max 3 stars)
Dos Reis et al. (1995) ? ??
Rajkhowa et al. (1996) ?? ?? ??
Ciampelli et al. (1998) ? ??
Cibula et al. (2000) ? ?? ?
Dunaif et al. (2001) ? ? ? ?? ??
Yaralı et al. (2001) ?? ? ??
Glueck et al. (2003) ?? ? ??
Faloia et al. (2004) ? ?? ??
Phy et al. (2004) ? ?? ??
Sir-Petermann et al. (2004) ? ? ? ??
Apridonidze et al. (2005) ?? ?
Legro et al. (2005) ? ? ?? ??
Diamanti-Kandarakis et al. (2005) ?? ?? ??
Dokras et al. (2005) ? ? ? ?? ??
Sawathiparnich et al. (2005) ? ?? ?
VrbI´kova´ et al. (2004) ? ? ??
A´lvarez-Blasco et al. (2006) ? ? ? ? ??
Boudreaux et al. (2006) ? ? ? ?? ? ? ?
Carmina et al. (2006) ?? ? ??
Coviello et al. (2006) ?? ?? ??
Leibel et al. (2006) ? ?? ??
Lo et al. (2006b) ?? ? ??
Welt et al. (2006) ? ?? ??
C¸alıs¸kan et al. (2007) ?? ?? ??
Shroff et al. (2007a) ?? ?? ??
Shroff et al. (2007b) ? ? ? ?? ??
Cheung et al. (2008) ?? ?? ??
Cussons et al. (2008) ?? ?? ?
Echiburu´ et al. (2008) ? ? ? ? ??
Gulcelik et al. (2008) ?? ?? ??
Ma´rquez et al. (2008) ?? ? ??
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Selection
(max 4 stars)
Comparability
(max 2 stars)
Exposure
(max 3 stars)
Attaoua et al. (2008) ? ? ? ? ??
Shaw et al. (2008) ? ?
Alvarez-Blasco et al. (2009) ? ? ?? ? ??
Bhattacharya and Jha (2011) ?? ??
Moini and Eslami (2009) ?? ? ??
Fulghesu et al. (2010) ?? ?? ??
Gambineri et al. (2009) ?? ?? ??
Kawai et al. (2009) ?? ??
Lankarani et al. (2009) ? ? ? ? ??
Lee et al. (2009) ?? ? ?
Nur et al. (2009) ?? ?? ??
Vrbikova et al. (2009) ? ?
Wei et al. (2009) ?? ??
Zhang et al. (2009) ?? ? ??
Huang et al. (2010) ? ? ? ?? ??
Karaer et al. (2010) ? ?? ??
Luque-Ramı´rez et al. (2010) ? ? ? ?? ??
Pall et al. (2010) ? ? ? ? ??
Tan et al. (2010) ? ? ? ? ??
Veltman-Verhulst et al. (2010) ?? ??
Wiltgen and Spritzer (2010) ? ??
Zhao et al. (2010) ?? ?
Amato et al. (2011) ? ? ? ?? ??
Hudecova et al. (2011a) ?? ? ??
Hudecova et al. (2011b) ?? ? ??
Melo et al. (2011) ? ? ? ??
Rizzo et al. (2011) ?? ?? ??
Schmidt et al. (2011) ?? ? ??
VrbI´kova´ et al. (2011) ? ?? ??
Wang et al. (2011) ? ? ? ?? ? ? ?
Wickham et al. (2011) ?? ?? ??
Wijeyaratne et al. (2010) ? ? ? ?? ??
Yilmaz et al. (2011) ?? ??
Karoli et al. (2013) ? ?? ??
Li et al. (2012) ? ? ? ? ??
LIANG et al. (2012) ? ? ??
Nandalike et al. (2012) ? ? ? ? ??
Rahmanpour et al. (2012) ?? ??
Zhang et al. (2012) ? ? ? ??
Dalamaga et al. (2013) ? ? ? ??
Celik et al. (2013) ? ? ? ??
Chan et al. (2013) ? ? ??
Li et al. (2013b) ? ? ? ? ??
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Selection
(max 4 stars)
Comparability
(max 2 stars)
Exposure
(max 3 stars)
Panidis et al. (2013) ?? ? ??
Roe et al. (2013) ? ? ? ? ??
Albu et al. (2015) ? ? ? ? ??
Celik et al. (2014) ?? ? ? ?
Chen et al. (2015) ? ? ? ? ??
Guleria et al. (2014) ? ? ? ?? ??
Hosseinpanah et al. (2014) ? ? ? ??
HU et al. (2014) ?? ? ??
Tehrani et al. (2014) ? ? ? ? ??
Thathapudi et al. (2014) ? ? ? ? ??
Sirmans et al. (2014b) ?? ? ??
Ramos and Spritzer (2015) ? ? ? ? ??
Hart et al. (2011) ? ? ? ?
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Table 5. Read codes to identify PCOS cases.
medcode description
C164.12 Stein - Leventhal syndrome
C165.00 Polycystic ovarian syndrome
7E25300 Endoscopic drilling of ovary
K591100 Oligomenorrhoea
K591200 Primary oligomenorrhoea
K591300 Secondary oligomenorrhoea
K594.00 Irregular menstrual cycle
K594z00 Irregular menstrual cycle NOS
22D8.00 O/E - hirsutism
C161000 Hypersecretion of ovarian androgen
M240.00 Alopecia
M240000 Alopecia unspecified
M240200 Male pattern alopecia
M240300 Frontal alopecia of women
M240400 Premature alopecia
M240z00 Alopecia NOS
M241.00 Hirsutism - hypertrichosis
M260.00 Acne varioliformis
M260000 Acne frontalis
M260z00 Acne varioliformis NOS
M261.00 Other acne
M261000 Acne vulgaris
M261100 Acne conglobata
M261600 Cystic acne
M261A00 Pustular acne
M261E00 Acne excoriee des jeunes filles
M261F00 Acne fulminans
M261G00 Acne agminata
M261J00 Acne necrotica
M261K00 Acne keloidalis
M261X00 Acne, unspecified
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medcode description
M261z00 Other acne NOS
Myu6300 [X]Other androgenic alopecia
Myu6800 [X]Other acne
Myu6F00 [X]Acne, unspecified
4473 Serum testosterone
4473100 Serum testosterone level abnormal
4474 Free androgen index
4474100 Free androgenic index abnormal
447G.00 Plasma testosterone level
447H.00 Androgen level
4Q26.00 Dihydrotestosterone level
4Q2E.00 Free testosterone level
4Q2F.00 Calculated free testosterone
ZRBs.00 Ferriman and Galwey score
K53..11 Ovarian cysts
K532.00 Other ovarian cysts
K532z00 Ovarian cyst NOS
Kyu9500 [X]Other and unspecified ovarian cysts
B540.00 Malignant neoplasm of adrenal gland
B540000 Malignant neoplasm of adrenal cortex
B540100 Malignant neoplasm of adrenal medulla
B540z00 Malignant neoplasm of adrenal gland NOS
B587.00 Secondary malignant neoplasm of adrenal gland
B7H0.00 Benign neoplasm of adrenal gland
B8yy100 Carcinoma in situ of adrenal gland
B922.00 Neoplasm of uncertain behaviour of adrenal gland
BB5h.00 [M]Adrenal cortical tumours
BB5h000 [M]Adrenal cortical adenoma NOS
BB5h100 [M]Adrenal cortical carcinoma
BB5h300 [M]Adrenal cortical adenoma, heavily pigmented variant
BB5h400 [M]Adrenal cortical adenoma, clear cell type
BB5h500 [M]Adrenal cortical adenoma, glomerulosa cell type
BB5h600 [M]Adrenal cortical adenoma, mixed cell type
BB5hz00 [M]Adrenal cortical tumours NOS
BBCF.00 [M]Adrenal rest tumour
BBD7.00 [M]Extra-adrenal paraganglioma, NOS
C15..00 Disorders of adrenal glands
C153.00 Other corticoadrenal overactivity
C155000 Adrenal medullary insufficiency
C15y.00 Other specified adrenal disorders
C15yz00 Other specified adrenal disorder NOS
C15z.00 Adrenal gland disorder NOS
Cyu4A00 [X]Other specified disorders of adrenal gland
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medcode description
PK1..00 Anomalies of adrenal gland
PK10.00 Aberrant adrenal gland
PK12.00 Accessory adrenal gland
PK13.00 Hypoplasia of adrenal gland
PK14.00 Ectopic adrenal gland
PK1y.00 Other specified anomalies of adrenal gland
PK1y000 Congenital cyst of adrenal gland
PK1yz00 Other congenital anomaly of adrenal gland NOS
PK1z.00 Anomalies of adrenal gland NOS
2226.11 O/E - cushingoid facies
C150.00 Cushing’s syndrome
C150000 Idiopathic Cushing’s syndrome
C150100 Iatrogenic Cushing’s syndrome
C150111 Drug-induced Cushings syndrome
C150200 Pituitary dependent Cushing’s syndrome
C150300 Ectopic ACTH secretion causing Cushing’s syndrome
C150500 Alcohol-induced pseudo-Cushing’s syndrome
C150z00 Cushing’s syndrome NOS
Cyu4500 [X]Other Cushing’s syndrome
F395100 Myopathy due to Cushing’s syndrome
C150400 Nelson’s syndrome
BB5y400 [M]Prolactinoma
C131000 Hyperprolactinaemia
C134011 Hypoprolactinaemia
B542.00 Malignant neoplasm pituitary gland and craniopharyngeal duct
B542000 Malignant neoplasm of pituitary gland
B542z00 Malig neop pituitary gland or craniopharyngeal duct NOS
B7H2.00 Benign neoplasm of pituitary gland and craniopharyngeal duct
B7H2.11 Pituitary adenoma
B7H2000 Benign neoplasm of pituitary gland
B7H2z00 Benign neoplasm of pituitary and craniopharyngeal duct NOS
B8yy300 Carcinoma in situ of pituitary gland
B920.00 Neop uncertain behaviour pituitary and craniopharyngeal duct
B920000 Neoplasm of uncertain behaviour of pituitary gland
B920z00 Neop uncertain behaviour pituitary and craniopharyngeal NOS
BB5V.00 [M]Pituitary adenomas and carcinomas
BB5Vz00 [M]Pituitary adenoma or carcinoma NOS
C13..00 Disorders of pituitary gland and its hypothalamic control
C131.00 Other anterior pituitary hyperfunction
C134.00 Other anterior pituitary disorder
C134z00 Other anterior pituitary disorder NOS
C134z11 Anterior pituitary hormone deficiency NEC
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C137.00 Iatrogenic pituitary disorders
C137z00 Iatrogenic pituitary disorder NOS
C13z.00 Pituitary disorders NOS
Cyu4400 [X]Other disorders of pituitary gland
Cyu4M00 [X]Hyperfunction of pituitary gland, unspecified
K5B1.00 Female infertility of pituitary - hypothalamic origin
K5B1000 Primary pituitary - hypothalamic infertility
K5B1z00 Female infertility of pituitary - hypothalamic cause NOS
PK24.00 Anomalies of pituitary gland
PK24000 Aberrant pituitary gland
PK24z00 Anomaly of pituitary gland NOS
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Appendix F
Sample JAGS codes of Bayesian models for evidence synthesis
### Prevalence estimation for PCOS population with different ethnic backgrounds
model{
for( i in 1:I){
x[i]˜dbin(betau[i],m[i])
logit(betau[i])<- gamma[i]
gamma[i]˜dnorm(mu.gamma,tau.gamma)
}
# prior distribution
mu.gamma˜dnorm(-2.75,6.25)
# uniform distribution for tau.gamma
sigma.gamma˜dunif(0,2)
tau.gamma<-pow(sigma.gamma,-2)
# halfcauchy (as replacement prior for tau.gamma for sensitivity analysis)
# sigma.gamma <- abs(z.gamma)/pow(epsilon.gamma,0.5)
# z.gamma ˜ dnorm(0,tau.z.gamma)
# epsilon.gamma ˜ dgamma(0.5,0.5)
# tau.z.gamma <- pow(B.gamma,-2)
# B.gamma ˜ dunif(0,0.5)
# tau.gamma<-pow(sigma.gamma,-2)
# tau.gamma<-pow(sigma.gamma,-2)
p<-exp(mu.gamma)/(1+exp(mu.gamma))
}
### Meta-regression model for the evaluation of relative risk of metabolic disorders
among women with PCOS and controls
model{
for (s in 1:S){
pcos0evt[s]˜dbin(pi0[s],pcos0tl[s])
pcos1evt[s]˜dbin(pi1[s],pcos1tl[s])
logit(pi0[s])<-alpha+X1[s]*beta0+X2[s]*beta1+X3[s]*beta2+X4[s]*beta3
logit(pi1[s])<-alpha+X1[s]*beta0+X2[s]*beta1+X3[s]*beta2+X4[s]*beta3+delta[s]
delta[s]˜dnorm(mu.delta,tau.delta)
beta0˜dnorm(1.702,0.01)
beta1˜dnorm(1.296,0.01)
beta2˜dnorm(1.058,0.01)
beta3˜dnorm(0.967,0.01)
alpha˜dnorm(-3.585,0.01)
gamma[s]<-exp(delta[s])
}
# Prior distribution
mu.delta˜dnorm(0,2)
sigma.delta˜dunif(0,1)
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tau.delta<-pow(sigma.delta,-2)
# student-t distribution (as replacement prior for mu.delta for sensitivity analysis)
# mu.delta˜dt(0,0.5,v)
# v˜dunif(0,8)
rho<-exp(mu.delta)
p.harm<-1-step(mu.delta)
}
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Appendix G
Diagnostic plots for the assessment of model convergence with Gelman-Rubin statistics
provided for all model parameters.
Figure G.1: Convergence assessment for model estimating the incidence rates from probable to
diagnosed PCOS for standard model (left) and hierarchical model (right).
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Figure G.2: Convergence assessment for model estimating the incidence rates from diagnosed
PCOS to diabetes for standard model (left) and hierarchical model (right).
Figure G.3: Convergence assessment for model estimating the incidence rates from probable
PCOS to diabetes for standard model (left) and hierarchical model (right).
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